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Both G protein coupled receptor 10 (GPR10) and the muscarinic IVh  receptor are 
members of family A of the G protein coupled receptor superfamily. GPR10 is the 
human orthologue of a former orphan receptor for which prolactin releasing peptides 
(PrRP) have been identified as the cognate ligands. In contrast, the Mi  receptor 
represents a well-established receptor for which up until the discovery of AC-42 (4- 
(4-butyl-1-piperidinyl)-1-(2-methylphenyl)-1-butanone) it has been difficult to identify a 
selective agonist.
Little is known of the pharmacology of PrRPs and AC-42 at GPR10 and the human 
Mi  (hlVL) receptor, respectively. Similarly, the molecular nature of their respective 
binding sites is as yet unknown. In the studies in this thesis, the interaction of PrRPs 
with GPR10 and of AC-42 (and other ectopic agonists) with the hMi  receptor have 
been extensively characterised using a range of pharmacological techniques in both 
recombinant cell lines stably and transiently expressing the receptor(s) of interest 
and native tissue preparations. Furthermore, the molecular interactions between 
ligand and receptor have been probed using homology modelling, site-directed 
mutagenesis (SDM) and pharmacological evaluation.
The results generated reveal that PrRPs are high affinity, potent agonists at GPR10 
that cause the receptor to activate effector systems that are known to couple to Gq/n 
proteins. Radioligand binding studies suggest both high and low affinity sites for 
binding. In addition, homology modelling and SDM have been used to reveal key 
interactions of the C-terminal region of PrRP with transmembrane domain (TM) 6 
(D302) and TM7 (Q317) and extracellular loop (ECL) 2 (E213).
Selective activation of the Mt   receptor can be achieved using AC-42 and other novel 
ligands. Using functional calcium mobilisation assays, inositol phosphate assays and
2radioligand binding studies it has been possible to demonstrate that this class of 
compounds interacts with the receptor in an allosteric manner. SDM studies also 
suggest that residues distinct from the orthosteric binding site form part of the binding 
site for AC-42 and related compounds.
These studies provide the first extensive pharmacological analysis characterising the 
interaction of PrRP and GPR10 and identify the signal transduction cascade 
activated by this former orphan receptor. Furthermore, SDM studies have partly 
elucidated the molecular nature of the PrRP binding site. Both pharmacological and 
SDM based examination of the muscarinic Mi  receptor have revealed a unique 
allosteric method of activation by AC-42 and a novel class of allosteric agonists.
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15Chapter 1  
Introduction
161. G protein coupled receptors
(i)  Ligand gated ion channels and G protein coupled receptors.
Neuronal communication within the CNS is largely by means of chemical 
neurotransmission. This process involves the release of a chemical neurotransmitter 
from the nerve terminal of one neurone, diffusion across the synapse and interaction 
with a receptor protein on the cell surface of one or more post-synaptic neurones to 
instigate a physiological response in that neurone. Receptor proteins can mediate the 
actions of hormones, neurotransmitters, growth factors and cytokines. Receptors can 
be subdivided into four superfamilies, based on their molecular structure and 
mechanism of signal transduction (Rang etal.,  1999). The four families are ligand 
gated ion channels (LGIC), G protein coupled receptors (GPCR), kinase linked 
receptors and nuclear receptors. LGICs are plasma membrane bound receptors that 
couple directly to an ion channel to mediate fast, millisecond neurotransmission in 
the CNS e.g. nicotinic acetylcholine receptors (Rang etal., 1999). GPCRs are also 
plasma membrane bound receptors, but they couple to intracellular effector systems 
via guanine nucleotide binding (G) proteins (Rang etal.,  1999). Typically, GPCRs 
mediate slower neurotransmission than ligand gated ion channels, over a time frame 
of seconds rather than milliseconds, and include receptors for noradrenaline, 
acetylcholine, 5-HT and dopamine. Kinase linked receptors, that are also membrane 
bound, incorporate an intracellular protein kinase domain in their structure. They 
include receptors for insulin as well as cytokines and growth factors (Rang etal.,
1999). The final family are the nuclear receptors. Unlike the other three, nuclear 
receptors are not membrane bound and are usually found, as their name suggests, in 
the nuclear compartment (though are also present in the cytosol), where they 
regulate gene transcription. This family includes receptors for steroid hormones, 
thyroid hormone and vitamin D (Rang etal.,  1999). Responses mediated via kinase
17linked receptors and nuclear receptors occur over the timeframe of minutes and 
hours.
(ii)  The G protein coupled receptor superfamily
The GPCR superfamily is characterised by proteins which contain seven distinct 
hydrophobic regions, each 20-30 amino acids in length and each of which forms an 
a-helical transmembrane domain (Figure 1; Schoneberg etal., 1999). These are 
connected by intracellular and extracellular loops and the receptor is completed by 
an extracellular N-terminus and an intracellular C-terminal tail (Kristiansen, 2004). 
The sequence of the human genome revealed 616 putative GPCRs (Venter etal.,
2001), many of which have been discovered recently with the development of 
genome and cDNA research (Gether, 2000). In 1994, mammalian GPCRs were 
classified into 3 families, A, B and C, by sequence homology and predicted structure 
(Kolakowski, 1994). Since that time the classification has been widened to include 
newly discovered GPCRs and the mammalian superfamily now encompasses 7 
families, namely A, B, large N-terminal family B, C, Frizzled/Smoothened, taste 2 and 
vomeronasal 1   (Kristiansen, 2004).
By far the largest and best studied of the families is family A, i.e. those receptors 
showing close relation to the light receptor, rhodopsin (Gether, 2000). The majority of 
family A receptors are olfactory GPCRs, although nearly 200 non-olfactory GPCRs, 
recognising over 80 ligands, have also been characterised (Pierce etal., 2002). 
Phylogenetically, family A can be further subdivided into six major groups, as shown 
in Table 1. The overall homology between members of family A is low and restricted 
to several highly conserved key residues. Most notable is the arginine residue that is 
part of the Asp-Arg-Tyr (DRY) motif at the interface of TM3 and intracellular loop 2 
and which is conserved in almost all family A receptors (Gether, 2000; Figure 1).
18Biogenic amine receptors
CCK, endothelin, tachykinin, NPY, bombesin, TRH, vertebrate opsin 
receptors
CO
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O
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Invertebrate opsins & bradykinin receptors
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E
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ia .
Adenosine, cannabinoid, melanocortin and olfactory receptors
Chemokine, gonadotropin-releasing hormone, eicosanoid, leukotriene, 
follicle-stimulating hormone, lutenising hormone, thyroid-stimulating 
hormone, galanin, nucleotide, opioid, oxytocin, vasopressin, 
somatostatin, protease-activated receptors.
Melatonin receptors and other non-classified.
Table 1. Six phylogentically defined subgroups of family A GPCRs (adapted from 
Gether et al., 2002).
19Figure 1. Membrane topology of the p2  adrenoceptor, a typical member of family A 
GPCRs. This subfamily of receptors is characterised by a series of highly conserved 
key residues (black letter in white circles). In most family A receptors, a disulphide 
bridge connects ECL2 and ECL3 (white letters in black circles). Additionally, the 
majority of the receptors have a palmitoylated cysteine in the carboxy-terminal tail 
causing formation of a putative fourth intracellular loop.
20Family B consists of approximately 25 members, including receptors for 
gastrointestinal peptides (eg. secretin, glucagon, vasoactive intestinal peptide), 
corticotrophin-releasing hormone and parathyroid hormone (Pierce etal., 2002; 
Gether, 2000). The most prominent characteristic of family B GPCRs is the large 
extracellular N-terminus of approximately 100 aa, which contains a number of 
cysteine residues thought to form a network of disulphide bridges (Ulrich etal.,
1998). The DRY motif, found in family A receptors, is notably absent in receptors in 
family B (Gether, 2000).
Family C is also small and contains the metabotropic glutamate receptors, the 
GABAb receptor and the calcium sensing receptor (Schoneberg, 2002; Pierce etal.,
2002). These receptors are characterised by an extremely large N-terminal domain 
(500 -  600 aa) that shows homology with bacterial periplasmic binding proteins and 
which is thought to be involved in ligand binding and receptor activation (Pin etal.,
2003).
The remaining families are those that have been created to better classify new 
GPCRs as they are discovered and now also include some receptors that were 
previously classified in family B (large N-terminal family B 7TM receptors, 
Frizzled/Smoothened) or family C (taste 2 and vomeronasal 1   receptors).  Large N- 
terminal family B 7TM receptors share some similarities with family B receptors in 
their TM domains (Fredriksson etal., 2003) and include brain specific angiogenesis 
inhibitor receptor (BAI  1-3) and calcium independent receptor of a-latrotoxin (CIRL 1- 
3; Kristiansen, 2004). Similarly, Frizzled and Smoothened receptors show low but 
significant homology with family B receptors (Foord etal., 2002), but are sufficiently 
different in their N-termini to warrant a separate subfamily. Vomeronasal  1   receptors 
are a family of 12 weakly homologous receptors for pheromones that have short N- 
terminal domains, suggesting that their ligands bind within the TM bundle
21(Kristiansen, 2004). Their significant differences from family C receptors led to their 
re-classification into a novel family, along with the bitter-sensing taste 2 receptor.
(iii)  Structure of GPCRs
A possible development in the understanding of the structure of GPCRs, particularly 
those belonging to family A, was the determination of the crystal structure of the 
photoreceptor, rhodopsin (Palczewski etal., 2000). The crystal structure of rhodopsin 
has confirmed the molecular architecture of an extracellular N-terminus, an 
intracellular C-terminus and seven TM domains connected by alternating intracellular 
and extracellular loops (Palczewski etal., 2000). GPCRs are also often subject to a 
number of post-translational modifications, including N-glycosylation and 
palmitoylation (Schoneberg, 2002). Glycosylation sites are usually found in the N- 
terminal domain, but can also be found in the extracellular loops. Some GPCRs, 
such as the adenosine A2 receptor and human o c 2B  adrenergic receptor, lack 
consensus sites for glycosylation, yet are fully functional in the absence of this 
modification (Schoneberg, 2002). For others, such as the parathyroid hormone 
receptor and human calcium sensing receptor, glycosylation is a pre-requisite for 
correct function or cell surface expression (Schoneberg, 2002). Another post- 
translational modification is palmitoylation and the best example of this is found in 
several family A GPCRs where the so-called fourth intracellular loop is formed by a 
palmitoylated cysteine in the C-terminus. This loop’ adopts an a-helical formation 
running parallel to the plasma membrane and as such has been termed helix VIII 
(Palczewski etal., 2000). Furthermore, the majority of family A and family B GPCRs 
are characterised by pair of conserved cysteine residues linking the first and second 
extracellular loops via a disulphide bond (Schoneberg, 2002). Mutation of these 
cysteine residues for a number of GPCRs has resulted in a loss of high affinity ligand 
binding (Perlman etal., 1995; Schoneberg, 2002), suggesting that this disulphide
22bond may be critical to the formation of the ligand binding site for some GPCRs. In 
support of this hypothesis, in the crystal structure of rhodopsin the second 
extracellular loop actually dips down into the TM bundle (Palczewski etal., 2000).
Whilst rhodopsin remains the only GPCR for which the crystal structure has been 
determined, the strong conservation of key amino acid residues amongst family A 
receptors has allowed researchers to construct homology models of the 
transmembrane domains of other receptors (Lu etal., 2002). These residues include 
the asparagine in TM1  (Asn 1.50), the aspartate in TM2 (Asp 2.50), the Asp-Arg-Tyr 
triad at the cytoplasmic face of TM3 (Asp 3.49, Arg 3.50, Tyr 3.51; Glu-Arg-Tyr in 
bovine rhodopsin), the tryptophan in TM4 (Trp 4.50) and the conserved prolines in 
TM5 (Pro 5.50), TM6 (Pro 6.50) and TM7 (Pro 7.50; Gether, 2000; Kristiansen,
2004). Iterative modelling of the docking of ligands into such homology models can 
identify key ligand contact points on the receptor. The most common method to 
assess whether residues are involved in the binding of ligand involves mutating either 
single residues or regions of a receptor protein to alter the amino acid sequence, a 
technique known as site-directed mutagenesis (SDM). The effect of different 
mutations on ligand binding and receptor signalling can then be assessed. A 
common mutation that is used for pharmacological analysis is the conversion of 
residues to alanine to remove any side chain beyond the p-carbon, yet preserve the 
integrity of the receptor structure. More investigative mutations are often used to 
probe specific side-chain function e.g. mutation of Y82 and Y85 to both 
phenylalanine and alanine has been used to determine whether either the hydroxyl or 
aromatic moiety of these tyrosine residues is involved in the binding of [3H]NMS in 
the muscarinic M1   receptor (Lee etal.,  1996). SDM is now a common technique that 
has been useful to determine the key residues for both ligand binding (Berkhout et 
a!., 2003; Bikker etal.,  1998; Hirst etal., 2003) and receptor activation (Fanelli etal., 
1998; Greasley etal., 2002) for a number of GPCRs.
23(iv)  GPCR ligand diversity
Despite the similar molecular architecture of seven TM domains which characterises 
the entire superfamily, GPCRs have evolved to be activated by a vast array of 
different stimuli. These include small biogenic amines (eg. acetylcholine, dopamine), 
amino acids (eg. glutamate), photons, ions (eg. Ca2+), peptides (eg. neurokinins, 
orexins), large glycoproteins (eg. human immunodeficiency virus coat protein) and 
proteases (which can cleave the N-terminus of GPCRs leaving a truncated N- 
terminus that can interact with the TM bundle to activate the receptor; Schoneberg,
2002). These ligands can be extremely small, such as photons and calcium ions, 
which activate rhodopsin and the calcium-sensing receptor, respectively. 
Alternatively, the ligands can be very large, such as orexin-A peptide (molecular 
weight = 3561; Sakurai etal.,  1998) or viral coat proteins such as gp120 (molecular 
weight ~ 100,000; Kenakin, 2004).
The GPCR binding site for small endogenous agonists, such as biogenic amines, is 
located deep in the receptor in the TM bundle and formed by residues in TM3 (Asp 
3.32, Ser 3.36), TM5 (Ser/Thr 5.42, Ser 5.43, Ser/Thr 5.46), TM6 (Asn 6.55) and 
TM7 (Asp 7.36, Trp 7.40, Tyr 7.43; Gether, 2000; Kristiansen, 2004). This has been 
demonstrated for a number of aminergic GPCRs, including the (32 adrenoceptor 
(Strader etal., 1987,  1989) and the muscarinic M1   receptor (Lu etal., 2002). An 
important interaction is thought to be between the carboxylate side chain of a highly 
conserved Asp in TM3 (18 residues N-terminal of the invariant Arg of TM3) and the 
charged amine group of biogenic amines such as noradrenaline (Gether, 2000), 
acetylcholine (Spalding etal.,  1994), serotonin (Wang etal., 1993), dopamine 
(Mansour etal., 1992) and histamine (Gantz etal., 1992).
24In addition to these findings, it has also been demonstrated that residues in the ECL2 
are involved in the binding of some small molecules, such as phentolamine at the a1 A  
adrenoceptor (Zhao etal., 1996) and ligands at the adenosine receptor (Kim etal., 
1996). It has been suggested that the loop may dip down into the binding crevice in 
the TM bundle due to the formation of a disulphide bridge between cysteine residues 
in ECL2 and top of TM3, (Kim et a!.,  1996).
In contrast to aminergic receptors, the binding sites for peptide receptors in family A 
are generally considered to be more extracellular, incorporating residues in the 
extracellular loops and N-terminus, as has been demonstrated for the receptors for 
angiotensin II, neuropeptide Y, oxytocin, bradykinin and neurotensin (Gether, 2000). 
However, due to their size, some peptides may have additional points of interaction 
in the transmembrane bundle and may actually enter the TM binding crevice (Gether,
2000). This has been shown for longer peptides, including angiotensin (Yamano et 
a!.,  1995) and opiates (Befort etal.,  1996), but also for small tripeptides such as 
thyrotropin-releasing hormone (Perlman etal.,  1994). Despite the proximity of 
peptide binding sites to the binding site for biogenic amines, the residues in the TM 
bundle recognised by these peptides are largely distinct from those involved in the 
binding of biogenic amines (Gether, 2000).
(v)  Activation of GPCRs
An agonist is a ligand capable of binding to a specific recognition site on a receptor 
and causing that receptor to adopt an active state (Kenakin,  1997). For a GPCR, as 
has been discussed, a wide array of different ligands are capable of acting as 
agonists. Wherever their binding site on the receptor, they cause a change in the 
conformation of the receptor such that it is able to bind and activate G protein(s) to 
propagate the signal to the intracellular compartment (Rasmussen & Gether, 2002).
25In contrast, a competitive antagonist is able to bind to the receptor, but does not 
make the necessary contacts to trigger receptor activation. However, its presence in 
the binding site is capable of blocking agonist mediated receptor activation.
In practice, it is likely that most ‘antagonists’ are actually inverse agonists. These 
ligands act to stabilise the receptor in its inactive conformation and therefore reduce 
any constitutive activity of the receptor (activity in the absence of bound agonist; 
Kenakin, 1997). Atropine and A/-methylscopolamine (NMS) have been reported to 
display inverse agonist at muscarinic acetylcholine receptors (Hulme etal., 2003). 
Both of these ligands contain a phenyl group which is thought to further stabilise the 
hydrophobic intramolecular interactions in the endofacial region of the TM domains 
which hold the receptor in an inactive conformation (Hulme etal., 2003).
GPCR activation is accompanied by movement of the TM domains in order to allow 
the receptor to bind G protein(s). Studies to determine the active conformations of 
both rhodopsin and the (32 adrenoceptor suggest that agonist binding triggers an 
outward tilting of TM6, an anticlockwise rotation of TM5 and an increased flexibility of 
the lower half of TM7 as well as movements of TM1, TM2 and TM3 (Gouldson et a!.,
2004).  These movements break the intramolecular bonds that hold the receptor in 
the inactive state; in turn, new intramolecular bonds that hold the receptor in an 
active conformation are formed (Rasmussen & Gether, 2002).
Varying intracellular portions of GPCRs have been implicated in mediating 
interactions with G proteins. The first (formyl peptide and cholecystekinin CCKA  
receptors), second (GABAb receptor) and third (endothelin ETB  receptor) intracellular 
loops have all been shown to participate in G protein activation (Schoneberg, 2002). 
Furthermore, studies suggest that it is residues close to the TM helix -  intracellular 
loop interface that are responsible for mediating interactions with G proteins. In both
26the muscarinic M3 receptor and the neurokinin NK-1  receptor, deletion of large 
portions of the third intracellular loop has little or no effect on ligand binding and 
receptor function (Schoneberg etal., 1995; Nielsen etal.,  1998).
(vi)  G protein coupled receptor signalling
When an extracellular agonist ligand such as a biogenic amine or a peptide interacts 
with its GPCR, the ligand induces a conformational change in the receptor that 
activates a heterotrimeric guanine nucleotide binding protein (G protein; Cabrera- 
Vera etal., 2003). G proteins are composed of a-, p- and y- subunits and are found 
on the inner membrane surface of the cell - Ga subunits are often post-translationally 
lipidated (eg. N-terminal myristoylation of Gocj) to allow the protein to anchor to the 
plasma membrane (Ho & Wong, 2002). Prior to receptor activation, the Ga subunit of 
the heterotrimeric G protein has a molecule of guanine diphosphate (GDP) bound. 
Upon agonist binding and receptor activation, the Ga subunit binds to the receptor. 
Various regions of Ga contribute to the association with GPCRs, most notably the 
extreme C-terminal region (Ho & Wong, 2002). Indeed, replacement of the five 
C-terminal amino acids of Gaq with those of Gaj2 >  Gao, Gaz or Gag alters the profile of 
receptor coupling (Conklin etal., 1993,1996).
Upon Ga binding to the GPCR a molecule of GDP is released and exchanged for a 
molecule of guanine triphosphate (GTP). This transition precipitates the dissociation 
of the Gafrom both the GPy subunit and the receptor. Both Ga-GTP and Gpyare 
then accessible to activate downstream effector systems (Cabrera-Vera etal., 2003). 
The duration of action is determined by the rate of the intrinsic GTPase hydrolysis 
rate of the Ga subunit, which, once it has hydrolysed GTP to GDP, re-associates with 
Gpy. Both Ga and Gpyare capable of modulating different intracellular effector 
systems and multiple subtypes of heterotrimeric G proteins provide an extremely
27Figure 2. Agonist mediated activation of a GPCR induces a conformational change in 
the receptor that activates a heterotrimeric guanine nucleotide binding protein (G 
protein; Cabrera-Vera etal., 2003). G proteins are composed of a-, p- and y- subunits 
and are found on the inner membrane surface of the cell. Prior to receptor activation, 
the Ga subunit of the heterotrimeric G protein has a molecule of guanine 
diphosphate (GDP) bound. Upon agonist binding and receptor activation, the 
molecule of GDP is released and exchanged for a molecule of guanine triphosphate 
(GTP). This transition precipitates the dissociation of the Gafrom both the 
Gpy subunit and the receptor. The duration of action is determined by the rate of the 
intrinsic GTPase hydrolysis rate of the Ga subunit, which, once it has hydrolysed 
GTP to GDP, re-associates with Gpy.
28diverse range of signal transduction pathways that can be modulated by GPCRs. The 
G protein cycle is shown in Figure 2.
Whilst there are five different Gp subunits and thirteen different Gy subunits that have 
been identified to date (Carera-Vera etal., 2003), G proteins are usually referred to 
by their Ga subunit. There are four families of Ga subunit, namely Gas, Gaj, Goq and 
Ga12. The Gs  family consists of Gas and Gaoif and activation of Gs  coupled receptors 
is generally associated with stimulation of adenylyl cyclase (AC) and a subsequent 
increase the intracellular concentration of cAMP (Ho & Wong, 2002; Cabrera-Vera et 
at., 2003).
The Gj family of Ga proteins consists of Gan, Goci2, Gai3, Gao, Gaz, Ga^, Ga^ and 
Gag. In contrast to the Gs  family, GaM , Gai2  Gai3, Gao and Gaz proteins inhibit 
adenylyl cyclase to lower the intracellular levels of cAMP, although GaoCan stimulate 
phosphoinositide 3-kinase and Ga^ and Ga^ regulate cGMP phosphodiesterases 
(Ho & Wong, 2002). The Gq  family consists of Goq, Ga1 1 s  Ga14 and Ga16, all of which 
act to stimulate phospholipase-Cp to convert phosphatidyl inositol bisphosphate 
(PIP2) into inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 then is able to 
activate its receptor in the membrane of the smooth endoplasmic reticulum to cause 
the release of intracellular calcium (Ho & Wong, 2002). Finally, the G1 2  family 
consists of Ga12 and Ga13. Both are known to stimulate the Btk tyrosine kinase 
receptor and Ga1 2  is known to simulate phospholipase-Ce (Ho & Wong, 2002).
In addition to this wide variety of effectors, Ga subunits are known regulate a 
plethora of ion channels, monomeric G proteins, transcription co-factors, G protein 
receptor kinases and tyrosine kinases (Cabrera-Vera etal., 2003; Ho & Wong, 2002). 
With almost as many regulatory roles for the Gpy subunits as for Ga subunits, the 
variety and control of signal transduction pathways mediated by GPCRs is extensive.
29Such signal transduction pathways have been extensively studied and there are a 
number of pharmacological tools available with which to probe signal transduction 
mechanisms in vitro. The Gj family of G proteins (except Gaz) is unique in their 
sensitivity to the bacterial pertussis toxin (PTX) which inactivates the Ga subunit by 
ADP ribosylation. The Gs  family is similarly sensitive to permanent activation by the 
bacterial cholera toxin which inhibits GTP hydrolysis (Cassel & Selinger,  1977). Of 
greatest interest in these studies are GPCRs linked to the mobilisation of intracellular 
calcium and there are a number of tools available with which to monitor the signal 
transduction of Gq  / Gn coupled receptors. U73122 is a well characterised PLC 
inhibitor (Marshall etal., 2003; Thompson etal., 1991), 2-APB is a non-competitive 
inhibitor of the IP3 receptor (Maruyama et al.,  1997; Ma et al, 2001; Gregory &
Barritt, 2003) and thapsigargin is an inhibitor of the smooth endoplasmic reticulum 
Ca2+-ATPase that causes depletion of intracellular calcium stores (Marshall et al., 
2003). Very recently, Takasaki etal. (2004) have described a novel specific peptide 
inhibitor of the Goq subunit, YM-254890, although it is not currently commercially 
available.
(vii)  Second messengers and effector systems
The coupling of GPCRs to such a wide array of different Ga and Gpy subunits as 
described above leads to control of a highly divergent range of effector systems 
(Pierce etal., 2002; Rang etal., 1999). Broadly these comprise (i) activation or 
inhibition of AC and cAMP-dependent pathways, (ii) activation or inhibition of cyclic 
nucleotide phosphodiesterase and cGMP-dependent pathways, (iii) activation of 
phospholipase-Cp, DAG, IP3 and Ca2+ dependent pathways, (iv) inhibition of voltage 
gated calcium channels, (v) stimulation of inwardly rectifying potassium channels and 
(vi) activation of guanine nucleotide exchange factors of small G proteins eg. Ras 
(Rang etal.,  1999; Landry etal., 2006).
30Ten isoforms of adenylyl cyclases have been cloned, nine of which are membrane 
bound and are regulated by G proteins (AC1  -  AC9). Gets activates all nine 
membrane bound adenylyl cyclases, whereas Gotj selectively inhibits AC5 and AC6 
and Goto is thought to inhibit AC1  (Landry etal., 2006). Interestingly, Gpy subunits, 
probably from Gj and G0 inhibit AC1, AC5 and AC6 but activate AC2, AC4 and AC7. 
Activation of adenylyl cyclases increases cAMP which activates protein kinase A 
(Rang etal., 1999). This kinase phosphorylates serine and threonine residues on a 
number of target proteins, including voltage sensitive calcium channels (eg. after 
activation of pi adrenergic receptors in the heart; Landry etal., 2006). Increases in 
cAMP and cGMP activate cyclic nucleotide phosphodiesterases (PDEs) which 
catalyse their breakdown to 5’-AMP and 5’-GMP, respectively. There are eleven 
different PDE families which show varying selectivity for cAMP and cGMP.
Of the three common mammalian PLC subtypes, p, y and 6, only PLCp is thought to 
regulated by G proteins (Landry etal., 2006), although Gai2 does activate PLCe (Ho 
& Wong, 2002). Activation of PLCp is predominantly via Gctq and results in the 
conversion of PIP2 into IP3 and DAG. However, Gpy subunits of various G proteins 
are also capable of activating PLCp (Landry etal., 2006). IP3 usually activates its 
own receptor in the membrane of the smooth endoplasmic reticulum to cause the 
release of intracellular calcium (Ho & Wong, 2002). DAG participates in the activation 
of various isoforms of protein kinase C, a process which also requires membrane 
lipids or cytosolic calcium (Landry etal., 2006).
Gpy subunits play an important role in the control of ion channels by GPCRs.
Gpy dimers from PTX sensitive GPCRs inhibit P/Q-type, N-type and R-type calcium 
channels, all of which are found pre-synaptically and control the calcium entry into 
the nerve terminal governing neurotransmitter release (Landry etal., 2006). Inwardly
31rectifying K+ channels are also subject to modulation by Gj3y subunits -  activation of 
muscarinic M2 receptors in the heart stimulates Gj2 and Gi3 j which, in turn, activates 
K+ currents Kir3.1  and Kir3.4 (Landry etal., 2006). Additionally, L-type calcium 
channels can be activated by phosphorylation by protein kinase A and protein kinase 
C in response to activation of receptors coupled to Gs, Gi and Gq  (Landry et al.,
2006).
GPCR mediated signalling can also influence signal cascades that modulate 
transcription factors in the nucleus (Challiss & Nahorski, 2002; Landry etal., 2006). 
Ga1 2 /13, Gpy subunits and PIP3 are all capable of stimulate guanine nucleotide 
exchange factors which can activate small G proteins such as Ras, Rho, Rab,
Arf/Sar and Ran (Landry etal., 2006). Activated Ras,  Rho and others are capable of 
interacting with their own cytosolic effectors, such as MAP kinase kinase kinase. This 
in turn phosphorylates MAP kinase kinase, which phosphorylates MAP kinase 
(Challiss and Nahorski, 2002). MAP kinases include the extracellular signal-regulated 
kinases-1  and -2 (ERK1/2), c-Jun N-terminal protein kinases and p38 MAP kinases 
(Challiss and Nahorski, 2002). ERK1/2 activation can lead to nuclear translocation 
where it can directly affect transcription through phosphorylation of ternary complex 
factors such as Elk-1, or indirectly through activation of other protein kinases such as 
p90R S K  which phosphorylates the cAMP response element binding protein which 
regulates transcription factor activity (Challiss and Nahorski, 2002).
(viii)  Role of GPCRs in disease
Given their extensive role in neurotransmission and other essential physiology it is 
unsurprising that naturally occurring mutations in GPCRs should be the cause of a 
number of pathologies. Mutations can arise from either the germline (i.e. inherited) or 
can occur postzygotically. Disease-causing mutations of GPCRs can be classified
32into two broad groups. Firstly, they can cause a loss of receptor function which can 
occur at any number of levels from precluding normal formation of stable mRNA or 
protein to abnormal membrane trafficking or impaired high affinity agonist binding 
(Spiegel etal., 1995). Alternatively, mutations can result in a gain of function by 
causing GPCRs to become stabilised in an active conformation -  this includes 
mutations of residues which take part in intramolecular interactions to hold a GPCR 
in the inactive, uncoupled state (Spiegel etal., 1995). A vast range of diseases result 
from loss of function mutations in GPCRs, including colour blindness (cone opsins), 
retinitis pigmentosa (rhodopsin), nephrogenic diabetes insipidus (vasopressin V2 
receptor), familial hypothyroidism (thyroid stimulating hormone receptor) and 
congenital bleeding (thromboxane A2 receptor; Spiegel etal.,  1995). Interestingly, at 
least 27 different mutations that cause nephrogenic diabetes insipidus have been 
identified in the vasopressin V2 receptor, a number of which result in truncated 
receptors which are thought to be non-functional (Spiegel etal., 1995). Diseases that 
are associated with gain of function mutations include congenital night blindness 
(rhodopsin), sporadic hyperfunctional thyroid nodules (thyroid stimulating hormone 
receptor) and familial hyperparathyroidism (calcium sensing receptor; Spiegel etal., 
1995). In the latter disease, mutation of either of two acidic residues in the large N- 
terminal domain of the calcium sensing receptor appears to increase the sensitivity of 
the receptor to calcium itself (Spiegel etal.,  1995).
(ix)  Life-cycle of GPCRs
GPCRs are subject to extensive regulation. It is now known that there are systems in 
place to desensitise and traffic GPCRs after activation in order to regulate their 
signalling and expression (Hepler & Saugstad, 2002). Desensitisation of GPCRs can 
occur very rapidly after agonist activation and can be either homologous (where only 
the response of the activated receptor is affected) or heterologous (whereby
33activation of one receptor causes desensitisation of others that are utilising similar 
effector cascades; Hepler & Saugstad, 2002). For the (32 adrenoceptor, homologous 
desensitisation is caused by phosphorylation of serine and threonine residues in the 
third intracellular loop by G protein coupled receptor kinases (GRKs). However, 
heterologous desensitisation is caused by phosphorylation of serine residues in both 
the third intracellular loop and the C-terminal tail by protein kinase A (Bunemann & 
Hosey, 1999).
Following GRK phosphorylation, arrestin proteins are recruited from the cytosol to 
bind to the phosphorylated residues, forming an arrestin-GPCR complex that 
prevents further G protein binding (Pierce etal., 2002; Hepler & Saugstad, 2002). 
There are seven different GRK isoforms and four different arrestin isoforms, which 
allow a complex array of differential of GPCR regulation (Pierce etal., 2002).
The arrestin-GPCR complex is then targeted to microdomains of the plasma 
membrane to aid endocytosis. It has been suggested that arrestins and GRKs may 
also bind to other proteins to facilitate the internalisation of GPCRs. These include 
caveolin and actin for GRKs and clathrin for arrestins (Hepler & Saugstad, 2002). 
Interestingly clathrin is the protein coating the plasma membrane pits which pinch off 
to precipitate receptor internalisation (Hepler & Saugstad, 2002). Endocytosis can 
lead to recycling of the receptor, eventually returning it to the plasma membrane, or 
receptor degradation in lysosomal compartments. Longer term desensitisation can be 
achieved through changes in expression or stability of receptor mRNA and 
subsequent changes in receptor expression levels. This can often be a result of 
chronic drug treatment or progressive pathological states (Hepler & Saugstad, 2002).
342.  GPR10 and prolactin-releasing peptide
(i)  RF amide peptides and their receptors
RF-amides are peptides characterised by an amidated arginine-phenylalanine motif 
at their C-terminus. There are multiple non-mammalian RF-amide peptides, many 
found in annelids and molluscs, including FMRF-amide, Pol-RF-amide, ACEP-1  and 
Antho-RF-amide (Hinuma etal., 1999; Table 2). With the discovery of these peptides 
many groups sought to identify potential mammalian RF-amide peptides. The most 
well characterised mammalian RF-amides are neuropeptide-FF (NPFF) and 
neuropeptide-AF (NPAF; Yang etal., 1985), which are thought to modulate the 
central opioid system (Yang etal.,  1985; Roumy & Zajac,  1998) and possibly 
stimulate prolactin secretion (Aarnisalo etal., 1997). NPFF and NPAF are thought to 
be the cognate ligands of an orphan receptor identified as HLWAR77 (Elshourbagy 
et al., 2000; Kotani et al., 2001a) that is thought to signal through the Gj family of G 
proteins as it both stimulates the binding of the radiolabelled, non-hydrolysable form 
of GTP, [35S]GTPyS, and inhibits forskolin induced increases in intracellular cAMP 
levels in CHO cells stably expressing HLWAR77 (Kotani etal., 2001a).
More recently, Hinuma and co-workers have searched for novel RF-amide peptide 
genes in the GenBank/EMBL database (Hinuma etal., 2000). Using this method, 
they cloned 3 possible RF-amide peptide genes and isolated human, bovine, rat and 
mouse cDNAs for the peptides, designated RFRP-1  (12 aa), RFRP-2 (12 aa) and 
RFRP-3 (8 aa). Unlike RFRP-1  and -3, RFRP-2 contains a serine residue in place of 
the C-terminal phenylalanine. The C-terminus of hRFRP-1  is identical to that of the 
chicken RF-amide peptide, LPLRF-amide (Dockray etal.,  1983) and the C-terminal 4 
amino acids of hRFRR-3 identical to those in NPFF (Yang etal.,  1985), suggesting 
that these peptides all originate from a common evolutionary ancestor. By using
35Peptide Sequence
AnthoRF- amide pEGRF-CONH2
AF-2 k h e y l r f-c o n h 2
ACEP-1 s g q s w r p q g r f-c o n h 2
FLRF-amide f l r f-c o n h 2
FMRF-amide f m r f-c o n h 2
PrRP-20 t p d in p a w y t g r g ir p v g r f-c o n h 2
Kiss(107-121) k d l p n y n w n s f g l r f-c o n h 2
Kiss(112-121) y n w n s f g l r f-c o n h 2
PQRF-amide p q r f-c o n h 2
Neuropeptide FF f l f q p q r f-c o n h 2
Neuropeptide AF a g e g l n s q f w s l a a p q r f-c o n h 2
RFRP-1 m p h s f a n l p l r f-c o n h 2
RFRP-3 v p n l p q r f-c o n h 2
Neuropeptide Y y p s k p e d m a r y y s a l r h y in l it r q r y -c o n h 2
Table 2. Peptide sequences for a range of RF-amides. Adapted from Han et al. 
(2002).
36synthetic RFRP peptides as ‘bait’ to lish’ against a variety of recombinantly 
expressed orphan GPCRs, the authors suggested that RFRP-1  and RFRP-3 may be 
cognate ligands of the rat orphan GPCR, OT7T022 (Hinuma etal., 2000). RFRP-1 
and -3, but not RFRP-2, activate OT7T022 when expressed in CHO cells and act to 
inhibit forskolin stimulated levels of intracellular cAMP, suggesting coupling through 
the Gj family of G proteins. The lack of activity of RFRP-2 suggests that the presence 
of the C-terminal phenylalanine in the RF-amide peptide may be crucial to activity.
KiSS-1  is a human metastasis suppresser gene (Lee etal., 1996) that has been 
shown to encode an RF-amide peptide of 54 aa, termed metastin (Ohtaki etal., 
2001). In a similar ‘reverse pharmacology’ approach, this peptide was purified from 
human placental tissue and shown to potently stimulate intracellular calcium 
mobilisation in CHO cells stably transfected with the orphan GPCR, hOT7T175 
(Ohtaki etal., 2001). The non-amidated acid form (with C-terminal -COOH group as 
opposed to -CONH2) was approximately 1000-fold less potent at stimulating calcium 
mobilisation. These data also suggest that the amide group is key to normal metastin 
function at hOT7T175 and that this receptor may signal through the Gq/n pathway. 
Concurrent studies also identified the same 54 aa peptide from human placenta 
along with two other N-terminally truncated variants of 14 aa and 13 aa (Kotani etal., 
2001b). These peptides were termed kisspeptin-54, kisspeptin-14 and kisspeptin-13, 
respectively. In this study, the kisspeptins were shown to be equipotent agonists at 
both the human and rat orphan receptor GPR54 when stably co-expressed with Ga16 
in CHO cells (Kotani etal., 2001b). Consistent with the studies of Ohtaki etal., 
(2001), the non-amidated peptides were inactive. This same family of kisspeptins 
have also been shown to be potent agonists at another orphan receptor, AXOR12 
(Muir etal., 2001). These combined data suggest another subfamily of mammalian 
RF-amide peptides with a potential family of related kisspeptin receptors.
37Similar ‘reverse pharmacology’ studies have also shown that a number of RF-amide 
peptides can act as moderate potency surrogate agonists at the orphan GPCRs, 
MrgA1  and MrgC11, and that these receptors are likely to couple through the Gq/n 
pathway (Han et al., 2002). Further studies may help identify more potent, likely 
cognate, ligands for these receptors.
The RF-amide family of peptides and their receptors are clearly an expanding field 
and the popularity of the novel ‘reverse pharmacology’ approach will undoubtedly 
reveal further ligand-receptor pairings in the future.
(ii)  Identification of GPR10 - PrRP ligand pair
The RF-amide peptide receptors are an excellent example of the modern ‘reverse 
pharmacology’ approach, where ligands are identified from native tissue extracts or 
synthesised based on genetic sequences. These are then screened against a variety 
of orphan receptor targets, often co-expressed with a promiscuous G protein that can 
couple to any GPCR to allow signalling through the PLC-calcium pathway eg. Goci6 
(Wilson etal.,  1998).
This technique, often referred to as ‘ligand fishing’, was used to identify the RF-amide 
peptide, prolactin-releasing peptide (PrRP), as the cognate ligand of the orphan 
receptor, GPR10.
GPR10 is a novel 370 aa GPCR identified by polymerase chain reaction and 
genomic DNA library screening (Marchese etal., 1995). It is the human orthologue of 
rat Unknown Hypothalamic Receptor-1  (UHR-1; Welch etal., 1995) and shares the 
highest level of homology with the neuropeptide Y receptor family (31% overall, 46% 
in the transmembrane domains; Marchese etal., 1995). A receptor termed hGR3 
(Hinuma etal.,  1998) is identical at the amino acid level to GPR10. The same
38authors used a similar ligand fishing’ approach as above to identify potential ligands 
for hGR3/ GPR10.
Ligand identification for the receptor was carried out utilising an arachidonic acid 
release assay using Chinese hamster ovary (CHO) cells stably transfected with 
hGR3 / GPR10, in which bovine hypothalamic extracts were positive.
Chromatographic purification of the extracts led to the identification of a human 
preproprotein cDNA encoding 87 aa and rat and bovine orthologues. The N-terminal 
portion of the cDNA displayed the typical profile of a secretory signal peptide, which 
left two peptide sequences with identical C-terminal regions, one of which appears to 
be a truncated form of the other (Hinuma etal., 1998). Studies showed that the PrRP 
preproprotein can be cleaved at two different positions to give rise to two forms of 31 
or 20 aa; PrRP-31  and PrRP-20 respectively. Rat and bovine PrRPs have also been 
identified and occur as 31  or 20 aa forms; these peptides are highly conserved 
between species (Figure 3; Hinuma etal.,  1998).
Human  :   SR0H0HSMEIRTPDINPAWYA0RGIRPVGRF  :   31
Rat  :   SRAHQHSME0RTPDINPAWY0GRGIRPVGRF  :   31
Bovine  :   SRAHQHSMEIRT  PDINPAWYAGRGIRPVGRF  :   31
T  T
PrRP-31  PrRP-20
Figure 3. Alignment of the amino acid sequences of human, rat and bovine prolactin 
releasing peptide. Arrows indicate the N-termini of the two isoforms of the peptides, 
PrRP-31  and PrRP-20. Amino acid residues that differ from the consensus sequence 
are shaded. Sequence homology with human PrRP-31  is 84% (rat) and 90%
(bovine).
39(iii)  Expression profile of PrRP and GPR10
Studies using reverse transcriptase PCR in rat brain tissue have detected PrRP 
mRNA in the medulla oblongata, with moderate levels in the hypothalamus (Table 3; 
Hinuma etal., 1998; Fujii etal., 1999). In situ hybridisation studies in rat brain have 
also detected PrRP mRNA in neurones of the nucleus of the tractus solitarius (NTS), 
the ventral and lateral reticular nuclei (VLRN) of the medulla and the dorsomedial 
hypothalamus (DMH). The strongest hybridisation was observed in the NTS (Lee et 
al., 2000; Maruyama etal.,  1999; Minami etal., 1999; Roland etal.,  1999; Ibata et 
al., 2000). Peripherally, PrRP mRNA has been detected in the adrenal gland, 
pancreas, placenta and testis (Fujii etal., 1999; Nieminen etal., 2000).
PrRP immunoreactivity has been detected by enzyme immunoassay, in rank order of 
high to low expression levels, in rat hypothalamus, midbrain, pituitary, medulla, 
adrenal gland and plasma (Table 3; Matsumoto etal.,  1999). Studies using 
radioimmunoassay also detected PrRP in the human hypothalamus and to a lesser 
extent in the medulla (Takahashi etal., 2000). These assay methodologies detect 
bioactive PrRP and, in agreement with studies determining arachidonic acid release 
with tissue extracts (Hinuma et al., 1998), suggest that the hypothalamus contains 
the highest levels of PrRP, despite the greater amount of mRNA being found in the 
medulla.
Immunohistochemical studies have also detected PrRP in the NTS, VLRN, DMH and 
pituitary of the rat brain (Chen etal., 1999; Maruyama etal., 1999; Yamakawa etal., 
1999; Matsumoto etal., 1999). The distribution of PrRP in the NTS and VLRN was 
also shown to be co-localised with tyrosine hydroxylase, suggesting that PrRP was 
present in noradrenergic neurones (Chen etal.,  1999). Given that the hypothalamus 
contains the highest reported levels of bioactive PrRP, it is possible that PrRPs
40mRNA
PrRP
Protein
GPR10/UHR-1 
mRNA  Protein
Medulla Hypothalamus Pituitary Thalamus
Hypothalamus Midbrain Cerebellum Hypothalamus
NTS Pituitary Hypothalamus NTS
DMH Medulla Thalamus Area postrema
VLRN PVN Spinal cord
BST Adrenal gland
Table 3. Summary of distribution of PrRP and GPR10 / UHR-1  mRNA and protein. 
Data are taken from Hinuma etal., 1998; Fujii etal.,  1999; Lee etal., 2000; 
Maruyama etal., 1999; Minami etal., 1999; Roland etal., 1999; Ibata etal., 200; 
Nieminen etal., 2000; Matsumoto etal., 1999; Takahashi etal., 2000; Chen etal., 
1999; Maruyama etal., 1999; Yamakawa etal.,  1999; Welch etal., 1995; Ellacott et 
al., 2005.
41produced in the cell bodies of the NTS (where PrRP mRNA is most prominent) are 
transported to the hypothalamus. PrRP has also been detected in the paraventricular 
nucleus (PVN) and the bed nucleus of the stria terminalis (BST), suggesting more 
varied CNS roles for PrRPs.
The literature on distribution of GPR10 or UHR-1  is scarcer than that for PrRP. The 
mRNA for the UHR-1, as determined by RT-PCR, is expressed in rat pituitary, 
cerebellum and hypothalamus (Table 3; Welch etal., 1995), although other studies 
have also observed mRNA in thalamus, spinal cord, and adrenal gland (Hinuma et 
al., 1998; Roland etal., 1999). In contrast, early autoradiographic studies with [125l]- 
hPrRP-31  have shown receptor binding only in thalamus and hypothalamus in the rat 
brain (Table 3; Roland etal., 1999), with more recent studies showing specific 
binding of [125l]-hPrRP-20 in the NTS and area postrema (Ellacott etal., 2005). Other 
studies have detected levels of specific binding of [125l]-hPrRP-31  in membranes 
prepared from rat hypothalamus, medulla, pituitary and cerebellum and also heart, 
soleus muscle, adipose tissue, kidney, adrenal gland, testis and small intestine 
(Satoh etal., 2000). These data suggest that binding sites for PrRP may be widely 
expressed in both the brain and the periphery, in common with a number of 
suggested roles for PrRP including stress responses, cardiovascular regulation and 
food intake.
Interestingly, analysis of the binding sites of [125l]-hPrRP-31  by chemical cross-linking 
suggested a binding site of Mw = 69,000 in hypothalamus, but of only 41,000 in heart 
and soleus muscle (Satoh etal., 2000). The size of the binding site in hypothalamus 
is far in excess of that predicted from the sequence of UHR-1  (Mw = 41,165) and is 
probably due to differences in receptor glycosylation (Satoh etal., 2000). The size of 
the binding site in heart and soleus muscle suggests either a non-glycosylated form 
of UHR-1, or more likely a truncated or cleaved form of UHR-1. This phenomenon
42has been suggested in a recent publication on the anorectic effect of PrRP-31  in rats, 
where a polymorphism in the putative translational initiation site of UHR-1  results in 
an ATG to ATA change, potentially resulting in a truncated receptor with translation 
starting at a later in-frame start codon (Ellacott etal., 2005). In rats expressing the 
polymorphism, PrRP-31  still evoked an anorectic response (see below), although 
there was no specific binding of [125l]-hPrRP-20 in brain slices from these animals, 
unlike in slices from rats expressing non-polymorphic UHR-1  (Ellacott etal., 2005). It 
is possible that an alternative receptor for PrRP exists (data from Welch et al. (1995) 
suggested that UHR-1  may one of a family of receptors). However, PrRP may simply 
be binding elsewhere in the brain with its detection being missed due to low cell 
surface expression or because it is beyond the limits of film autoradiography.
(iv)  Physiological function of PrRP and GPR10
Hinuma etal. (1998) demonstrated that bovine PrRP-31, in a rat pituitary adenoma 
derived cell line which had been shown to express UHR-1  mRNA, caused prolactin 
secretion in a concentration-dependent manner. Similarly,  PrRP-31  stimulated 
prolactin secretion from anterior pituitary cells harvested from lactating female rats 
with a similar potency to that of thyrotropin releasing hormone (TRH), a hormone that 
is already known to stimulate prolactin secretion (Lamberts & Macleod,  1990). PrRP- 
31  did not alter the release of other anterior pituitary hormones (growth hormone, 
follicle stimulating hormone, lutenising hormone, thyroid stimulating hormone and 
adrenocorticotropin) and stimulated prolactin secretion in a perifusion assay protocol 
within 15 min to 1  h of application. These data suggested that the effect of PrRP-31 
on prolactin release was both selective and direct and led to the naming of the 
peptides as ‘prolactin releasing peptides’ or PrRP. Subsequently, the same group 
demonstrated the prolactin-releasing effects of PrRPs in vivo (Matusmoto etal., 
1999). However, many recent studies have questioned the role of PrRPs as
43physiological prolactin releasing agents, suggesting stimulation of prolactin release 
with PrRP only occurs, if at all, at pharmacological concentrations (Samson etal., 
1998; Jarry etal., 2000; Curlewis etal., 2002). Morphological studies further question 
the role of PrRPs in prolactin release, suggesting the absence of PrRP in the external 
lamina of the median eminence, an area of the hypothalamus where recognised 
releasing and inhibiting factors of hypothalamic origin gain access to the hypophysial 
portal vasculature and the anterior lobe (Taylor & Samson, 2001).
Since the initial claim of prolactin releasing effects, a large number of alternative 
functions for PrRP have been suggested, largely based on the varied CNS 
distribution of the peptide. Based on the expression of PrRP in the DMH, one of the 
suggested roles for PrRP is in food intake and body weight regulation.  Lawrence et 
al. (2000) provided evidence to suggest that the number of PrRP mRNA containing 
neurones was dramatically reduced in the DMH and NTS of both fasting and lactating 
rats, both states of negative energy balance. This effect was coupled by a reduction 
in food, but not water, intake in rats dosed with intracerebroventricular (i.c.v.) PrRP 
(Lawrence etal., 2000). This effect was independently verified (Seal etal., 2001), but 
also shown to diminish after repeated dosing with PrRP (Ellacott etal., 2003), 
suggesting a short term effect on energy balance. Furthermore, the GPR10 knockout 
mouse displays a hyperphagic and obese phenotype (Gu etal., 2004). These data 
strongly suggest that PrRP acts centrally to inhibit food intake.
In common with a number of other neuropeptides, PrRP has also been shown to 
interact with leptin to regulate energy homeostasis, as i.c.v. injection of PrRP with 
leptin produces an additive anorectic effect (Ellacott etal., 2002). PrRP has also 
been shown to increase the release of neurotensin and a-melanocyte-stimulating 
hormone from a hypothalamic explant culture (Seal etal., 2001). Both of these 
transmitters are known inhibitors of food intake, suggesting a possible indirect effect
44of PrRP on food intake. However, the effects of PrRP on food intake are not blocked 
by the melanocortin receptor-3/4 antagonist, SHU-9119, but are blocked by the 
corticotropin-releasing hormone (CRH) receptor antagonist astressin (Lawrence et 
al., 2004). Finally, studies in humans found no significant association between a 
GPR10 coding polymorphism (P305L) and obesity parameters, although the same 
study suggested that the polymorphism has only a small effect on receptor function in 
vitro (Bhattacharyya et al., 2003). Taken as whole, these data strongly suggest that 
PrRP inhibits food intake in rodents, although the precise mechanism of action 
remains to be fully determined.
There is also evidence that PrRP modulates the hypothalamic-pituitary-adrenal axis 
as a stimulator of CRH neurones in the PVN (Matsumoto etal., 2000). Administration 
of PrRP into the PVN results in increased plasma adrenocorticotropic hormone (Seal 
etal., 2002) and centrally administered PrRP-31  causes increased plasma 
corticosterone levels (Samson etal., 2003). This effect was blocked with anti-serum 
to CRH, but not by a-helical CRH(9-41), suggesting PrRP acts not only on CRH- 
producing neurones, but also on other adrenocorticotropic hormone secretagogues 
such as oxytocin or vasopressin, as proposed previously (Maruyama etal., 1999). 
These data suggest a role for PrRP in mediating responses to stressors. Additionally, 
noradrenergic fibres in the medulla have been shown to mediate stress responses in 
the CNS and PrRP has been shown to co-localise with tyrosine hydroxylase in these 
neurones (Chen etal.,  1999). Foot-shock, haemorrhage and conditioned fear stimuli 
have also been shown to activate PrRP neurones in the medulla (Morales & 
Sawchenko, 2003; Zhu & Onaka, 2003), further implicating PrRP as playing a role in 
mediating stress responses.
The localisation of PrRPs in regions of the brainstem such as the NTS, the 
ventrolateral medulla and the area postrema suggest a possible involvement in
45cardiovascular regulation. Central administration of PrRP-31  in the rat has been 
shown to produce a profound increase in mean arterial blood pressure (Samson et 
al., 2000), an effect that was independently verified and also shown to be dose- 
dependent (Horiuchi etal., 2002). Furthermore, in genetic studies in humans, the 
GPR10 polymorphism, P305L, was shown to be associated with significantly lower 
blood pressure (Bhattacharyya etal., 2003). Additionally, other roles have been 
suggested for PrRPs including regulation of sleep (Zhang etal., 2000), the lutenising 
hormone surge (Hizume etal., 2000; Watanobe, 2001) and growth hormone 
regulation (lijima etal., 2001; Rubinek et al., 2001).
In summary, the varied expression profiles described for PrRPs and their receptor 
has led to a wide range of investigations into the physiological roles of PrRPs beyond 
the initial description of them as prolactin releasing factors. There now seems to be 
substantial evidence to implicate PrRPs as having roles in food intake, stress 
responses and possibly cardiovascular regulation.
463.  Muscarinic Mi acetylcholine receptors
(i)  Nicotinic and muscarinic acetylcholine receptors
In 1914, Henry Dale classified two types of pharmacological activity mediated by the 
chemical transmitter, acetylcholine (ACh), as muscarinic and nicotinic. Muscarinic 
activity was the activity of ACh that could be replicated by muscarine, the active 
agent found in the poisonous mushroom Amanita muscaria and could then be 
blocked by low concentrations of atropine. Muscarinic activity corresponds closely to 
that of ACh released at postganglionic parasympathetic nerve endings (except ACh- 
mediated generalised vasodilatation and secretion from sweat glands; Rang etal., 
1999). After blockade of muscarinic receptor activity with atropine, large doses of 
ACh mediate effects similar to those observed with nicotine, including stimulation of 
autonomic ganglia and voluntary muscle and secretion of adrenaline from the adrenal 
medulla. These nicotinic effects correspond to ACh acting on autonomic ganglia of 
the sympathetic and parasympathetic nervous systems, the neuromuscular junction 
and secretory cells of the adrenal medulla (Rang et al.,  1999).
Acetylcholine receptors are now broadly defined along the divide established 
pharmacologically by Dale. Nicotinic ACh receptors are ligand gated ion channels, 
whereas muscarinic ACh receptors are GPCRs.
Nicotinic ACh receptors (nAChR) consist of two broad subtypes, the neuromuscular 
and neuronal nAChRs (Colquhoun etal.,  1987). The neuromuscular receptor is a 
pentameric structure made up of four subunits (aa(3ye in human;  Rang etal.,  1999), 
whereas the neuronal nAChR is more varied, especially in the brain, consisting of 
various permutations of eight different a-subunits and four p-subunits (McGehee & 
Role,  1995). Neuromuscular and neuronal nAChRs can be distinguished 
pharmacologically -  decamethonium and epibatidine are potent and subtype 
selective neuromuscular and neuronal nAChR agonists, respectively, whereas
47a-bungarotoxin and mecamylamine are respective selective nAChR receptor 
antagonists (Rang etal., 1999).
In the periphery, muscarinic receptor agonists mediate smooth muscle contraction, 
glandular secretions and the modulation of heart rate and force of contraction 
(Caulfield & Birdsall., 1998). In the CNS, muscarinic receptor agonists are thought to 
be involved in motor control, temperature regulation, cardiovascular regulation and 
memory (Caulfield & Birdsall, 1998).
(ii)  Characterisation of muscarinic receptor subtypes
The first evidence of the existence of more than one muscarinic ACh receptor 
subtype was the relatively selective actions of gallamine on the heart (Riker & 
Wescoe, 1951). Subsequently Barlow etal. (1976) demonstrated that there were 
significant differences in the pharmacology of muscarinic receptors in atrial and ileal 
tissue. Together with the development of pirenzepine, a muscarinic receptor 
antagonist which shows a limited degree of selectivity for the Mi  receptor subtype 
(Hammer etal., 1980; Brown etal., 1980), researchers concluded that there were at 
least three pharmacologically defined muscarinic receptor subtypes (Birdsall & 
Hulme,  1983). These receptor subtypes, now known as Mi, M2 and M3, are 
sometimes still referred to by the tissue type in which they are predominantly 
expressed, namely ‘neural’, ‘cardiac’ and ‘glandular’ muscarinic receptors. Given that 
the most pronounced pharmacological differences were seen between the 
muscarinic receptor population in the forebrain and the heart, it was from porcine 
receptors in these tissues that the first partial amino acid sequences for the 
muscarinic receptors were derived (Haga & Haga, 1983; Peterson etal.,  1984). This 
led to full length cloning of the respective cDNAs for the Mi and M2 muscarinic 
receptors (Kubo etal.,  1986a; Kubo etal., 1986b), which was rapidly followed by the 
cloning of a further three muscarinic receptor subtypes, namely M3,  M4 and M5
48(Bonner etal., 1987; Bonner etal., 1988).  All five genes encode proteins that have 
similar structural features suggesting they are members of the seven transmembrane 
domain GPCR superfamily. There is a significant degree of homology between 
muscarinic receptor subtypes (Hulme etal.,  1990) and sequences are highly 
conserved across mammalian species (Ellis, 2002).
(iii)  Expression profile and physiological role of muscarinic Mi receptors
Subsequent to the cloning of the muscarinic receptor family, the distribution of the 
five members has been extensively characterised. Indeed, it was the 
pharmacological differences between muscarinic receptors found in brain, heart and 
ileum that first suggested the presence of more than one muscarinic receptor 
subtype. All five subtypes are expressed in the brain (Ellis, 2002), although the Mi 
receptor subtype predominates in the forebrain regions (cortex, hippocampus, 
striatum and thalamus) with higher levels of M2 receptor in the brainstem and 
cerebellum. The M4 receptor is found in many brain regions, but mostly in the 
striatum, whereas the M3 and M5 receptor subtypes are only expressed at very low 
levels, although the M5 receptor subtype does have a very discrete localisation in the 
substantia nigra (Ellis, 2002). Peripherally, the Mi  receptor is also localised in 
glandular tissues. The M2 receptor subtype is strongly expressed in the heart, but 
also in smooth muscle and lung, whereas the M3 receptor subtype is localised mainly 
to smooth muscle and glandular tissues (Ellis, 2002). The M4 and M5 receptor 
subtypes appear to be only expressed peripherally at very low levels, if at all, 
although the M4 receptor subtype is highly expressed in rabbit lung (Lazareno etal., 
1990), although not in the lung tissue of other species (Zaagsma etal., 1997).
49Receptor subtype
M1 m2 M3 m4 Ms
Preferred 
G protein(s)
G q /11 G i/o G q /1 1 G j/o G q /1 1
Second
messenger(s)
PLC; 
IP3 /DAG; 
Ca2+/ PKC
Adenylyl
cyclase
(inhibition)
PLC; 
IPs/DAG; 
Ca2+/ PKC
Adenylyl
cyclase
(inhibition)
PLC; 
IP3 /DAG; 
Ca2+/ PKC
Expression
profile
Cortex,
hippocampus
Heart Smooth
muscle
Basal
forebrain
Substantia
nigra
Glands Hindbrain Glands Striatum
Sympathetic
ganglia
Smooth
muscle
Brain
Functional
Response(s)
M-current
inhibition
K+ channels 
(py activates)
Inhibit Ca2+ 
channels
I Heart rate 
and force
i Neuro­
transmitter 
release 
(presynaptic)
Smooth
muscle
contraction
Gland
secretion
1  Neuro­
transmitter 
release 
(presynaptic)
Inhibit Ca2+ 
channels
’
Table 4. Signal transduction, distribution and physiological function of muscarinic 
acetylcholine receptor subtypes.
50The physiological functions of the Mi receptor tie in well with its localisation. Mi 
receptors are thought to generate slow excitatory post-synaptic potentials in the 
forebrain regions by inhibition of a K+ current, termed the M-current (lM ) due to its 
control by muscarinic receptor agonists. Hence, mice lacking the Mi  receptor gene 
display loss of inhibition of \M  (Hamilton etal., 1997). Other notable phenotypes 
include reductions in long term potentiation in the hippocampus (Ellis, 2002), 
impaired performance in spatial memory tasks (Anagnostaras etal., 2003) and a loss 
of muscarinic receptor agonist induced mitogen-activated protein (MAP) kinase 
activity in the cortex (Veinbergs etal., 2003). These observations strongly suggest 
that the Mi  receptor plays a role in learning and memory processes within the CNS. 
Indeed, the selective loss of cholinergic neurones in the basal forebrain seen in 
Alzheimer’s disease is accompanied by severe cognitive deficits (Ellis, 2002).
(iv)  Muscarinic Mi receptor signalling & pharmacology
The signal transduction mechanisms of muscarinic receptors have been extensively 
studied. In general, the ‘odd-numbered’ receptors, namely M^ M3 and M5, have been 
shown to couple via the Ga subunits of the Gq/n family to stimulate phospholipase-Cp 
(PLCp) mediated conversion of phosphatidyl inositol 4,5-bisphosphate (PIP2) into 
inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 then binds to its cognate 
receptor in the membrane of the smooth endoplasmic reticulum to cause the release 
of intracellular calcium (Caulfield,  1993; Caulfield & Birdsall,  1998; Ellis, 2002). In 
contrast, the ‘even-numbered’ receptors, M2 and M4, preferentially couple via the Gj 
family to inhibit adenylyl cyclase (AC) and reduce the intracellular concentration of 
cAMP (Caulfield,  1993; Caulfield & Birdsall, 1998; Ellis, 2002). This coupling of the 
M2 and M4 receptors is sensitive to PTX treatment, which ADP ribosylates both Gaj 
and Goto.
51However, with the discovery of more complex signal transduction pathways, 
signalling  via G(3y subunits, cross-talk between receptor subtypes and even G protein 
independent signalling, the transduction pathways mediated  via muscarinic receptors 
are now known to be diverse (Ellis, 2002). In addition to its release of calcium from 
intracellular stores, the Mi  receptor has been shown to stimulate a range of other 
effector systems, including arachidonic acid release (Conklin etal.,  1988), 
phospholipase-D (Ellis, 2002) and the MAP kinase cascade (Berkeley etal., 2001).
Additionally, muscarinic receptors have been shown to modulate a variety of ion 
channel conductances in the CNS. In fact a neuronal potassium current has been 
termed the M-current (lM ), because it was inhibited by muscarinic receptor agonists 
(Brown & Adams,  1980). In recombinant cell studies, Gq/n coupled receptors reduce 
lM  in a manner that suggests a diffusible second messenger mediated inhibition 
(Robbins etal.,  1993); recent studies suggest that depletion of membrane 
phosphatidylinositol bisphosphate (PIP2) may be involved (Suh & Hille, 2002). 
Pharmacological studies on lM  in the superior cervical ganglion (SCG) suggest that 
the current may be inhibited  via the M!  receptor (Bernheim et al,  1992); this 
observation was seemingly confirmed by studies which showed the absence of 
muscarinic receptor agonist induced inhibition of lM  in the Mi  receptor knockout 
mouse (Hamilton etal., 1997). The Mi  receptor has also been shown to inhibit N-type 
and L-type calcium currents in the SCG, an effect that is insensitive to PTX and has a 
slow time course consistent with a diffusible second messenger mediated inhibition 
(Ellis, 2002). These effects were also shown to be absent the Mi  receptor knockout 
mouse (Shapiro et al., 2001). Muscarinic receptors also mediate fast inhibition of N- 
and P/Q-type calcium channels, but this effect has been shown to be PTX sensitive 
and is absent in the SCG of M2 knockout mice (Shapiro etal., 2001), suggesting that 
it is this subtype that mediates the inhibition.
52There is a wide array of pharmacological tools with which to study populations of 
muscarinic receptors.  A/-methyl scopolamine (NMS), quinuclidinylbenzilate (QNB), 
pirenzepine and darifenacin amongst muscarinic receptor antagonists and ACh and 
oxotremorine-M amongst muscarinic receptor agonists have been radiolabelled and 
extensively used to characterise muscarinic receptors. Unfortunately, most of the 
pharmacological tools available show low levels of selectivity (often 10-fold or less) 
between the muscarinic receptor subtypes (Caulfield & Birdsall,  1998; Ellis, 2002). 
This is primarily due to the high level of conservation amongst the residues forming 
the orthosteric binding site of muscarinic receptors, which prevents the design of 
subtype selective agonists and antagonists. Given the mixed muscarinic receptor 
population in most tissues and the relative lack of selectivity amongst radioligands 
and other reagents, a large amount of pharmacology has been carried out in 
recombinant cell lines stably expressing single subtypes of muscarinic receptors.
(v)  Characterisation of the muscarinic A /h  orthosteric binding site
As discussed earlier, the elucidation of the crystal structure of rhodopsin has 
increased the understanding of the structure of family A GPCRs (Section 1, iv). One 
of the best studied in this regard has been the muscarinic Mi  receptor. The . 
orthosteric binding site of aminergic family A receptors comprises a network of 
residues in the TM bundle including residues from TM3, TM4, TM5, TM6 and TM7 
(Gether, 2000;  Kristiansen, 2004).
Studies using [3H]ACh mustard (an analogue of ACh that both activates and 
covalently binds to muscarinic receptors) have shown that the conserved Asp residue 
in TM3 (D105 in both rat and human IVh  receptors) is the primary site of interaction 
for the amine group of ACh (Spalding etal.,  1994). Further studies using both point 
and scanning mutagenesis have comprehensively identified the residues that are
53involved in the binding of ACh and atropine-like muscarinic receptor antagonists such 
as NMS. The amine headgroup of ACh interacts with D105; even the conservative 
D105E mutation reduces ACh potency 1000-fold (Hulme etal., 1995) and strongly 
reduces the high agonist affinity component of agonist binding (Page etal.,  1995). 
This interaction is thought to be stabilised by contacts with Y404, C407 and Y408 in 
TM7 of the rat Mi  receptor. The mutations Y404A and Y404F both reduce ACh 
binding affinity, but only Y404A reduces the maximal phosphoinositide response (Lu 
etal., 2001). Similar results were seen for Y408 (Lu etal., 2001). These data suggest 
it is the hydroxyl group that is involved in the binding of agonist, but it is the aromatic 
moiety that is involved in receptor activation. Two tyrosine residues in TM2, Y82 and 
Y85 in the rat Mi  receptor, are close to D105, Y404 and Y408 and have been 
implicated in agonist binding and receptor activation. Loss of the hydroxyl group 
alone, or in combination with the aromatic ring, reduces the affinity of the ACh 
analogue, carbachol and its potency to stimulate phosphoinositide hydrolysis (Lee et 
al.,  1996).
ACh is also thought to interact with residues in TM6, including W378 and Y381. The 
mutation Y381F reduces ACh potency ~70-fold; Y381A reduces the potency -3000- 
fold, suggesting that this tyrosine residue plays a major role in receptor activation 
(Ward etal.,  1999).
The ammonium headgroup of NMS has also been shown to interact with D105,
Y381, Y404 and Y408 (Lu etal., 2002), but NMS is a larger molecule than ACh and 
hence the phenyl ring is thought to plunge deep into the TM bundle between TM3, 
TM5 and TM6 (Lu etal., 2002). Some studies have suggested that N382 in TM6 is 
involved in antagonist binding alone (Huang et al.,  1999), although loss of this 
asparagine has been shown to markedly reduce agonist potency (Ward etal.,  1999; 
Spalding etal., 2002).
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Figure 4. NMS (A) and ACh (B) docked into a homology model of the muscarinic Mi 
receptor showing the proximity of the amino acid residues in TM3, TM6 and TM7 that 
have been implicated in their binding (figure taken from Hulme etal., 2003).
55Both NMS and ACh have been docked into a homology model of the muscarinic Mt 
receptor (Hulme et al., 2003) which shows their close proximity to amino acids in 
TM3, TM6 and TM7 (Figure 4). The smaller ACh molecule is also thought to interact 
with residues towards the top of TM5 and TM6, mutation of which affect ACh, but not 
NMS binding. Mutation of T192 in TM5 reduces both ACh potency and affinity, with 
no effect on antagonist binding (Huang etal.,  1999). Similarly, loss of L386 in TM6 
reduces ACh affinity, potency and efficacy (Huang etal., 1999).
There are also thought to be key residues more extracellular to the main interaction 
site of ACh and NMS that facilitate the access of these diffusible ligands into the TM 
bundle. Mutation of W157 in TM4 causes a large decrease in [3H]NMS binding and 
ACh signalling efficacy (Lu etal.,  1999) as well as ACh affinity (Hulme etal., 2003). 
This residue is very close to the exofacial acidic residue in TM3 that is adjacent to the 
cysteine residue that forms a disulphide bridge with another cysteine in the second 
extracellular loop (Lu etal. 2002). This configuration is thought to facilitate the access 
and egress of ligands to the deeper binding site.
The invariant arginine residue (R123) at the base of TM3 found in all family A GPCRs 
(part of the DRY motif), is key to receptor activation -  all mutations which result in a 
loss or reversal of charge at this position drastically reduce ACh potency in 
phosphoinositide hydrolysis assays (Hulme etal., 1995). However, a range of other 
residues have been implicated in activation of the Mi  receptor, including D71  (TM2; 
Fraser etal.,  1989), N414,  P415 and Y418 (all TM7; Lu etal., 2001). These latter 
residues form part of a conserved NSxxNPxxY motif which is thought to form 
intramolecular interactions to hold the receptor in the ground state; upon agonist 
binding these interactions are broken and new intramolecular bonds are made to 
hold the receptor in the active state (Lu etal., 2001).
56The residues implicated in the binding of ACh and NMS are highly conserved across 
the muscarinic receptor family (Figure 5). The consequence of this conservation, as 
discussed earlier, is difficulty in distinguishing between receptor subtypes with 
pharmacological tools directed against the orthosteric binding site. It is likely that any 
pharmacological selectivity is probably achieved through allosteric ligand 
interactions, such as is observed for the non-competitive selective Mi  receptor 
peptide antagonist, muscarinic toxin (MT)-7 (Mourier etal., 2003) and the recently 
described novel Mi  receptor agonist, AC-42 (Spalding etal., 2002; see Chapters 5 
and 6).
57*  20  *  40  *  60  *  80  *  100
hMl  :   --------------------------------------------------------MNTSAPP-AVS  PNITVLAPGKGPWQVAFIGITTGLLSLATVTGNLLVL  :   47
hM2  :   --------------------------------------------------MNNST  NSSNNSLAL-TSP  YKTFEWFIVLVAGSLSLVTIIGNILVM  :   45
hM3  :   MT  LHNN  S  T  T  S  PLF  PNIS  S  SWIH  S  PS  DAGL  P  PGT  VT  HF  GSYNVS  RAAG-------NFSSPD-GT— TDDPLG-GHTVHQWFIAFLTGILALVTIIGNILVI  :   90
hM4  :   --------------------------------------------------MANFTPVNGSSGNQSVRLVTSS  SHNRYETVEMVFIATVTGSLSLVTWGNILVM  :   54
hMS  :     ‘ ----- --- ------------ MEGDSYHNATTVN-GTPVNHQPLE-RHRLWEVITIAAVTAWSLITIVGNVLVM :   52
120 140
hMl  :   ISFKVNTELKTVNNYFLLSLACABLIIGTFSMNI 
hM2  :   VSIKVNRHLQTVNNYFLFSLACA«LIIGVFSMN] 
hM3  :   vsfkvnk ql kt vnn yf lls la caIli ig vis mn:  
hM4  :   ls ik vnr ql qt vnn yf lfs la caIliigafsmnj 
hM5  :   ISFKVNSQLKTVNNYYLLSI*ACaJlIIGIF  SMN]
LMGHWALGTLACDLWLAI 
VIGYWPLGPWCDLWLAI 
triMNRWALGNLACDLMLAlS 
IKGYWPLGAWCDLWLAI 
LMGRWALGS  LACDL1HLALB
/ASNASVMNLLLISFI 
fSNASVMNLLIISFI 
fVASNASVMNLLVISFI 
fWSNASVMNLLII  SFI 
/ASNASVMNLLVISFI
180  *  200 
H fs vt rpl sy ra krt pr raa lm igl
H F CVTKELTYPVKRTTKMAGMMIAA 
HFSITRELTYRAKRTTKRAGVMIGL 
H F CVTKPLTYPARRTTKMAGLMIAA 
HF  SITR  ELTYRAKRTPKRAGIMIGL
148
146
191
155
153
hMl AWLVSFVL
hM2 AKTVLSFIL
hM3 AWVISFVL
hM4 AWVLSFVL
hM5 AWLISFIL
220  *  240  *  260  *  280  *  300
U?AILFWQYLVGERTVLAGQCYIQFLSQPIITFGTAMAAFYLPVTVMCTLYWRIYRETENRARELAALQGSET  PGKGGGSSSSSERSQPGAE  :   24  9 
^PAILFHQFIVGVRTVEDGECYIQFFSNAAVTFGTAIAAFYLPVIIMTVLYWHISRASKSRIKKDKK-EPVANQDPVS  PSLVQGRIVKPN-N  :   245 
^PAILFBQYFVGKRTVPPGECFIQFLSEPTITFGTAIAAFYMPVTIMTILYWRIYKETEKRTKELAGLQASG— TEAETENFVHPTGSSRSC :   290 
^PAILFWQFWGKRTVPDNHCFIQFLSNPAVTFGTAIAAFYLPWIMTVLYIHISLASRSRVHKHRP-EGPKEKKAKTLAFLKS  PLMKQSVK  :   255 
( lPAILCHQYLVGKRTVPLDECQIQFLSEPTITFGTAIAAFYIPVSVMTILYCRIYRETEKRTKDLADLQGSDSVTKAEKRKPAH-RALFRSC  :   253
hMl
hM2
hM3
hM4
hM5
*  320  *  340  *  360  *  380  *  400
GSPETPPGRCCRCCR  ■ -   A :   265
NNMPSSDDG-LEHNKIQNGKAPRDPVTENCVQGEEKESSNDSTS  —       V  :  289
SSYELQOQSMKRSNRRKYGRCHFWFTTKSWKPSSEQMDQDHSSSDSWNNNDAAASLENSASSDEEDIGSETRAIYSIVLKLPGHSTILMSTKLPSSDNLQV :   391
KPRPGGRPGGLRNGKLEEAPPPALPPPPRPVA— DKDTSNESSS  G :  298
--LRCPRPTLAQRERNQAS  WSSSRRSTSTTGKPSQATGPSANWAKAEQLTTCSSYPSSEDED-KPATDPVXQWYKSQGKES  PG-EEFSA :  339
*  420  *  440  *  460  *  480  *  500
hMl  :   PRLLQAYStJKEEEEEDEGSMESLTSSEGEE-  PGSE— WIKMPM-VDPEA-QAPTKQPPRSSPNTVKRPTKKGRDRA  GKGQKPRGKEQLAKRKTFSLV  :  358
hM2  :   SAVASNMRDDEITQDENTVSTSLG  HSKDEN— SKQTCIRIGTKT  PKSDSCTPTNTTVEWGSSGQNGDEKQNIVARKIVKMTK-QPAKKKPPP-  S  :   380
hM3  :   PEEELGMVDLE-RKADKLQAQKSVDDGGSF-  PKSFSKLPIQLE  SAVDTAK-TSDVNSSVGKSTATLPLSF  KEAT  —   LAKRFALKTRSQITKRKRMSLV  :  484
hM4  :   SAT-QNTKERPATELSTTEATTPAMPAPPLQPRALNPASRWSKIQIVTKQ-TGNECV  TAIEIVPATEAGMRPAAN-VARKFASIARNQVRKKRQMA-A  :  392
hM5  :   EETEETFVKAETEKSDYDTPNYLLSPAAAHRPKSQKCVAYKFRLWKADG-NQETNNGCHK-VKIMPCPFPVAKEPS  TKGLNPNPSHQMTKRKRWLV  :  435
520
hMl  :   KEKKAARTLSAILLAFILTHTPj 
hM2  :   REKKVTRTILAXLLAFIITWAPj 
hM3  :   KEKKAAQTLSAILLAFIITHTPl
hM4  :   RERKVTRTIFAILLAFILTHTPl
hM5  :   KERKAAQTLSAILLAFIITWTP|
540
STFCKDCVPETLKtEL 
NTFCAPCIPNTVWTI 
TFCDSCIPKTF13NL 
TFCQSCIPDTVBSI 
STFCDKCVPVTLWHL
LCQlNSTI
*  580  *  600
CNKAFRDTFRLLLLCRWDKRRWRK-IPKRPGSV--- HRT :   455
CNAT  FKKTFKHLLMCKYKNI  GAT  R--------------   :   4  66
LCNKTFRTTFKMLLLCQCDKKKRRKQQYQQRQSVIFHKRA  :   585
iCNATFKKTFRHLLLCQYRNIGTAR--------------   :   47  8
XCNRTFRKTFKMLLLCRWKKKKVEEKLYWQGNS-----KL :   531
hMl  : PSRQC 460
hM2  : --------------- -
hM3  : PEQAL 590
hM4  : --------------- -
hM5  : P---- 532
Figure 5. Alignment of the amino acid sequences of the five cloned human 
muscarinic acetylcholine receptors (hIVh - M5 ). Red shading indicates the residues 
implicated in the binding of orthosteric ligands that are fully conserved across all five 
subtypes; lighter shading indicates residues that are conserved in 4 out of 5 
subtypes. The invariant DRY motif of family A GPCRs is labelled in blue.
58(vi) Allosterism at GPCRs
The concept of allosterism was first introduced into the field of enzymology (Monod et 
al.,  1963) where enzymes were described as containing a number of topographically 
distinct binding sites in addition to the primary substrate binding site. The site on a 
GPCR analogous to the substrate binding site of an enzyme is the orthosteric site 
that binds the endogenous ligand for that receptor (Christopoulos etal.,  1998). By 
definition, an allosteric ligand binds to a site on a GPCR that is topographically 
distinct from the orthosteric site yet is able to alter orthosteric ligand binding and / or 
receptor function (Christopoulos & Kenakin, 2002;  May etal., 2004). Allosteric 
ligands can be agonists, antagonists or positive modulators (increasing the affinity of 
an agonist though lacking intrinsic agonist activity in its own right).
The most obvious allosteric modulators at GPCRs are the G proteins themselves, 
which bind to the intracellular domains of the receptor and can alter orthosteric ligand 
binding (May etal., 2004). However, in terms of pharmacological manipulation and 
drug development, the greatest interest remains in small molecule allosteric ligands 
which target extracellular allosteric sites on a receptor (May et al., 2004).
The simplest form of allosteric ligand - GPCR interaction involves the ligand altering 
the confirmation of the receptor such that the affinity of the receptor for an orthosteric 
ligand is changed (Christopoulos etal.,  1998; Christopoulos & Kenakin, 2002). This 
alteration in affinity can be either positive or negative i.e. the presence of the 
allosteric ligand can either increase or decrease the receptor affinity for an orthosteric 
ligand (Avlani et al., 2004). The interaction is a reciprocal one, in so much as the 
binding at either the allosteric or orthosteric site will affect the binding at the other site 
in the same way and the same degree (Christopoulos et al.,  1998).
59At their simplest, these allosteric actions are defined by a model that allows the 
receptor to be simultaneously occupied by two ligands, known as the allosteric 
ternary complex model (Figure 6; Ehlert etal.,  1988). This model describes the 
interaction between an orthosteric ligand, A, and an allosteric ligand, B, with a 
receptor,  R. The constants KA  and KB  denote equilibrium dissociation constants for 
the binding of A and B, respectively, to their binding sites on the unoccupied 
receptor. However, these constants alone do not fully characterise allosteric 
interactions. The co-operativity factor, a, is a measure of the degree of co-operativity 
for the interaction between a given allosteric and orthosteric ligand pair at a receptor 
(Ehlert etal.,  1988; Christopoulos & Kenakin, 2002). Values of a > 1   denote positive 
co-operativity whereas values of a < 1   denote negative co-operativity; a value of a =
1   denotes an allosteric interaction that does not alter the ligand affinity (Christopoulos 
& Kenakin, 2002).  In contrast, values of a that approach zero are difficult to 
distinguish from competitive antagonism (Christopoulos etal.,  1998). 
Thermodynamically, a is the ratio of the affinity of a ligand for the occupied receptor 
versus the affinity of the ligand for the unoccupied receptor (Christopoulos et al.,
1998). There is a rapidly increasing literature on allosteric ligands acting at GPCRs, 
including ligands acting at the dopamine D2 receptor (Hoare & Strange,  1996), the 
adenosine A1   receptor (Bruns & Fergus,  1990) and metabotropic glutamate receptor 
5 (Spooren et al., 2001).
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Figure 6. Simple allosteric ternary complex model.  Ft denotes the receptor, A and B 
denote the orthosteric and allosteric ligand, respectively and KA  and KB  denote the 
equilibrium dissociation constants of AR and BR, respectively. The symbol a denotes 
the co-operativity factor and is a quantitative measure of the maximal, reciprocal 
alteration of affinity of A and B for their respective binding sites when both ligands 
bind simultaneously to form the ternary complex, ARB.
Unlike orthosteric ligands, allosteric ligands display some unique properties. 
Irrespective of its affinity for a receptor, it is theoretically possible for an allosteric 
ligand to display neutral la = 1). or close to neutral, co-operativity with all subtypes of 
a given receptor except the subtype of interest (May et al., 2004). This property has 
been termed ‘absolute subtype selectivity’ (Lazareno etal.,  1998) and is a potentially 
powerful means of positively or negatively modulating a single subtype of a receptor 
family while having no net effect on the function of the other subtypes. This may well 
prove a route to developing novel, selective tools for receptor subtypes within 
families where targeting the orthosteric site has failed to deliver suitably selective 
agents. Such an example has been shown recently with the thiamine metabolite, 
thiochrome, which exerts positive co-operativity with ACh at the M4 receptor subtype,
61while having neutral co-operativity at the  M2j M3 and M5 receptor subtypes 
(Lazareno etal., 2004).
The effects of allosteric modulators are also saturable; once all the allosteric sites on 
a receptor population are fully occupied then no further allosteric effect is observed 
(Christopoulos, 2002).  In contrast, orthosteric competitive antagonism is theoretically, 
if not practically, infinite, depending as it does on the relative concentrations of the 
two competing molecules (Figure 7; Christopoulos, 2002). This saturation effect has 
been observed with both positive and negative allosteric modulators at muscarinic 
acetylcholine receptors. A/-chloromethylbrucine (NCMB) is a positive allosteric 
modulator at the M3 receptor subtype and produces concentration-dependent 
leftward shifts in concentration response curves to ACh in functional [35S]GTPyS 
binding assays. However, there is a limit to the degree of leftward shift achievable 
beyond which further increases in NCMB will have no additive effect (Birdsall et al.,
1999). Similarly, gallamine gives a concentration-dependent rightward shift of 
concentration response curves to ACh evoked contractions of the guinea-pig left 
atrium (Christopoulos, 2000). However, as with NCMB, the effects of gallamine are 
saturable and reach a maximal shift beyond which further increases in the gallamine 
concentration have no effect. This profile results in a shallow, curvilinear Schild plot, 
which, if the saturation point was reached in the assay, reaches a plateau (Figure 7; 
Christopoulos, 2000; Christopoulos & Kenakin, 2002).
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Figure 7. Analysis of concentration-response curves for a competitive inhibitor, a 
negative allosteric modulator and a positive allosteric modulator. Theoretical dose- 
response curves are shown for an agonist (EC50 = 100 nM) in the presence 
increasing concentrations of a test agent with a KD  = 10 nM, which is either (A) a 
competitive inhibitor, (B) a negative allosteric modulator, or (C) a positive allosteric 
modulator. The parallel rightward shift of the agonist curve in the presence of inhibitor 
is expressed as a dose-ratio (ratio of equi-effective agonist concentrations in the 
presence and absence of inhibitor) and the Schild plot (D) shows the log (dose-ratio 
-1) plotted against the log concentration of inhibitor. The Schild plot of the 
competitive inhibitor is a straight line with a slope of unity, whereas the Schild plot of 
the negative allosteric modulator curves and eventually reaches an asymptotic value, 
which is approximately equal to -log co-operativity (where negative co-operativity 
has values < 1). For both competitive and allosteric inhibitors the log concentration of
63Figure 7 cont.
inhibitor associated with zero on the Y axis (i.e. causing a 2-fold increase in the 
agonist EC50) is the log KD  of the inhibitor. In the affinity ratio (or potency ratio) plot 
(E) 1/dose-ratio is plotted against the log concentration of allosteric agent: the curves 
start at 1   and reach an asymptotic value equivalent to the co-operativity.  For both 
positive and negative allosteric agents the log EC50 or log IC50 values correspond to 
the log Kd of the allosteric agent. Taken from Birdsall & Lazareno (2005).
64In the studies with both NCMB and gallamine, the maximal degree of shift of the 
agonist concentration response curve seen is governed by the co-operativity factor, 
a, for the ligand pair. For example, a value of a = 0.1  suggests negative co- 
operativity and would permit a maximal 10-fold rightward shift in the concentration 
response curve to the orthosteric agonist (Figure 7). Similarly, if the value of a was 
10, then this would suggest positive co-operativity and permit a maximal 10-fold 
leftward shift in the concentration response curve to the orthosteric agonist (Figure 7; 
Christopoulos & Kenakin, 2002). In the studies by Christopoulos (2000), the value of 
a for gallamine and ACh was 0.0053, as observed by the maximal ~200-fold 
rightward shift in the ACh concentration response curve. If the a value cannot be 
derived from the concentration-response curves because the allosteric effect has not 
saturated (possible with very low a values) then the log (CR -1) value on the Y-axis 
of the estimated plateau of the Schild plot can be taken as an estimate of log a 
(Figure 7, Christopoulos & Kenakin, 2002).
The saturability of effect makes allosteric ligands and their binding sites attractive 
drug targets. Having a limit beyond which a drug will no longer ‘stimulate’ or ‘inhibit’ a 
receptor system is an inherent safety device that could prevent the undesirable 
effects of an overdose (May et al., 2004). This is seen as a clinical advantage of the 
benzodiazepines, which act allosterically at the GABAa receptor, compared to ligands 
acting directly at the GABA binding site.
It is clear that the effects of allosteric modulators can be detected functionally, as 
demonstrated with the studies using NCMB and gallamine already discussed 
(Birdsall etal.,  1999; Christopoulos, 2000). Visualisation of positive co-operativity is 
relatively straightforward, displaying a parallel leftward shift of the concentration- 
response curve to an orthosteric agonist. However, allosteric ligands with a high 
degree of negative co-operativity can appear indistinguishable from competitive
65antagonists (Christopoulos & Kenakin, 2002). In this case a wide range of 
‘antagonist’ concentrations should be used and analysis performed using the Schild 
equation (Arunlakshana & Schild, 1959):
log (concentration ratio -1 ) = log [B] -  log KB
where the concentration ratio is the equiactive concentration  ratio of agonist 
concentrations measured alone or in the presence of an antagonist and [B] and KB  
are the antagonist concentration and equilibrium dissociation constant for the 
receptor -  antagonist complex.
A competitive interaction would be predicted to give a linear Schild plot with a slope 
of unity (Figure 7). However, many conditions can result in non-parallel 
concentration-response curves (eg. irreversible or non-competitive antagonism; 
Kenakin,  1997) or non-linear Schild regressions (eg. non-equilibrium conditions such 
as the presence of agonist removal / uptake mechanisms; Kenakin,  1997). Allosteric 
antagonism, as observed with the gallamine data in the guinea-pig heart 
(Christopoulos, 2000), can result in non-linear Schild plots.  Functional assays can 
also be used to detect allosteric modulators by combining a second, competitive 
antagonist along with the ‘test antagonist’ and the agonist.  If both antagonists are 
competitive then their effects should be additive i.e. the combined concentration ratio 
for two competitive antagonists, B and C, would be defined as follows (Paton &
Rang,  1964):
CRB c = CRb + CRc ~ 1
However, if one of the antagonists is allosteric, then this can produce marked 
deviations in this model and result in ‘greater than additive’ or ‘less than additive’ 
combination concentration ratios. The combination of A/-methyl scopolamine (NMS)
66and alcuronium at the muscarinic M2 receptor produces a much greater than 
predicted antagonism of the carbachol mediated contractions of the guinea-pig left 
atrium (Lanzafame etal., 1997). This confirms the allosteric nature of alcuronium and 
is consistent with its positive co-operativity with respect to NMS and negative co- 
operativity with respect to carbachol.
Equally well used to detect allosteric interactions are radioligand binding assays with 
orthosteric site radioligands. The most well characterised effects of allosteric ligands 
on radioligand binding are alteration of radioligand dissociation rate. It is the 
alteration of orthosteric ligand kinetics that underlies the effects of allosteric 
modulators on orthosteric ligand affinity (Christopoulos & Kenakin, 2002). There are 
a number of examples, particularly with muscarinic receptors, of allosteric ligands 
that can both increase (eg. amiloride at human ociA-adrenergic receptor; Leppik etal.,
2000)  and decrease (eg. gallamine at the human muscarinic Mt  receptor; 
Christopoulos etal.,  1999; Avlani etal., 2004) the rate of orthosteric radioligand 
dissociation.
The same alteration of orthosteric radioligand affinity can be observed in saturation 
analysis binding studies as an apparent parallel shift in the saturation isotherm (when 
plotted as % specific binding versus the logarithm of the radioligand concentration; 
Lanzafame & Christopoulos, 2004). As with the functional studies discussed earlier, 
the shift is saturable and governed in its extent by the co-operativity factor, a. This 
change in affinity of the receptor for the orthosteric radioligand allows simple 
inhibition binding assays to be used to detect allosteric ligands at GPCRs 
(Christopoulos & Kenakin, 2002). In inhibition binding assays (often referred to as 
‘competition binding’), a single concentration of radioligand is used, often around 0.5 
-  1   x Kd for the radioligand at the target receptor. This represents conditions 
designed to yield a reasonable signal-to-noise ratio without high receptor occupancy.
67The presence of a negative allosteric modulator may increase the KD  of the 
orthosteric radiolabel and hence place the assay on a different part of the saturation 
binding curve (Figure 8). In these circumstances, the allosteric ligand may be unable 
to fully inhibit the orthosteric radioligand binding to non-specific levels (Figure 8; 
Christopoulos & Kenakin, 2002). Even if the negative allosteric modulator is capable 
of full inhibition of radioligand binding, a 10 or 100-fold increase in the radioligand 
concentration shifts the assay to a different part of the saturation curve and often 
reveals incomplete inhibition and hence the presence of allosterism (Christopoulos & 
Kenakin, 2002). In contrast, a competitive antagonist should, theoretically, always be 
able to overcome the specific binding of a radioligand. Incomplete inhibition of 
specific orthosteric ligand binding has been observed with a number of negative 
allosteric modulators, including gallamine (Stockton etal.,  1983) and C7 /3-phth 
(heptane-1,7-bis(dimethyl-3'-phthalimidopropyl)ammonium bromide; Christopoulos et 
al.,  1999). However, it must be remembered that not all negative allosteric ligands 
can be detected using equilibrium inhibition binding assays; neither tetra-W84 
(hexane-1,6-bis[methyl-bis~3’-phthalimidopropyl] ammonium bromide) nor CPCCOEt 
(7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester) have any 
effect on [3H]NMS and [3H]glutamate equilibrium binding at the muscarinic M2 and 
metabotropic glutamate 1a receptors, respectively, despite these being receptors at 
which they are known allosteric ligands (Kostenis & Mohr,  1996; Litschig etal.,
1999). In the case of tetra-W84, allosteric effects are only observed when the 
compound is assessed using the dissociation rate technique described above 
(Kostenis & Mohr,  1996).
In contrast, the effects of an allosteric ligand with positive co-operativity are relatively 
easy to assess, often giving concentration-dependent potentiation of orthosteric 
radioligand binding, as is the case with alcuronium at the muscarinic M2 receptor 
(Christopoulos, 2000).
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Figure 8. Inhibition of orthosteric radioligand binding by negative allosteric 
modulators. (A) Saturation binding curve for a radioligand shifted to the right by a 
maximally effective concentration of negative allosteric modulator with a  = 0.2. The 
curve to the left of the panel shows the displacement of a defined concentration of 
radioligand by a range of concentrations of allosteric antagonist. Note how the 
displacement does not reduce the bound counts to non-specific binding levels. (B) As 
for A but for a more powerful negative allosteric modulator (a = 0.01). In this case, 
the displacement counts are reduced to non-specific binding levels. Adapted from 
Christopoulos & Kenakin (2002).
694. Aims of thesis research
The studies on GPR10 reported in this thesis were aimed at (a) characterising the 
pharmacology of PrRP and GPR10 using radioligand binding and functional assays 
and (b) probing the interaction between PrRP and GPR10 using site directed 
mutagenesis.
Whilst the binding of various radiolabelled forms of [125l]-PrRP to cells stably 
transfected with GPR10 has been previously described (Hinuma etal., 1998; Roland 
etal.,  1999), the binding of these ligands has yet to be fully characterised in terms of 
affinity and kinetics. The studies in Chapter 3 have fully characterised the binding of 
[125l]-hPrRP-20 to the GPR10 receptor stably expressed in HEK293 cells (Wilson et 
al., 1998) using saturation, inhibition and kinetic assays. Similarly, with exception of 
studies in rat pituitary primary cultured neurons (Kimura etal., 2000), the intracellular 
biochemistry of GPR10 signalling has not been assessed. Functional aspects of rat 
and human PrRPs have also been assessed using calcium mobilisation, cAMP 
Flashplate technology and inositol phosphate accumulation assays in the same cell 
line to assess the signal transduction pathways involved after activation of GPR10.
Furthermore, several studies have sought io identify the structural components of the 
PrRP peptides required for binding to and activation of GPR10 (Roland et al.,  1999; 
Danho etal., 2003; Boyle etal., 2005).  Flowever, no complementary studies have 
been attempted to identify the molecular nature of the binding pocket on the GPR10 
receptor for PrRP. Chapter 4 describes the construction of a homology model of the 
receptor based on the published crystal structure of rhodopsin, which, in turn, has 
allowed prediction of proposed molecular interactions between hPrRP-20 and 
GPR10. On this basis, site-directed mutagenesis has been carried out and mutant 
constructs assessed using [125l]-hPrRP-20 binding and functional calcium
70mobilisation to determine the validity of the model in predicting the key residues 
involved in PrRP-20 binding to GPR10.
Due to the lack of pharmacological tools for GPR10, which has prevented a more 
thorough characterisation of the receptor, the second half of the thesis has focussed 
on examining the pharmacology of the muscarinic IVh  receptor with particular 
reference to  the novel, selective, ‘ectopic’ agonist, AC-42. The mechanism of agonist 
action of AC-42 at the IVh  receptor remain unknown - is the unique selectivity of this 
compound derived from an allosteric interaction with the receptor? Understanding of 
the mechanism of this compound may enable the future development of further 
selective agonists for this receptor subtype.  Furthermore, the signal transduction 
pathway(s) stimulated by IVh  receptor activation with AC-42 are largely unknown. 
Also, there is currently little or no literature describing the effects of this novel class of 
agonists in native tissue preparations. In Chapter 5 these points have been 
addressed through a thorough pharmacological characterisation of AC-42, a closely 
related analogue, 77-LH-28-1  and two novel, unrelated compounds which also 
purport to be ‘ectopic’ agonists, compound A and compound B (structures 
undisclosed for patent reasons). Radioligand binding, functional calcium mobilisation, 
inositol phosphate accumulation and eiectrophysiological assays, in both 
recombinant cells and native tissue, have been used to characterise the interaction of 
these compounds with the Mi  receptor.
Having characterised the pharmacology of the allosteric mode of action of these 
agonists with the Mi  receptor, using a similar approach as with GPR10 in Chapter 4, 
the studies in Chapter 6 describe the construction of a homology model of the 
muscarinic IVh  receptor, based on the crystal structure of rhodopsin. Whilst the 
orthosteric site of the IVh  receptor has been well-characterised, with numerous 
residues implicated in the binding of ACh, carbachol and other agonists and
71antagonists (Hulme etal., 2003), the molecular nature of the binding site for AC-42 
and other similar agonists remains unknown. The model of the human Mi  receptor 
and subsequent docking of AC-42 and compound A has allowed the prediction of the 
site(s) of interactions of these compounds with the IVh receptor. These predictions 
have been assessed by both radioligand binding and functional studies with M1  
receptors containing appropriate point mutations.
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Methods
731.  Materials
[3H]NMS (81  Ci / mmol), [3H]QNB (42 Ci / mmol), [3H]-myo-inositol (86 Ci / mmol) and 
[125l]_hPrRP-20 (2000 Ci / mmol) were from Amersham Bioscience (U.K.); [3H]- 
oxotremorine-M (75.8 Ci / mmol) and cAMP FlashPlate kits were from NEN Life 
Science (U.S.A.). HEK293, HEK293-GPR10, CHO-K1  and CHO-hM! cell lines were 
cloned / subcloned in house; U20S cells were obtained from the American Type 
Culture Collection. All cell culture reagents were from Invitrogen (U.K.); Accutase 
was obtained from  PAA Labs (U.K.). All drugs and reagents were from Sigma-Aldrich 
(U.K.) except Complete™ tablets (Roche, U.K.), [pGlu1, Trp2, Lys3, Leu4] hPrRP(25- 
31), substance P, neurokinin-A, Me-Phe7-neurokinin-B, neuropeptide-Y, 
neuropeptide-FF (Bachem, U.K.), rat / human PrRP-20/ PrRP-31  and hPrRP(25-31) 
(in house), YSi-SPA beads (Amersham Bioscience, U.K.), oxotremorine-M (Tocris, 
U.K.), Ca2+-plus, Ca2+-3 and Fluo-4AM dyes (Molecular Devices,  U.S.A.), NaCI, KCI, 
MgCI2,  NaFl2P04, NaHC03, CaCI2, glucose and sucrose (BDFI, U.K.) and all 
oligonucleotides (Sigma-Genosys Ltd., U.K.).
2.  Molecular biology
(i) Plasmid construction and site-directed mutagenesis (SDM)
The construction of the mutant GPR10 and muscarinic hMt  receptors was performed 
by Angela Bridges, Abby Sukman and Jim  Fornwald (GlaxoSmithKline). Mutations 
E212A and E213A were introduced into the wild-type GPR10 sequence using the 
QuikChange PCR-based mutagenesis kit (Stratagene, Netherlands) according to 
manufacturer’s instructions.  Mutations Q141A (forward primer 
CTGGTCTTCTTCCTGGCGCCGGTCACCGTC; reverse primer 
GACGGTGACCGGAGCCAGGAAGAAGACCAG),  E202A (forward primer 
CACCTATCACGTGGCGCTCAAGCCGCAC; reverse primer
74GTGCGGCTTGAGCGCCACGTGATAGGTG), N298A (forward primer 
CGCTGCACGTCTTCGCCCTGCTGCGGGAC; reverse primer 
GTCCCGCAGCAGGGCGAAGACGTGCAGCG), D302A (forward primer 
CAACCTGCTGCGGGCCCTCGACCCCCACGC; reverse primer 
GCGTGGGGGTCGAGGGCCCGCAGCAGGTTG) and Q317A (forward primer 
CTTTGGGCTCGTCGCGCTGCTCTGCCACTG; reverse primer 
CAGTGGCAGAGCAGCGCGACGAGCCCAAAG) were introduced using the 
modified PCR method of splicing by overlap extension (PCR SOEing; Horton etal, 
1990). Both rounds of PCR consisted of 3 min at 95°C followed by 30 cycles of 1   min 
at 95°C,  1   min at 55°C and 2 min at 72°C.  For both methods, the sequence of GPR10 
was amplified using primers which incorporate the desired point mutations, using the 
wild type expression vector, pCDN-GPR10, as the template for mutagenesis.
Mutations E397A (forward primer GCAAGGACTGTGTTCCCGCGACCCTGTGGG 
AGCTGGG; reverse primer CCCAGCTCCCACAGGGTCGCGGGAACACAGT 
CCTTGC), E401A (forward primer GTTCCCGAGACCCTGTGGGCGCTGGGCTAC 
TGGCTGTG; reverse primer CACAGCCAGTAGCCCAGCGCCCACAGGGTCTCG 
GGAAC), E397A/E401A (forward primer GCAAGGACTGTGTTCCCGCGACCCT 
GTGGGCGCTGGGCTACTGGCTGGC; reverse primer GCACAGCCAGTA 
GCCCAGCGCCCACAGGGTCGCGGGAACACAGTCCTTGC) and Y82F (forward 
primer CCTTCTCCATGAACCTCTTTACCACGTACCTGCTC; reverse primer 
GAGCAGGTACGTGGTAAAGAGGTTCATGGAGAAGG) were introduced into the 
human Mi  receptor using the QuikChange PCR-based mutagenesis kit (Stratagene, 
U.S.A.) according to manufacturer’s instructions. The mutation Y381A (forward 
primers GCCATCGAATTCGCCACCATGAACACTTCAGCCCCA and CCCTGA 
GT  GCCAT  CCT  CCT  G GCCTT  CAT  CCT  CACCTGG  ACACCG GCCAACAT  CAT  GGTGC 
TGGTGTCCACCTTCTGCAAGGACTGTGTTCC; reverse primers GAACACAGT 
CCTTGCAG  AAGGT  GG  ACACCAGCACCAT  GAT  GTT  GGCCGGT  GT  CCAGGT  G  AGG
75ATGAAGGCCAGGAGGATGGCACTCAGGG and GAGGTGGATATCCTGGTAACC 
CAGGGTCCTGGGAAG) was introduced using the modified PCR method of splicing 
by overlap extension (PCR SOEing; Horton etal., 1990).  For both methods, the 
sequence of the human muscarinic IVh  receptor was amplified using primers which 
incorporate the desired point mutations. Modified baculovirus containing the 
mammalian cytomegalovirus promoter (‘BacMam’; Ames etal., 2004b) was produced 
using the Bac to Bac Baculovirus Expression System (Invitrogen, U.S.A.). The 
accuracy of all PCR-derived sequences was confirmed by dideoxy sequencing of the 
mutant plasmids.
3.  Cell culture and transfection
(i) HEK293 and HEK293-GPR10
Human embryonic kidney 293 (HEK293) cells were routinely maintained in T80 or 
T175 flasks in Eagle’s Modified Essential medium (EMEM) containing 10% foetal 
bovine serum (FBS) and 1% L-glutamine (2 mM final) at 37°C in humidified 95% air / 
5% C 02. Cells were passaged twice weekly by harvesting with either PBS or 
Accutase (PAA Labs) followed by centrifugation (200 x g, 5 min) and resuspension in 
fresh media.
HEK293 cells were passaged at 1:2 one day prior to transfection. Cells were 
transiently transfected with plasmids coding for the various GPR10 constructs using 
Lipofectamine 2000 as follows. For each T80 flask to be transfected, Optimem (2.25 
ml) was mixed with 90 jllI  Lipofectamine 2000. In a second tube, Optimem (2.25 ml) 
was mixed with  15 jig cDNA. Mixtures were allowed to equilibrate for 5 minutes and 
then the Optimem-Lipofectamine and Optimem-cDNA mixtures combined and 
incubated at room temperature for 20 minutes before addition to the flask. Cells were 
harvested and assayed 48 h post-transfection.
76(ii) CHO-hMi, CHO-K1 and U20S
CHO-hM! cells were routinely cultured in T175 flasks in Alpha MEM with 
ribonucleosides plus 10% foetal bovine serum (FBS). CHO-K1  wild type cells were 
routinely cultured in T175 flasks in Alpha MEM with ribonucleosides plus 10% FBS 
and 0.45 mg / ml hygromycin-B. U20S cells (Ames etal., 2004a) were routinely 
cultured in T175 flasks in DMEM / F12 plus 10% FBS. All cells lines were kept in 
humidified atmosphere at 37°C in 95% air / 5% C 02 and passaged twice weekly by 
scraping in media, centrifugation (200 x g, 5 min) followed by resuspension of the 
pellet in fresh media.
For muscarinic Mi  receptor SDM constructs, recombinant BacMam virus (Ames et 
al, 2004b) expressing the sequence of wild-type and mutated Mi  receptor constructs 
was added to cell suspensions of CFIO-K1  or U20S cells to give a final viral titre of 
30 - 50 and 8 pfu. / cell, respectively.  For functional calcium mobilisation assays 
CFIO-K1  or U20S virus-cell mixtures were then seeded into clear bottomed black 
walled 96-well microtitre plates (100 pi / well; Costar, U.K.) at a density of 50,000 or 
25,000 cells / well, respectively.  For CHO-K1  membrane preparations, virus-cell 
mixtures ^ere seeded into T175 flasks at 2 x 108 cells per flask. Cells were assayed 
or harvested, as appropriate, 24h later.
4.  Membrane preparation
(i)  HEK293-GPR10 cell membrane preparation
Fluman embryonic kidney 293 (FIEK293) cells either stably or transiently transfected 
with GPR10 were harvested with phosphate buffered saline (PBS), pelleted and 
stored at -80°C until further use. Membranes were prepared using a modification of 
the method of Miyamoto etal. (1994); all procedures were carried out at 4°C. Cells
77were washed in 30 vols (w/v) of PBS with 0.2 mM EDTA. The suspension was 
homogenised using an Ultra-Turrax homogeniser and the subsequent homogenates 
centrifuged at 39,000 x gfor 15 min. The resultant pellets were resuspended in 30 
volumes of buffer containing 10 mM Na2C 03, 1  mM EDTA, 0.5 mM 
phenylmethylsulphonyl fluoride (PMSF),  1   jig / ml pepstatin and 1   x Complete™ 
serine and cysteine protease inhibitor tablet / 250 ml (pH 7.4). The suspension was 
then homogenised and centrifuged at 1,000 x gfor 10 min, the supernatant decanted 
and centrifuged at 48,000 x g for 20 min. The resultant pellets were resuspended in 
buffer containing 20 mM Tris-HCI, 0.25 M sucrose, 2 mM EDTA, 0.5 mM PMSF,  1   pg 
/ ml pepstatin and 1   x Complete™ serine and cysteine protease inhibitor tablet / 250 
ml (pH 7.4) to a volume of approx. 0.5 -1.2 x 107 cells / ml and stored at -80°C until 
used.
(ii) Rat cortex membrane preparation
Cerebral cortex from male Sprague Dawley rats (Charles River, U.K.) was rapidly 
dissected on ice; all subsequent procedures were carried out at 4°C. Tissue was 
homogenised using an Ultra-Turrax homogeniser in 2.5 vols (w/v) Tris-HCI (pH 7.7) 
and the subsequent homogenate was centrifuged at 24,000 x g for T5 min. The 
supernatant was discarded and the pellet resuspended in 2.5 vols fresh buffer and 
washed twice more before being resuspended at a protein concentration of 10 mg / 
ml and stored at -80°C until further use.
(iii) CHO-hMi and CHO-K1 cell membrane preparation
Cell membrane preparation was performed as described in Lanzafame & 
Christopoulos (2004); all procedures were carried out at 4°C. Stable CHO-hMi cells 
or CHO-K1  cells transiently transduced with muscarinic Mt  receptor constructs were 
harvested as described above. The cell pellet was resuspended in 5 ml of ice-cold
78buffer containing 50 mM Tris-HCI, 3 mM MgCI2 and 0.2 mM EGTA (pH 7.4) and then 
homogenised using an Ultra-Turrax homogeniser for 30 s. The homogenate was 
centrifuged at 1000 x gfor 10 min. The remaining pellet was discarded and the 
supernatant was re-centrifuged at 39,000 x gfor 30 min. The resulting cell membrane 
pellet was resuspended in the same buffer at protein concentrations of 2 mg / ml 
(CHO-hM^ or 1   mg / ml (CHO-K1), as determined by the method of Bradford 
(Bradford,  1976). Aliquots were stored at -80°C until further use.
5.  Radioligand binding studies
(i) HEK293-GPR10 [1 25l]-hPrRP-20 saturation binding assays
HEK293-GPR10 cell membranes (400 pi; 4 pg protein / well) were incubated in a 
total volume of 0.5 ml with assay buffer (50 pi) containing 20 mM Tris-HCI, 5 mM Mg- 
acetate, 2 mM EGTA, 0.5 mM PMSF,  1   pg / ml pepstatin and 1   x Complete™ serine 
and cysteine protease inhibitor tablet 250 / ml and 0.1  % (w/v) BSA (pH 7.4) and 
varying concentrations of [125l]-hPrRP-20 (50 pi;  10 pM -  20 nM) at 25°C for 90 min. 
Non-specific binding was defined as that remaining in the presence of 0.1  pM rat 
PrRP-31. The reaction was terminated by rapid filtration through Whatman GF/B filter 
mats pre-soaked in 1   % PEI  using a 48-well Brandel cell harvester (Semat,  U.K.) 
Filters were washed with 5 x 1   ml ice-cold harvest buffer containing 50 mM Tris-HCI, 
10 mM MgCI2 (pH 7.4) and allowed to dry before bound radioactivity was measured 
by gamma counting. Specific binding data were analysed using the program Radlig 
(Biosoft, U.K.) to provide estimates of KD  and Bm ax values (Appendix 1). Protein 
content was assayed using the Bradford method (Bradford,  1976) using bovine 
serum albumin (BSA) as a standard. Results are presented as means (± s.e.m.) of at 
least 3 independent experiments.
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Inhibition binding studies were performed by incubating HEK293-GPR10 cell 
membranes (400 pi; 2 pg protein / well) with [125l]-hPrRP-20 (50 pi; 0.2 nM) and a 
range of concentrations of the test compound (50 pi) at 25°C for 90 min. The final 
assay volume was 0.5 ml. Compounds were serially diluted in assay buffer (158 pi 
compound + 342 pi buffer, equivalent to 0.5 log) to give 10 different test 
concentrations over a 5 log unit range using either the Biomek FX (Beckam Coulter, 
U.S.A.) orTecan Genesis (Tecan, U.K.) liquid handling systems. Buffer composition, 
non-specific binding determination, reaction termination and radioactivity 
determination were all as for HEK293-GPR10 saturation binding. Inhibition curves 
were analysed by non-linear least-squares fitting to a four parameter logistic equation 
(equation 1; Appendix 1) in Microsoft Excel in order to determine IC50 values (Bowen 
& Jerman,  1995).
^   D  „   Top-Bottom 
Y = Bottom+
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Top and Bottom represent the maximal and minimal asymptotes of the curve, IC50 is 
the concentration of compound required to inhibit 50 % of specific radioligand binding 
and nH  is the Hill slope. R values were then derived from the IC50 values using a KD  
value of 0.1  nM to take into account binding to both high (KD  = 0.03 nM) and low (KD  
= 0.6 nM) affinity binding sites (equation 2; Appendix 1; Cheng & Prussoff, 1973);
K   = .  / C 5 0
1+ W
K d
Where K, is the inhibition constant for the competing ligand, KD  is the dissociation 
constant for the radioligand (concentration required to occupy 50 % of specific
80binding sites) and [L] \s the radioligand concentration.  Protein content was assayed 
as for saturation binding. Results are presented as means (± s.e.m.) of at least 3 
independent experiments.
(iii) [1 25l]-hPrRP-20 radioligand kinetic binding assays
Association kinetic studies were performed by measuring triplicate determinations 
total and non-specific binding of [125l]-hPrRP-20 (50 pi; 0.2 nM) at various time points 
after the addition of HEK293-GPR10 cell membranes (400 pi; 2 pg protein / well).
The final assay volume was 0.5 ml. Buffer composition, total and non-specific binding 
determination, reaction termination and radioactivity determination were all as for 
HEK293-GPR10 saturation binding.
For dissociation studies, HEK293-GPR10 cell membranes (400 pi; 2 pg protein / 
well) were pre-incubated with [125l]-hPrRP-20 (50 pi; 0.2 nM) and either assay buffer 
(50 pi) or rat PrRP-31  (50 pi; 0.1  pM final) for 90 min in a final assay volume was 0.5 
ml. Triplicate determinations of total and non-specific binding of [125l]-hPrRP-20 as 
defined above were then measured at various time points after the addition of 50 pi 
1.1  pM rat PrRP-31  (0.1  pM final). Buffer composition, reaction termination and 
radioactivity determination were all as for HEK293-GPR10 saturation binding. Kinetic 
data were analysed by GraFit (Erithacus Software) to provide estimates of ko n  and 'ko ff 
values (Appendix 1).  Results are presented as means (± s.e.m.) of at least 3 
independent experiments.
(iv) Rat cortex [3H]QNB inhibition binding assays
Inhibition binding studies were performed by incubating rat cortical membranes (400 
pi; 8 pg protein / well) with [3H]QNB (50 pi; 0.3 nM) and a range of concentrations of
81the test compound (50 pi) at 37°C for 40 min in buffer containing 50 mM Tris-HCI (pH 
7.7). The final assay volume was 0.5 ml. Compounds were serially diluted in Tris-HCI 
buffer (158 pi compound + 342 pi buffer, equivalent to 0.5 log) to generate 10 
different test concentrations over a 5 log unit range using either the Biomek FX 
(Beckam Coulter, U.S.A.) orTecan Genesis (Tecan, U.K.) liquid handling systems. 
Non-specific binding was defined as that remaining in the presence of 1   pM atropine. 
The reaction was terminated by rapid filtration through GF/B filter mates pre-soaked 
in 0.05 % PEI using a 48-well Brandel cell harvester (Semat, U.K.) Filters were 
washed with 5 x 1   ml ice-cold 50 mM Tris-HCI (pH 7.7) and allowed to dry before 
bound radioactivity was measured using liquid scintillation counting with Ultima Gold 
MV scintillant (Perkin Elmer, U.K.). Inhibition curves were analysed by non-linear 
least-squares fitting to a four parameter logistic equation by Microsoft Excel in order 
to determine IC50 values (equation 1; Bowen & Jerman,  1995). K} values were then 
derived from the IC50 values using the KD  value of 0.3 nM (equation 2; Appendix 1; 
Cheng & Prussoff, 1973).  Results are presented as means (± s.e.m.) of at least 3 
independent experiments.
(v)  Rat cortex [3H]oxotremorine-M inhibition binding assays
Inhibition binding studies were performed by incubating rat cortical membranes (400 
pi;  100 pg protein / well) with [3H]oxotremorine-M (50 pi;  1.9 nM) and a range of 
concentrations of the test compound (50 pi) at 37°C for 40 min in buffer containing 50 
mM Tris-HCI and 2 mM MgCI2 (pH 7.7). The final assay volume was 0.5 ml. 
Compounds were serially diluted in Tris-HCI buffer (158 pi compound + 342 pi buffer, 
equivalent to 0.5 log) to generate 10 different test concentrations over a 5 log unit 
range using either the Biomek FX (Beckam Coulter, U.S.A.) or Tecan Genesis 
(Tecan, U.K.) liquid handling systems. Non-specific binding was defined as that 
remaining in the presence of 10 pM oxotremorine sesquifumarate. The reaction was
82terminated by rapid filtration through GF/B filter mates pre-soaked in 0.05 % PEI 
using a 48-well Brandel cell harvester (Semat, U.K.) Filters were washed with 5 x 1  
ml ice-cold 50 mM Tris-HCI (pH 7.7) and allowed to dry before bound radioactivity 
was measured using liquid scintillation counting with Ultima Gold MV scintillant. 
Inhibition curves were analysed by non-linear least-squares fitting to a four parameter 
logistic equation by Microsoft Excel in order to determine IC50 values (equation 1; 
Bowen & Jerman,  1995). K values were then derived from the IC50 values using the 
Kd value of 3 nM (equation 2; Cheng & Prussoff, 1973). Results are presented as 
means (± s.e.m.) of at least 3 independent experiments.
(vi)  CHO-hMi [3H]NMS saturation binding assays
CHO-hM1  cell membranes (400 pi;  10 pg protein / well) were incubated in a total 
volume of 0.5 ml with assay buffer (50 pi) containing 50 mM HEPES,  110 mM NaCI, 
5.4 mM KCI,  1.8 mM CaCI2,  1   mM MgS04, 25 mM glucose and 58 mM sucrose (pH 
7.4) and varying concentrations of [3H]A/-methyl-scopolamine (NMS; 50 pi;  5 pM -  
10 nM) at 37°C for 1   h. Non-specific binding was defined as that remaining in the 
presence of 1   pM atropine. The reaction was terminated by rapid filtration through 
GF/B filter mates pre-soaked in ddH20  using a 48-well Brandel cell harvester (Semat, 
U.K.) Filters were washed with 5 x 1   ml ice-cold 0.9 % (w/v) NaCI solution and 
allowed to dry before bound radioactivity was measured using liquid scintillation 
counting with Ultima Gold MV scintillant. Specific binding data were analysed using 
GraphPad Prism (GraphPad, U.S.A.) to provide estimates of KDand Bm ax values 
(Appendix 1).  Protein content was assayed using the Bradford method (Bradford, 
1976) using bovine serum albumin (BSA) as a standard.
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Inhibition binding studies were performed by incubating CHO-hlVh cell membranes 
(400 pi;  10 pg protein / well) with [3H]NMS (50 pi; 0.2 nM or 2 nM) and a range of 
concentrations of the test compound (50 pi) at 37°C for 1   h. The final assay volume 
was 0.5 ml. Compounds were serially diluted in assay buffer (158 pi compound + 342 
pi buffer, equivalent to 0.5 log) to give 10 different test concentrations over a 5 log 
unit range using either the Biomek FX (Beckam Coulter, U.S.A.) or Tecan Genesis 
(Tecan, U.K.) liquid handling systems. Buffer composition, non-specific binding 
determination, reaction termination and radioactivity determination were all as for 
CHO-hMi saturation binding.
Data for inhibition curves at 0.2 nM and 2 nM radioligand were analysed 
simultaneously using the following equation (3) in Prism 4 (GraphPad, U.S.A.):
Y  [A ]
m ax  [A ] + Ka-'  Kb+[B\  a 
yKg  + [B\/a
where  Y/Ym ax represents fractional receptor occupancy, [A] and [B\ represent the 
concentrations of radioligand and allosteric ligand, KA  and KB  represent equilibrium 
dissociation constants of the radioligand and allosteric ligand for the unoccupied 
receptor and a represents the co-operativity factor between the two ligands. For 
each series of inhibition curves, the negative logarithm of the KA  value for [3H]NMS 
was fixed at 9.6, and the KB  and a parameters were constrained to be shared across 
both curves.  Results are presented as means (± s.e.m.) of at least 3 independent 
experiments.
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Inhibition binding studies were performed by incubating membranes from CHO-K1 
cells transiently expressing muscarinic Mi  receptor SDM constructs (400 pi;  10-20 pg 
protein / well) with [3H]NMS (50 pi; 0.2 nM) and a range of concentrations of the test 
compound (50 pi) at 37°C for 1  h. The final assay volume was 0.5 ml. Compounds 
were serially diluted in assay buffer (100 pi +  900 pi buffer) to give 6 different test 
concentrations over a 6 log unit. Buffer composition, non-specific binding 
determination, reaction termination and radioactivity determination were all as for 
CHO-hMi saturation binding. Inhibition curves were analysed by non-linear least- 
squares fitting to a four parameter logistic equation (equation  1; GraphPad Prism v4, 
GraphPad) in order to determine IC50 values, /^ values were then derived from the 
IC50 values using the KD  value determined from saturation studies (equation 2; 
Appendix 1; Cheng & Prussoff,  1973). Results are presented as means (± s.e.m.) of 
at least 3 independent experiments.
(ix) CHO-hM1  [3H]NMS kinetic binding assays
Association kinetic studies were performed by measuring triplicate determinations of 
total and non-specific binding of [3H]NMS (50 pi; 0.2 nM) at various time points after 
addition of CHO-hMi cell membranes (400 pi;  10 pg protein / well). The final assay 
volume was 0.5 ml. Buffer composition, total and non-specific binding determination, 
reaction termination and radioactivity determination were all as for CHO-hM^ 
saturation binding.
For dissociation studies, CHO-hMi cell membranes (400 pi;  10 pg protein / well) were 
pre-incubated with [3H]NMS (50 pi; 0.2 nM) and either assay buffer (50 pi) or atropine 
(50 pi;  1   pM final) for 60 min in a final assay volume was 0.5 ml. Triplicate
85determinations of total and non-specific binding of [3H]NMS as defined above were 
then measured at various time points after the addition of 50 pi 11  pM atropine (1  pM 
final) either in the presence or absence of AC-42 (100 pM final), compound A (100 
pM final) or gallamine (1  mM final). Buffer composition, reaction termination and 
radioactivity determination were all as for CHO-hMi saturation binding.
Dissociation curves were described by a monoexponential function according to the 
equation (4):  .  ,
Bt = B0-  e  o ffo b s
where for allosteric interactions ko ffo b s  is described by the following equation (5):
In the above equations,  Btdenotes bound radioligand at time t after dissociation has 
started, B0 denotes bound radioligand at equilibrium, ko ffo b s denotes the observed 
radioligand dissociation constant, koff denotes the rate constant for dissociation from 
the free (unoccupied) receptor, k0m is the rate constant from the allosteric ligand 
occupied receptor, [B] is the concentration of allosteric ligand and a KB  is the 
dissociation constant of the allosteric ligand for the radioligand occupied receptor. 
Note that in the absence of allosteric modulator,  ko ffo b s is equal to ko ff.
6.  Signal transduction studies
(i)  FLIPR calcium mobilisation assays
Intracellular calcium was monitored using the wash-free fluorescent dyes Calcium- 
Plus (CHO-hMi cells), Calcium-3 (U20S and CHO-K1  cells). Calcium-3 was 
preferred for U20S and CHO-K1  cells as this dye is more sensitive than Calcium-
86Plus to excitation at 488 nm and a lower level of receptor expression was anticipated 
in transiently transduced cells. The high level of receptor expression and efficiency of 
coupling in CHO-hMi cells allowed use of the less sensitive Calcium-Plus dye. Fluo 
4AM, a fluorescent dye that requires a wash step, was used for studies with HEK293- 
GPR10 cells as previous studies with this cell line had utilised this dye. All calcium 
studies were carried out using a Fluorometric Imaging Plate Reader (FLIPR, 
Molecular Devices, U.K.). Calibration of the FLIPR for calcium measurements was 
carried by measuring fluorescence evoked by the dye with the addition of a calcium 
ionophore in the presence (Fm ax) and absence (Fm in ) of extracellular calcium (1.8 
mM). Changes in fluorescence measured experimentally (F) were directly 
proportional to the intracellular calcium concentration:
[Ca2+] = Kd- (F - Fm in ) / (Fm ax - F)
where KD   is the affinity of the dye used for calcium ions. For both Fluo-4AM and 
Calcium-3, the KD  = 345 nM; for Calcium-Plus the KD  = 390 nM.
HEK293 cells transiently expressing GPR10 (100 pi) were seeded in clear bottomed, 
black walled poly-D-lysine coated 96-well microtitre plates (Costar, U.K.) 24 hours 
before use at a density of 52,000 cells / well.  Prior to assay on FLIPR, cells were 
incubated with Fluo 4AM (1  pM) for 60 minutes at 37°C in Hank's buffered saline 
solution containing 0.1% BSA (w/v) and 2.5 mM probenicid.  Extracellular dye was 
then removed by washing three times with 150 pi Hank's buffered saline solution 
containing 2.5 mM probenicid without BSA using a Skatron 96-way plate washer.
Where tested, signal transduction  inhibitors (25 pi) were incubated with the cells for 
30 min at 37°C prior to agonist addition. Compounds were tested for agonist activity 
in FLIPR by adding 50 pi of test solution to a plate volume of 150 pi at 37°C and the
87fluorescence was monitored (^ex= 488 nm, XE m= 540 nm) before and after the 
addition of agonist at 1   s intervals for 60 s and at 5 s intervals for a further 60 s.
CHO-hMi and CHO-K1  cells (100 pi) were seeded into clear bottomed black walled 
96-well microtitre plates (Costar, U.K.) 24 hours before use at a density of 50,000 
cells / well. U20S cells (100 pi) were seeded at a density of 25,000 cells / well. Prior 
to assay on FLIPR, medium was removed and cells were incubated with Calcium 
Plus or Calcium-3 wash-free dye according to manufacturer’s instructions for 60
minutes at 37°C in Tyrode’s buffer (145 mM NaCI, 2.5 mM KCI, 1.2 mM MgCI2, 10 
mM Na-HEPES,  10 mM glucose,  1.5 mM CaCI2; pH 7.4) containing 2.5 mM 
probenicid.  For agonist studies, compounds were tested for activity in FLIPR by 
adding 50 pi of test solution to a plate volume of 50 pi (final assay volume 100 pi).
For antagonist studies, cells were pre-incubated with antagonist / buffer (50 pi), as 
appropriate, for 30 min prior to agonist addition on the FLIPR (50 pi; final assay 
volume 150 pi).  Fluorescence was monitored as for HEK293-GPR10 cells.
Peak stimulation minus basal was plotted versus concentration of test compound and 
iteratively curve fitted using a four parameter logistic equation (equation 6; GraphPad 
Prism v4, GraphPad) to assess agonist potency and maximal response.
w D „  Top-Bottom 
Y = Bottoms      „   y .
■ j  _ l_  -j Q(\ogEC5 0 -X).nH
Where  Top and Bottom represent the maximal and minimal asymptotes of the curve, 
EC50 is the concentration of agonist required to stimulate 50% of the maximal 
response and nH  is the Hill slope.
88Where appropriate concentration-response curves to agonist in the presence and 
absence of antagonist were analysed using a global allosteric model (Motulsky & 
Christopoulos, 2004) according to the following equation (7):
log(CR -1) = logf
where CR is the concentration ratio (the ratio of equiactive agonist concentrations 
obtained in the absence or presence of antagonist), [B] is the concentration of 
antagonist,  KB  is the dissociation constant of the antagonist for the receptor and a 
represents the allosteric co-operativity factor between the two ligands.
(ii)  Inositol phosphate accumulation scintillation proximity assays (SPA)
Inositol phosphate accumulation scintillation proximity assays (IP-SPA) were carried 
out as described in Brandish et at. (2003) with minor modifications. This assay 
methodology utilises SPA technology to discriminate between negatively charged 
inositol phosphates and parental inositol. Cell derived negatively charged [3H] inositol 
phosphates bind to the positively charged yttrium silicate beads and are in sufficient 
proximity to the scintlillant contained therein to emit a signal that can be detected by 
scintillation spectroscopy. Inositol lacks a negative charge and therefore remains free 
in the solution where it cannot excite the scintillant.
HEK293 cells transiently expressing GPR10 or CHO-hM1  cells (100 pi) were seeded 
into clear bottomed black walled 96-well microtitre plates (Costar, U.K.; poly-D-lysine 
coated for HEK293-GPR10 cells) at a density of 50,000 cells / well. After 24 h the cell 
medium was removed and replaced with 200 pi inositol-free (IF) DMEM containing 5 
pCi / ml [3H]-A7 7yoinositol (Amersham, U.K.). After 16 h, the [3H]-myo-inositol was 
removed and the cells washed with 2 x 200 pi IF-DMEM. Cells were then incubated 
with 100 pi agonist (made up in media) and 100 pi antagonist or media in IF-DMEM
89containing 5 mM LiCI for 1   h at 37°C. The reaction was terminated by the removal of 
the medium and the addition of 200 pi 0.1  M formic acid (Sigma Aldrich, U.K.). The 
cell solubilisation was allowed to continue for 1  h at room temperature after which 20 
pi samples of the lysates were removed from each well and combined with 80 pi 
RNA binding yttrium silicate SPA beads (12.5 mg / ml) in a opaque bottomed 96-well 
picoplates (Packard, U.K.). Plates were agitated for 1   h at room temperature and 
then the beads left to settle for 2 h. The accumulation of negatively charged [3H] 
inositol phosphates (IP4, IP3, IP2 and IPi) was determined on the TopCount plate 
counter (Packard, U.K.).
[3H]IPx accumulation (cpm) was plotted versus concentration of test compound and 
iteratively curve fitted using a four parameter logistic equation (equation 6; GraphPad 
Prism v4, GraphPad) to assess agonist potency and maximal response. Where 
appropriate, data analysis for allosteric interactions was carried out as for calcium 
mobilisation studies (equation 7).
(iii)  Cyclic AMP FlashPlate assays
Cyclic AMP assays were performed by Jon Chambers (GlaxoSmithKline). 
Intracellular cAMP levels were determined using FlashPlate technology (Watson et 
al.,  1998). This technique is a 96-plate based radioimmunoassay, relying on the 
competition of tracer [125l]cAMP and cell-derived cAMP for anti-cAMP antibody bound 
to scintlillant-coated wells in a 96-well microtitre plate. Only cAMP bound to antibody 
is sufficiently proximal to the scintillant to emit light to be detected by scintillation 
spectroscopy.
HEK293-GPR10 cells (50 pi) were dispensed into 96-well FlashPlates (50,000 cells / 
well) at 37°C and incubated with 0.5 mM isobutylmethylxanthene (IBMX) for 15
90minutes before human PrRP-20 and / or forskolin (30 (iM) were added 
simultaneously to a final volume of 100 |llI.  After 15 minutes the incubation was 
terminated with 100 pi detection buffer containing a cell lysis agent proprietary to 
Perkin Elmer and tracer [125l]cAMP (16.5 nCi / well). Plates were incubated at 25°C 
for 2 h and then counted in a TopCount scintillation counter (Packard, U.K.) to 
determine anti-cAMP bound radioactivity. Cyclic AMP levels were calculated by 
comparison with a standard cAMP curve.
7.  Homology modelling and ligand docking
(i) Nomenclature
Amino acid residues of specific receptor subtypes are described using the single 
letter amino acid code followed by the number of the residue in the receptor eg.
Y381. Where a residue is being described as conserved across a number of GPCRs, 
the Ballesteros-Weinstein nomenclature is used. This describes residues using the 
three letter amino acid code, followed by the TM domain in which the residue is found 
and its position with reference to the most conserved residue in the same helix, this 
being designated position 50 eg. Arg 3.50.
Amino acid residues in peptides are described using the three letter amino acid code 
to distinguish from residues in the receptor, followed by the numerical position of the 
residue in the peptide eg. Arg6.
(ii) Construction of the GPR10 and muscarinic Mi receptor homology models
Homology modelling was performed by Frank Blaney and Ben Tehan (GSK).
The initial model of the TM domain of the human GPR10 and Mi  receptors was 
constructed by homology with the published X-ray crystal structure of bovine
91rhodopsin (Palczewski etal., 2000).  Alignment between the GPR10, hMi sequences 
and bovine rhodopsin was based on the ‘classical’ motifs found in each TM region. 
These were the asparagine in TM1  (Asn 1.50, Ballesteros-Weinstein notation), the 
aspartate in TM2 (Asp 2.50), the ‘DRY’ motif (ERY in rhodopsin) of TM3 (Asp 3.49, 
Arg 3.50, Tyr 3.51), the tryptophan in TM4 (Trp 4.50), and the conserved prolines in 
TM5 (Pro 5.50), TM6 (Pro 6.50) and TM7 (Pro 7.50). These alignments were used, 
with the standard homology modelling tools in the Quanta program (Accelrys, La 
Jolla, CA) to construct the seven helical bundle domain of GPR10 and the hMi 
receptor.
The extracellular loop regions of the receptors were subsequently added using a 
procedure developed at GlaxoSmithKline, which makes use of a combined distance 
geometry sampling and molecular dynamics simulation (Blaney etal., 2001). The 
side chains of this model were then refined using the Karplus standard rotamer 
library (Dunbrack & Karplus,  1993). The final model was optimised fully (500 steps of 
Steepest Descent (SD) followed by 5000 steps of Adopted Basis Newton Raphson 
(ABNR)) with the CHARMm force field (Accelrys, La Jolla, CA) using helical distance 
constraints between the ith and i+4th residues (except proline) within a range of 
1.8A-2.5A, to maintain the backbone hydrogen bonds of the helix bundle.
(iii)  Ligand docking studies
Human PrRP(25-31) (GPR10) and AC-42 (hM!  receptor) were docked into the 
receptor models manually using a variety of low energy starting conformations. 
Adjustments of the receptor protein side chains were made where necessary, always 
ensuring that these side chains were only in allowed rotameric states (Dunbrack & 
Karplus,  1993).  Once again, full optimisation of the receptor-ligand complexes was 
performed using CHARMm, the only constraints used being those which maintained
92the hydrogen bonding pattern of the helical bundle.  This procedure allows full 
relaxation of both the ligand and the whole protein, something which is not possible 
with automated docking procedures.  From the initial low energy starting 
conformations, typically between 4 and 12 docking configurations were found to be 
possible. Binding orientations were assessed by calculating the approximate free 
energy of the receptor-ligand complex as a sum of the various electrostatic and van 
der Waals forces between each residue and the ligand. One docked orientation of 
hPrRP(25-31) in GPR10 and of AC-42 in the hM1   receptor was particularly favoured 
(lowest overall binding energy) and this was used as the basis for [pGlu1, Trp2, Lys3, 
Leu4] hPrRP(25-31) docking into GPR10 and compound A in the hIVL  receptor.
8.  Electrophysiology
(i) Network oscillations in rat temporal cortex
The studies described below were performed whilst on a collaborative placement 
with Prof. Miles Whittington and Anita Roopun in the Department of Biomedical 
Sciences, University of Leeds.
Experiments were performed using slices from young adult male Wistar rats, aged 
between 42 and 70 days, weighing approximately 150 g. All procedures were in 
accordance with the regulations stipulated in the UK Animals (Scientific Procedures) 
Act, 1986. Rats were euthanased with an overdose of isofluorane and the brain 
rapidly dissected out into ice-cold oxygenated sACSF (containing, in mM, 252 
sucrose, 3 KCI,  1.25 NaH2P04, 2 MgS04) 2 CaCI2, 24 NaHC03 and 10 glucose). 400 
|im thick coronal sections of brain tissue were cut using a Leica VT1000 vibratome 
and transferred to an interface chamber. Slices were maintained at 34°C at the 
interface between circulating oxygenated ACSF (flow rate 1-2 ml / min; containing, in 
mM,  126 NaCI, 3 KCI,  1.25 NaH2P04,  1   MgS04,  1.2 CaCI2, 24 NaHCQ3 and 10
93glucose) and humidified 95% 0 2 / 5% C 02. Brain slices were left to equilibrate for 1   h 
before the onset of recording.
Extracellular recordings from temporal cortex were obtained using glass 
micropipettes pulled from thin walled borosilicate tubing (1.2mm outer diameter x 
0.94 mm inner diameter), (Harvard Apparatus Ltd, Kent, UK) containing an inner 
filament, using a P-97 Flaming/Brown type horizontal puller (Sutter Instruments Co., 
U.S.A.). Micropipettes were filled with ACSF (resistance 2 - 5 MD).
Data were recorded in current-clamp mode, and amplified by an Axoclamp-2A 
amplifier (X10 Axon instruments Inc., U.S.A.) and a Neurolog AC-DC preamplifier 
(Digitimer Ltd.).  Extracellular data were band pass filtered at 0.002 - 0.42 kHz. Mains 
supply noise (50 Hz) was eliminated from the raw signal by Humbugs (Quest 
Scientific Instruments Inc., Canada). Data were redigitised at 10 kHz by an Instutech 
ITC-16 A/D board (Instutech Corp., U.S.A.) and stored on an AppleMac Power G4 
computer using AxoGraph 4.6 software (Axon Instruments) for off-line analysis.
The behaviour and properties of network oscillations were determined by calculating 
the power spectra of network activity by performing Fast-Fourier Transforms (FFTs) 
on 60 s worth of activity. Due to the variation in the peak frequencies between 
experiments the power of gamma oscillations in the frequency range 30 -  80 Hz was 
calculated. This quantitative measure of oscillatory strength was generated by using 
AxoGraph 4.6 to calculate the area under the spectra in this frequency range.
94Chapter 3
Pharmacological characterisation of GPR10
95(i)  Introduction
In the original paper identifying PrRP as the ligand for GPR10, [125l]-bovine PrRP-31 
was shown to bind to membranes from CHO cells stably expressing both GPR10 and 
the rat orthologue, UHR-1  (GPR10 and UHR-1  share 90% homology at the amino 
acid level). [125l]-bovine PrRP-31  bound with high affinity and almost identical KD  
values of 26 and 25 pM to GPR10 and UHR-1, respectively (Hinuma et al,  1998). 
Binding to both GPR10 and UHR-1  appeared to be monophasic, although the levels 
of specific binding were only defined by five data points and did not appear to fully 
saturate at up to approximately 30 nM ligand. A similar radioligand binding study with 
[125l]-human PrRP-31  in membranes from CHO-K1  cells stably expressing GPR10 
suggested that the radioligand bound to GPR10 in a monophasic fashion, although 
with a substantially higher Kd value of approximately 1   nM (Roland etal.,  1999). The 
same authors also described specific [125l]-human PrRP-31  binding to the reticular 
thalamic nucleus and to a lesser extent to the periventricular hypothalamus in coronal 
sections of rat brain. No other regions displayed any specific binding. These data 
may reflect a very specific localisation of UHR-1  or, more likely, a low level of 
expression of UHR-1  in regions other than the thalamus and hypothalamus beyond 
detection in this paradigm. Satoh etal. (2000) have also demonstrated [125l]-humar 
PrRP-31  binding in rat native tissue. [125l]-human PrRP-31  displayed specific binding 
in membranes from hypothalamus, medulla, cerebellum, pituitary, heart, soleus 
muscle, adipose tissue, kidney, adrenal gland, testis and small intestine. Highest 
levels of specific binding were observed in hypothalamus (50%), heart (46%), soleus 
muscle (45%) and pituitary (44%), where inhibition binding studies with [125l]-human 
PrRP-31  suggested IC50 values for unlabelled PrRP-31  of 5.2, 6.6, 9.8 and 1.4 nM, 
respectively. These data are largely in agreement with the affinity of [125l]-human 
PrRP-31  for CHO cells stably expressing GPR10 (Roland etal.,  1999), although
96substantially lower than the affinity of [125l]-bovine PrRP-31  binding to UHR-1 
(Hinuma etal.,  1998).
Studies in rat heart and hypothalamus also suggested rapid kinetics for the binding of 
[125l]-human PrRP-31, with equilibrium being reached within 5 minutes at 4°C and 
stable for up to 90 min, although not for longer than 30 min at room temperature 
(Satoh et al., 2000). Isotopic dilution induced dissociation at 4°C was initially rapid, 
though appeared biphasic with a much slower rate resulting in only 90 % and 70 % of 
[125l]-human PrRP-31  specific dissociation being complete after 60 min in heart and 
hypothalamic membranes, respectively (Satoh etal., 2000).
The signal transduction pathways for GPR10 have not yet been fully characterised, 
although there are a number of studies that have suggested signalling pathways 
through which GPR10 may couple. In the initial report describing PrRP as the ligand 
for GPR10, PrRP was claimed to induce intracellular calcium influx in cells stably 
expressing GPR10 (Hinuma etal., 1998). Furthermore, PrRP-31  stimulates calcium 
mobilisation in both HEK293 and CHO cells expressing GPR10 in the absence of any 
co-expressed promiscuous G protein with potencies in the 1   -  2 nM range (Wilson et 
al.,  1998; Boyle etal., 2005; Bhattacharyya etal., 2003;  Roland et al.,  1999). These 
data suggest that GPR10 may be signalling through the Gq/n pathway to stimulate 
PLC and intracellular calcium mobilisation in these assay systems.
However, in a study in both GH3 rat pituitary cells and primary cultures of rat anterior 
pituitary,  PrRP activated extracellular signal-regulated kinase (ERK) in an almost 
wholly PTX-sensitive manner (Kimura etal., 2000), presumably via activation of 
endogenously expressed UHR-1. In addition,  PrRP has been shown to inhibit cAMP 
production (Hinuma etal.,  1998) and stimulate [35S]GTPyS binding in CHO cells 
stably expressing GPR10 in a wholly PTX sensitive manner (Engstrom etal., 2003).
97In both the Engstrom  etal. (2003) and Kimura etal (2000) studies the potency of 
PrRP to activate GPR10 appears to be in line with the potency of PrRP-20 and PrRP- 
31  to stimulate arachidonic acid metabolism (Hinuma etal.,  1998) and calcium 
mobilisation (Wilson etal.,  1998; Roland etal.,  1999) in CHO cells stably expressing 
GPR10. Hinuma et al. (1998) do not show any data to support their claim that PrRP 
inhibits cAMP production.  Furthermore, the PrRP-mediated stimulation of [35S]GTPyS 
binding in CHO cells stably expressing GPR10 (Engstrom etal., 2003) is relatively 
small. However, these data suggest that at least part of the coupling of GPR10 may 
be through the G/G0 family of G proteins.
Additionally, Kimura etal. (2000) demonstrated that PrRP causes activation of c-Jun 
N-terminal protein kinase (JNK). This response is protein kinase C (PKC) dependent, 
as it is inhibited by pre-incubation with phorbol esters and insensitive to PTX 
treatment.
It is apparent from this small data set that the signal transduction cascade mediated 
by stimulation of GPR10 remains unclear. Given that all data (except that of Kimura 
et al. (2000)) has been generated in recombinant cells likely overexpressing GPR10, 
it is difficult to draw any firm conclusions on the physiological signal transduction 
pathway for GPR10 due to the possibility of promiscuous coupling to multiple G 
proteins. However, given the numerous reports of calcium mobilisation induced by 
PrRP in cells expressing GPR10, it seems likely that the receptor couples through 
the Gq/n pathway, although the signal transduction pathways for GPR10 clearly 
warrant further investigation.
More recently, the pharmacology of PrRPs at other RF-amide receptors has been 
investigated. Most interestingly, both hPrRP-20 and hPrRP-31  display high affinity for 
both the NPFF2 receptor stably expressed in CHO cells and the rat NPFF receptor in
98spinal cord (Engstrom etal., 2003). These data, generated using 
[125l](1 DMe)Y8Famide binding assays, suggested that both hPrRP-20 and hPrRP-31 
have nanomolar affinity for both the rat NPFF receptor in rat spinal cord and the 
NPFF2 receptor stably expressed in CHO cells, with affinities only approximately 30- 
fold and 5-fold, respectively, lower than the cognate ligand NPFF itself. Furthermore, 
in [35S]GTPyS binding studies in CHO cells stably expressing the NPFF2 receptor, 
both hPrRP-20 and hPrRP-31  appeared as full agonists, with EC50 values of 170 nM 
and 240 nM, less than  10-fold lower than that of NPFF (28 nM;  Engstrom etal., 
2003). Interestingly, this was the first report separating the efficacy of PrRP forms in 
that hPrRP-31  appeared as a ‘super agonist’, with substantially higher efficacy than 
hPrRP-20 and even NPFF and (1DMe)Y8Famide.
Studies conducted by Han etal. (2002) have determined PrRP-20 mediated 
stimulation of the orphan mas-related gene receptor, MrgC11, with an EC50 of 144 
nM, as measured by calcium mobilisation in HEK293 cells stably expressing MrgC11. 
PrRP-20 was shown to be inactive at a similar, related receptor, MrgA1. A range of 
other RF-amide peptides, including NPFF,  RFRP-3, antho-RF-amide and FMRF- 
amide, were also shown to activate MrgC11   with potencies in a similar range to 
PrRP-20, suggesting that the cognate ligand for this receptor may well be an, as yet, 
undiscovered member of this peptide family. Similarly, in the studies by Engstrom et 
al. (2003), a number of RF-amide peptides we re shown to bind to, and activate, the 
NPFF2 receptor with affinities and potencies within 10-fold of those displayed by 
NPFF. These data mark out GPR10 as unusual in displaying such selectivity for 
PrRPs versus other members of the RF-amide peptide family.
Initial studies have suggested that in contrast to other RF-amide peptide receptors, 
such as those for NPFF, GPR10 exhibits a high degree of selectivity for PrRPs 
amongst the RF-amide peptides and a wider range of ligands. Whilst PrRPs have
99been shown to activate GPR10 at concentrations of approximately 1   -  2 nM  (Wilson 
etal.,  1998; Boyle etal., 2005; Bhattacharyya etal., 2003; Roland etal.,  1999) and 
bind to GPR10 with similarly high affinity (Roland et al.,  1999), no other ligands have 
been shown to bind to, or activate, GPR10 with such high affinity or potency. GPR10 
displays no significant affinity for NPFF, NPAF,  RFRP-1,  RFRP-3 and neuropeptide- 
Y(18-36) as measured by [125l]-PrRP-20 inhibition binding assays (Engstrom et al., 
2003) and neither NPY, NPFF nor NPAF stimulated calcium mobilisation in HEK293 
cells stably expressing GPR10 (Wilson etal., 1998). Furthermore, non-PrRP RF- 
amide peptides (FMRF-amide, antho-RF-amide and pol-RF-amide) only weakly 
stimulated calcium mobilisation, with EC50 values in excess of 10 p.M (Wilson etal., 
1998). Radioligand binding studies using [125l]-hPrRP-31  in rat hypothalamus, heart, 
soleus muscle and pituitary also showed that thyrotropin-releasing hormone, 
lutenising hormone-releasing hormone, growth hormone-releasing hormone, 
somatostatin, calcitonin, a-calcitonin gene related peptide, amylin, galanin, arginine 
vasopressin, endothelin-1, substance P, cholecystekinin, glucagon, glucagon like 
peptide-2, rat pancreatic polypeptide nor neuropeptide-Y display any significant 
affinity for GPR10 at concentrations up to 1  pM (Satoh et al., 2000). These data 
further underline the selectivity of GPR10 for the PrRPs.
Despite the studies described above, relatively little is known with regard to the 
pharmacology of the interaction of PrRP and GPR10 and the subsequent signal 
pathways involved. The studies on GPR10 reported in this chapter were aimed at 
characterising the pharmacology of PrRPs and GPR10 using radioligand binding and 
functional assays. These studies have fully characterised the binding of [125l]-hPrRP- 
20 to the GPR10 receptor stably expressed in FIEK293 cells using saturation, 
inhibition and kinetic assays. Functions of rat and human PrRPs have also been 
assessed using calcium mobilisation, cAMP Flashplate technology and inositol 
phosphate accumulation assays to assess the signal transduction pathways involved
100after activation of GPR10. Most functional assays were carried out using HEK293 
cells transiently expressing GPR10 due to an intractable infection in the stable cell 
line.
(ii)  HEK293-GPR10 [1 25l]-hPrRP-20 saturation binding assays
Saturation assays were carried out to determine the affinity and maximal binding 
capacity of [125l]-hPrRP-20 binding to membranes from HEK293 cells stably 
expressing GPR10. Specific binding of [125l]-hPrRP-20 represented more than 90% of 
total binding and was saturable, whereas non-specific binding increased linearly with 
radioligand concentration (Figure 9a).  Non-specific binding was defined using rat 
PrRP-31  to eliminate the possibility of pseudo-specific binding. Non-linear regression 
analysis of binding data revealed that [125l]-hPrRP-20 bound to two sites on the 
HEK293-GPR10 membranes with equilibrium dissociation constant (KD ) values of 
0.026 ± 0.006 nM and 0.57 ±0.14 nM, with respective maximal binding capacity 
(Bm ax) values of 3010 ± 400 fmol / mg protein and 8570 ± 2240 fmol / mg protein 
(Figure 9b). This was reflected in the clearly curvilinear nature of the Scatchard 
regression (Figure 9b).  Each individual experiment showed a two site fit to be 
statistically better than a one site fit (p < 0.05, F-test). No specific binding was 
detected in membranes from wild-type HEK293 cells (data not shown). Specific 
binding of [125l]-hPrRP-20 to membranes from HEK293 cells transiently transfected 
with wild-type GPR10 displayed similar high and low affinity KD  and Bm ax values to 
those of the stable cell line (Langmead et al., 2000). Analysis of binding data 
revealed that [125l]-hPrRP-20 bound to two sites on membranes from the HEK293 
cells transiently expressing GPR10 with KDvalues of 0.05 ± 0.01  nM and 
1.55 ± 0.52 nM and respective Bm ax values of 2605 ± 1072 fmol mg protein'1  and 
6275 ± 800 fmol mg protein'1.
101A
30000-1
25000-
M o  ®  20000-
15000-
rJL,  O
“   E
CM  S —
10000-
0.0  0.5  1.0  1.5  2.0  2.5  3.0  3.5  4.0
Total
B
[125l]-PrRP-20 (nM)
1.0  -i
0.8  -
3 £ 0.6
■o
|  0-4
CO
0.2  -
0.0
Scatchard data points 
High affinity; KD= 0.017 nM 
Low affinity;  KD = 0.61  nM
0.00  0.01  0.02  0.03  0.04  0.05
Bound (nM )
" " "  i ~  i
0.06  0.07
Figure 9. (A) Total, non-specific and specific binding of [125l]-hPrRP-20 binding to 
membranes from HEK293 cells stably expressing GPR10 with increasing radioligand 
concentration. Data represents a single, representative experiment, with each point 
determined in quadruplicate, which was replicated six times with similar results. (B) 
Scatchard transformation of the data from (A). Dashed lines indicate high and low 
affinity binding sites.
102(iii) HEK293-GPR10 [1 25l]-hPrRP-20 kinetic binding assays
Kinetic studies of [125l]-hPrRP-20 binding to HEK293-GPR10 cell membranes were 
performed in order to determine the time course of radioligand association and 
dissociation. Association studies indicated that [125l]-hPrRP-20 binding to HEK293 
cell membranes reached equilibrium within 60 min. Association curves appeared to 
be biphasic and in 3 out of 5 studies a two-site fit was preferred to a single-site by 
statistical analysis (F-test). However, estimates of observed association constants for 
the two site fits were extremely variable and hence all data were analysed based on 
monophasic exponential association (Figure 10a and inset linear transformation).
Dissociation of [125l]-hPrRP-20 upon addition of excess cold rat PrRP-31  was very 
slow and appeared monophasic, with 50% of specific binding being dissociated after 
120 min (Figure 10b and inset linear transformation).
Single site analysis of these kinetic data yielded a ko b s  value of 0.077 ± 0.008 min'1  
and a koff value of 0.0048 ± 0.0002 min'1, leading to a calculated ko n  value of 396 ± 54 
min'1  pM'1. The KD  value derived from these data was 0.012 nM, which is similar to 
the value for the high affinity site derived from the saturation studies.
(iv)  HEK293-GPR10 [1 2 5 l]-hPrRP-20 inhibition binding assays
Human PrRP-20, human PrRP-31, rat PrRP-20 and rat PrRP-31  displayed high 
affinity for GPR10 receptors, with pK) values of 9.59 ± 0.18, 9.19 ± 0.31, 9.62 ± 0.08 
and 9.68 ± 0.03, respectively (Table 5;  Figure 11). All inhibition curves appeared to 
be monophasic and Hill slopes did not differ significantly from  1   (F-test). These 
values agree well with previous estimates of affinity for the PrRP isoforms (Hinuma et 
al.,  1998;  Roland etal.,  1999).
103A range of other drugs which are known ligands at receptors which share limited 
homology with GPR10 were tested against [125l]-hPrRP-20 binding to determine the 
selectivity of GPR10 for the PrRPs. None of the compounds tested displayed any 
affinity for GPR10 receptors at concentrations of up to 30 pM (3 pM for SB-213698; 
Table 6).
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Figure 10. Time course of (A) association and (B) dissociation of [125l]-hPrRP-20 to 
and from membranes from HEK293 cells stably expressing GPR10. Insets show data 
transformed as semi-log plots where Bt is specific binding measured at time t and Be  
is the specific binding at equilibrium. Data represents a single experiment in duplicate 
that was repeated 5 (association) and 3 (dissociation) times with similar results.
105Peptide / Species Human Rat
PrRP-20 9.59 ±0.18 9.62 ± 0.08
PrRP-31 9.19 ±0.31 9.68 ± 0.03
Table 5. Affinities of PrRP variants for GPR10. Data are the mean of 3 independent 
experiments (± s.e.m.). Affinity {pK) values calculated from IC50 values as described 
in Appendix 1.
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Figure 11. Concentration-dependent inhibition of [125l]-hPrRP-20 binding from 
membranes of HEK293 cells stably expressing GPR10 by (A) rat PrRP-20 and rat 
PrRP-31  and (B) human PrRP-20 and human PrRP-31.  Data shown are the mean of 
3 experiments; error bars show s.e.m..
107Compound Native receptor p/C/ at GPR10
Substance P NK-1 <4.5
Neurokinin-A NK-2 <4.5
Methyl-Phe7-Neurokinin-B NK-3 <4.5
DAMGO p-opioid <4.5
U-50488 K-opioid <4.5
SB-213698 8-opioid <5.5
Nociceptin ORL-1 <4.5
Naloxone p-opioid <4.5
Neuropeptide-Y NP-Y <4.5
Neuropeptide-FF NP-FF <4.5
Somatostatin SST-R <4.5
Table 6. Affinities of a range of drugs active at G protein coupled receptors which 
share limited homology with GPR10. p/C/values are from 2 - 3 determinations.
108(v) HEK293-GPR10 calcium mobilisation assays
Previous studies have demonstrated that PrRPs are capable of activating GPR10 to 
mobilise intracellular calcium in cells recombinantly expressing this receptor (Roland 
et al., Bhattacharyya et al., 2004; Boyle etal., 2005). Human PrRP-20 stimulates 
intracellular Ca2+ mobilisation in HEK293 cells transiently transfected with the GPR10 
receptor; an example trace of the temporal calcium response to 1   pM hPrRP-20 is 
shown in Figure 12.  Furthermore, human PrRP-20, human  PrRP-31, rat PrRP-20 and 
rat PrRP-31  were approximately equipotent in stimulating calcium mobilisation 
(Figure 13); all four PrRPs appeared as agonists with pEC50 values of 9.54 ± 0.09, 
9.34 ±0.12, 9.77 ±0.14 and 9.46 ± 0.02 respectively, with Hill slopes not significantly 
different from unity (F-test). Agonist activity was assumed to be full as PrRPs are the 
cognate ligands for GPR10.  PrRPs did not stimulate calcium mobilisation in 
untransfected HEK293 cells (data not shown).
(vi)  HEK293-GPR10 Ca2 +  mobilisation -  signal transduction studies
Signal transduction studies were carried out on the calcium mobilisation response 
mediated  via GPR10 to determine whether the response was consistent with 
coupling to the Gq/n-phospholipase-C-IP3 pathway. The effects of a range of signal 
transduction inhibitors on the calcium mobilisation responses to hPrRP-20 are shown 
in Figure 14. The phospholipase-C inhibitor, U73122 (Thompson etal.,  1991;  10 j l iM), 
inhibited hPrRP-20 stimulated calcium mobilisation, reducing the maximal response 
to approximately 30 % of the maximal control response. The non-competitive inhibitor 
of the inositol triphosphate (IP3) receptor, 2-APB (Maruyama etal.,  1997; 100 pM), 
similarly reduced the maximal response to hPrRP-20 to approximately 30 % of the 
control response. The Ca2+-ATPase inhibitor, thapsigargin (Marshall etal., 2003;  1  
fiM),
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Figure 12. Temporal calcium response to hPrRP-20 (1  pM) in HEK293 cells 
transiently expressing GPR10. Peptide was added at t = 10 s. Data represents the 
mean of 8 independent calcium measurements; error bars represent s.e.m..
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Figure 13. Concentration-dependent stimulation of intracellular Ca2 +  mobilisation in 
HEK293 cells transiently expressing GPR10 by (A) rat PrRP-20 and rat PrRP-31  and 
(B) human PrRP-20 and human PrRP-31. Data are the means of 4 experiments; 
error bars show s.e.m..
I l labolished the calcium mobilisation response to hPrRP-20. The phosphoinositide-3- 
kinase and phospholipase-D inhibitor, wortmannin (1  pM), did not significantly alter 
the calcium mobilisation response to hPrRP-20 (F-test). No cellular toxicity was 
observed with any of the inhibitors and the final DMSO concentration was always 
^ 1% (v/v). The effects of U73122, 2-APB and thapsigargin on the hPrRP-20 
stimulated calcium response are consistent with GPR10 coupling to the Gq/n- 
phospholipase-C-IP3 pathway.
(vii) HEK293-GPR10 inositol phosphate accumulation
Inositol phosphate accumulation assays were performed to confirm whether PrRP 
mediated activation of GPR10 led to the hydrolysis of PIP2 and the production of 
inositol phosphates. Human PrRP-20 potently stimulated inositol phosphate 
accumulation in HEK293 cells transiently transfected with GPR10 with a pEC50 of 
10.21  ± 0.05 and an Em ax of 435 ± 5 cpm (Figure 15). Carbachol, acting via activation 
of endogenous muscarinic M3 receptors (Brandish et al., 2003), stimulated inositol 
phosphate accumulation with a pEC50of 4.95 + 0.09 and an Em ax of 534 ±12 cpm in 
the same cell line (Figure 15).
(viii) cAMP accumulation studies
Human PrRP-20 (10 pM) did not elevate intracellular cAMP levels in HEK293-GPR10 
cells (2.96 ± 0.42 pmol / 106 cells compared to basal level of 4.09 ± 0.57 pmol 106 / 
cells;  Figure 16). Human PrRP-20 (10 pM) also failed to significantly decrease cAMP 
levels following stimulation with concomitantly administered forskolin (30 pM; 508 ± 
12.6 pmol  106 / cells compared to control level of 502 ± 17.8 pmol 106 / cells;  Figure 
16).
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Figure 15. Concentration-dependent stimulation of inositol phosphate accumulation 
by hPrRP-20 and carbachol in HEK293 cells transiently expressing GPR10. Data 
shown are the means of 4 experiments; error bars represent s.e.m..
113(ix)  Discussion
These studies indicate that [125l]-hPrRP-20 is a high affinity radioligand for the 
GPR10 receptor. Saturation studies clearly suggested the existence of two distinct 
binding sites for [125l]-hPrRP-20 which bind with sub-nanomolar affinity (KD  values of 
0.026 nM and 0.57 nM respectively).
Kinetic studies were unable to accurately discern two distinct binding sites and 
although a trend towards biphasic association was observed, this was not 
consistently replicated. Dissociation of [125l]-hPrRP-20 was very slow and apparently 
monophasic. Single site analysis of the data produced a KD  of 0.012 nM, which is 
similar to the value for the higher affinity site obtained from saturation studies. The KD  
value of the higher affinity site determined by saturation studies is similar to that 
reported by Hinuma etal. (1998) for bovine [125l]-PrRP-31  binding to hGR3/GPR10 
and UHR-1. The KD  of the lower affinity site is similar to the affinities of human and 
rat PrRP-20 and PrRP-31  determined by inhibition of [125l]-hPrRP-20 binding and also 
the affinity of [125l]-hPrRP-31  as determined by Roland etal. (1999).
The apparently monophasic saturation analysis initially described by Hinuma et al. 
(1998) represents a rather incomplete 5 data point study in which the binding of the 
radioligand did not saturate. The saturation study by Roland etal. (1999) was more 
extensive, covering 9 data points, yet the higher concentration range tested may 
have missed any higher affinity binding site at lower radioligand concentrations.
Several different possibilities could result in the observed two-site binding of [125l]- 
hPrRP-20.  Firstly, it may be that there are two physically distinct sites of attachment 
for different parts of the peptide. Whilst it has been recognised both in these studies 
(Chapter 4) and in the literature (Roland etal., 1999) that hPrRP(25-31), a truncated
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Figure 16. Effect of hPrRP-20 on basal and forskolin-stimulated cAMP levels in 
HEK293 cells stably expressing GPR10. Data shown are the means of 3 
experiments; error bars represent s.e.m..
115seven amino acid C-terminal portion of hPrRP-20, retains agonist activity at GPR10, 
the potency of the truncated peptide is reduced approximately 30 to 100-fold 
compared to the full length peptide. This implies that the N-terminal region must 
contribute to the higher potency of PrRP-20 compared to PrRP(25-31), either by 
stabilising the C-terminal region in the binding pocket or through a direct interaction 
with the receptor. The possibility of two direct receptor-peptide interactions mediating 
the observed biphasic binding is discussed further in Chapter 4.
An alternative possibility is that receptors coupled to heterotrimeric G proteins may 
bind the agonist peptide with higher affinity than uncoupled receptors. The existence 
of a ‘high agonist affinity state’ has been extensively described for small molecule 
agonist G protein coupled receptors, such as 5-HT1 A  (Newman-Tancredi etal., 1998), 
muscarinic M2 (Birdsall etal.,  1981) and dopamine D2 (Lahti etal., 1992) receptors. 
The availability of non-hydrolysable analogues of GTP, such as GppNHp, permits 
experimental determination of such states. By carrying out ‘GTP-shift’ studies, where 
inhibition or saturation isotherms are carried out in the presence of increasing 
concentrations of GppNHp, it should be possible to delineate whether the high affinity 
[125l]-hPrRP-20 binding occurs as a result of G protein coupling. If the high affinity 
binding site were to represent binding to G protein coupled receptors, the presence 
of GppNHp should shift the high affinity component into a low affinity state and result 
in a monophasic profile.
Alternatively, it is possible that PrRP-31  (used in both the studies by Hinuma et al. 
(1998) and Roland etal. (1999)), unlike PrRP-20, does not exhibit two site binding. 
Intuitively it might be expected that PrRP-20, as a truncate of PrRP-31, might exhibit 
a less, rather than more, complex binding profile than the longer analogue. However, 
in the absence of a comparative study with [125l]-hPrRP-20 and [125l]-hPrRP-31  this 
question remains unanswered.  Finally, it is possible that the iodination of hPrRP-20
116required in order to synthesise the radioligand may alter the conformation of the 
peptide such that it displays biphasic binding in a manner that the native peptide 
does not. This is, however, unlikely, as both the Hinuma etal. (1998) and Roland et 
al. (1999) studies employed iodinated ligands -  in neither of these studies were 
biphasic binding profiles observed. The data presented herein provide the most 
extensive characterisation of the binding of [125l]-hPrRP-20 to GPR10 to date and 
clearly suggest the presence of biphasic binding.
All four forms of PrRP (human 20 and 31  and rat 20 and 31) bound to GPR10 
receptors with high and similar affinity (pKj values » 9) in a competitive manner with 
Hill slopes not significantly different from unity. In contrast, no other ligand studied 
exhibited any affinity for the receptor at concentrations up to 3 pM. These 
observations are in agreement with the low levels of homology between GPR10 and 
other known G-protein coupled receptors. Indeed, the greatest identity (30% 
homology) is seen with the neuropeptide Y receptor family and here it has been 
shown that neuropeptide Y has very low affinity for GPR10 (pK, < 4.5). In addition, 
the mammalian RF-amide neuropeptide-FF displays similarly low affinity for the 
receptor (pK, < 4.5).  Further supporting this, neuropeptide-FF was also found to be 
inactive at GPR10 in calcium mobilisation studies (Wilson etal.,  1998). These data 
are in contrast to findings for other RF-amide peptide receptors, which have been 
shown to be activated by range of members of the RF-amide family, such as MrgA1 
and MrgC11  (Han etal., 2002) and NPFF-2 (Engstrom etal., 2003). Interestingly, the 
latter study demonstrated potent agonist activity of the prolactin-releasing peptides at 
the NPFF-2 receptor. Despite the apparent promiscuous activity of their cognate 
ligands, the findings described herein demonstrate the high degree of selectivity of 
GPR10 for the prolactin releasing peptides.
117In calcium mobilisation studies, all four PrRP peptides were shown to be potent, full 
agonists at the GPR10 receptor. The sub-nanomolar potencies of these peptides 
agreed with their affinities as determined by inhibition of [125l]-hPrRP-20 binding. 
Further calcium mobilisation studies showed that the response to hPrRP-20 was 
completely abolished by pre-incubation for 30 minutes with thapsigargin, an inhibitor 
of the endoplasmic reticulum Ca2+-ATPase.  Furthermore, the response to hPrRP-20 
was almost completely blocked by the inhibitor of phospholipase-C, U73122 and the 
non-competitive inhibitor of the IP3 receptor, 2-APB. The phosphoinositide-3-kinase 
and phospholipase-D inhibitor, wortmannin, did not alter the response to hPrRP-20. 
These results are entirely consistent with GPR10 mediating signalling through the 
Gq/n-phospholipase-C-IPa pathway to mobilise intracellular calcium, although in the 
absence of control data (eg. treatment of cells with the inactive isomer of U73122, 
U73443), non-specific cytotoxic effects of these inhibitors cannot be ruled out. 
However, in support of this hypothesis, hPrRP-20 potently stimulated IP 
accumulation in HEK293 cells transiently expressing GPR10, consistent with the 
phospholipase-C catalysed breakdown of PIP2 to IP3 and DAG. These observations 
are in good agreement with numerous previous studies that, although all employing 
recombinant systems, have shown GPR10 to couple to the mobilisation of 
intracellular calcium in the absence of any co-expressed G proteins (Wilson et al., 
1998; Roland etal.,  1999; Bhattacharyya etal., 2003; Boyle etal., 2005).
In contrast, studies on HEK293-GPR10 cells using Flashplate technology showed 
that human PrRP-20 had no effect on basal levels of intracellular cAMP. This implies 
that GPR10 does not couple through Gs, which would activate adenylyl cyclase to 
increase the cAMP concentration. Additionally, hPrRP-20 failed to decrease cAMP 
levels after stimulation with forskolin, indicating that GPR10 does not couple via Gj 
(which would inhibit adenylyl cyclase to lower cAMP levels). However, it must be 
noted that cAMP studies were carried out in the HEK293 cells stably expressing
118GPR10, rather than the transient expression systems used for all other functional 
data. These data are in contrast to that of Kimura et al. (2000), which showed that 
PrRP stimulated extracellular signal-regulated protein kinase (ERK) in both GH3 rat 
pituitary tumour cells and primary cultures of rat anterior pituitary. They demonstrated 
that the effect was largely pertussis toxin sensitive, indicating that the greatest 
coupling contribution was via G/G0 and likely to mediated via G(3y subunits. 
Additionally, they showed that ERK activation is independent of intracellular calcium. 
Furthermore, Engstrom et al. (2003) also demonstrated a small, but significant 
pertussis toxin sensitive stimulation of [35S]GTPyS binding in CHO cells stably 
expressing GPR10 by PrRPs.
However, Kimura et al. (2000) also demonstrate that activation of c-Jun N-terminal 
protein kinase (JNK) by PrRP is fully dependent on protein kinase C (PKC). This 
suggests the possibility that GPR10 also signals through a Gq  pathway to stimulate 
PLC to produce diacylglycerol (DAG) and activate PKC. Comparison of the findings 
of Kimura et al. (2000) and Engstrom et al. (2003) with the results presented here 
suggest that the coupling of GPR10 may be dependent on the cell system in which it 
is expressed and the pathway being monitored.
These studies have confirmed the high affinity binding of [125l]-hPrRP-20 to GPR10 
and further suggested the existence of high and low affinity binding sites., although 
their aetiology remains unknown. Functional studies clearly suggest that GPR10 
couples via Gq/n to the phospholipase C-IP3 signalling pathway, as hPrRP-20 has 
been shown to stimulate both calcium mobilisation and inositol phosphate 
accumulation when expressed in HEK293 cells. Furthermore, at least in this 
recombinant system, hPrRP-20 has been shown not to alter intracellular cAMP 
levels, suggesting that GPR10 does not couple via Gs  or G/G0 proteins.
119These results represent significant advances in understanding the binding profile of 
the PrRPs at GPR10 and elucidating the signal transduction pathway(s) of the 
receptor. [125l]-hPrRP-20 has been shown to be a high affinity, selective radioligand 
for GPR10 which may prove a very useful tool in future studies into the localisation 
and function of the receptor. The calcium mobilisation and inositol phosphate 
accumulation data clearly suggest that GPR10 is capable of robust coupling to the 
Gq/11 -phospholipase-C-1 P3 signalling pathway, at least in a recombinant system. 
However, it may be that, as described by Kimura etal. (2000), differential G protein 
coupling occurs in native systems. This, as yet, remains undetermined.
120Chapter 4
Characterisation of the PrRP-GPR10 interaction
121(i) Introduction
In common with other RF-amide peptide ligands, the amide group distal to the 
terminal phenylalanine residue of PrRP appears to be key to activity as bovine PrRP- 
31 -COOH (the non-amidated acid) neither binds to GPR10 nor stimulates 
arachidonic acid metabolism in CHO cells stably expressing GPR10 (Hinuma etal., 
1998; Nishimura etal.,  1998). Several subsequent studies have examined the 
structure of the PrRPs and attempted to identify key residues for activity at GPR10. 
The main structural feature of PrRP-20 as determined by NMR spectroscopy appears 
to be a flexible N-terminus with no regular secondary structure and an a-helical 
structure spanning the C-terminal ten amino acids (Danho etal., 2003; D’Ursi etal.,
2002). This basic template appears similar to the C-terminal structure of another 
amidated peptide, NPY (D’Ursi etal., 2002). These structural data provided rationale 
to support the observation that substantial agonist activity at GPR10 is retained in 
both C-terminal heptapeptide (Roland etal., 1999) and hexapeptide (Danho etal.,
2003) fragments of PrRP-20, albeit with reduced potency. The C-terminal 
heptapeptide fragment, PrRP(25-31), stimulates calcium mobilisation in CHO cells 
stably expressing GPR10 with an EC50 of approximately 30 nM as compared to ~ 1  
nM for PrRP-20 (Roland etal.,  1999). Similarly, successive N-terminal deletions from 
PrRP-20 to PrRP(25-31) resulted in successive reductions in peptide affinity as 
measured by [125l]-hPrRP-31  binding (Roland etal.,  1999). In an elegant study, the 
same authors performed alanine scanning of the heptapeptide PrRP(25-31) which 
resulted in reductions in affinity for GPR10 at all positions, but most markedly when 
Arg2 (Arg26 in PrRP-31) and Arg6 (Arg30 in PrRP-31) were substituted (Roland etal., 
1999). Furthermore, alignment of the sequences of NPY and hPrRP-31  revealed 
significant homology between the two (D’Ursi etal., 2002) and aligns Arg30 of hPrRP- 
31  with Arg35 of NPY. This residue has been shown to be crucial for NPY activity, 
since replacement of Arg35 by Ala results in a complete loss of affinity at all cloned
122NPY receptor subtypes (Cabrele & Beck-Sickinger, 2000).  Most recently, an 
extensive study has examined a large number of single replacement analogues of a 
C-terminal tridecapeptide fragment of hPrRP-31, PrRP(19-31) (Boyle etal., 2005). 
PrRP(19-31) retains significant potency and affinity at GPR10 as measured by 
calcium mobilisation and Eu-(Lys)PrRP-31  binding to HEK293 cells stably expressing 
GPR10 (EC50 = 20 nM; Kj = 5.3 nM). These studies have focussed mainly on the C- 
terminal six residues of the peptide, particularly on the Phe3 1   residue. Both 
methylation of Phe3 1  and substitution of the C-terminal amide with an acid or an 
alcohol effectively abolished functional agonist activity and affinity. Replacement of 
the C-terminal amide with a secondary methylamide and to a lesser extent a methyl 
ester had little effect on potency or affinity. The data suggested that the Phe3 1  
residue was key for activity, providing a hydrophobic side-chain in the L-position, a 
free NH on the backbone and a suitably blocked carboxyl terminus (Boyle etal., 
2005). Arg30appeared to be crucial to both potency and affinity at GPR10, as 
substitution by a range of other polar residues such as Lys, His, Ser or Glu was not 
tolerated. It is clear from the data that the appropriately located diffuse positive 
charge in the L-configuration provided by Arg30is essential (Boyle etal., 2005). 
Substitution of Gly29 was also poorly tolerated and the authors speculate that this 
residue lies in a functionally important position and that as a spacer residue it 
requires unhindered flexibility to allow the peptide to fold correctly.  Replacements of 
both Val28and Pro27 suggested the ‘reasonably sized’ hydrophobic side chain in the 
L-configuration, the free NH on the backbone of Val28and the small turn provided by 
Pro27 are the reasons for their being preferred in their respective positions. A similar 
hydrophobic side chain to that of Val28 was preferred when replacements were made 
for lie25. Substitution of Arg26 for Lys was well tolerated; however, other polar 
residues in position 26 resulted in inactive analogues. The data suggest that the 
positively charged side-chain of Arg26 is important for activity, but is less crucial than 
Arg30 (Boyle etal., 2005).
123These data, together with that of Roland et a!., (1999) and D’Ursi etal., (2002) 
suggest that whilst all seven C-terminal residues of PrRP-31  may have a role to play 
in binding to GPR10, Arg26 and Arg30 may have key roles in docking the peptide into 
the agonist binding site of the receptor.
Despite the extensive structural work that has been carried out on the PrRPs, the 
precise nature of the molecular interaction between PrRP and GPR10 is unknown. 
The studies detailed above have identified many of the structural components that 
are key to the activity of PrRP at GPR10 (Roland etal., 2005; Boyle etal., 2005). 
However, the cognate binding pocket of GPR10 has not been examined. The studies 
on GPR10 reported in this chapter were designed to characterise the molecular 
nature of the interaction between PrRP and GPR10 using site directed mutagenesis, 
radioligand binding and functional calcium mobilisation assays.
A homology model of the receptor has been constructed based on the published 
crystal structure of rhodopsin and this in turn has allowed the prediction of proposed 
molecular interactions between GPR10 and the C-terminal heptapeptide of hPrRP- 
20, hPrRP(25-31) and another heptapeptide analogue, [pGlu1, Trp2, Lys3, Leu4] 
hPrRP(25-31). On this basis, site-directed mutagenesis has been carried out and 
mutant constructs assessed using [125l]-hPrRP-20 binding and functional calcium 
mobilisation with hPrRP-20, hPrRP(25-31) and [pGlu1, Trp2, Lys3, Leu4] hPrRP(25- 
31) in order to partially determine the validity of the model in predicting the key 
residues involved in hPrRP-20 binding to GPR10.
The homology model and ligand docking was performed by Dr Frank Blaney (GSK). 
SDM constructs were made by Dr Angela Bridges (GSK).
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Figure 17. Sequences and structures of (A) hPrRP-20, (B) hPrRP(25-31) and 
(C) [pGlu1, Trp2, Lys3, Leu4] hPrRP(25-31).
125(ii) Ligand docking and site directed mutagenesis
Structures of hPrRP-20, hPrRP(25-31) and [pGlu1, Trp2, Lys3, Leu4] hPrRP(25-31) are 
shown in Figure 17. Manual docking of hPrRP(25-31) was performed by allowing only 
acceptable Ramachandran < > — < p  values of the peptide backbone (Ramachandran et al., 
1963) and reasonable rotamer states of the side chains. The initial placement was 
guided by the fact that hPrRP(25-31) contained two essential basic side chains (Arg2 
and Arg6) for which acidic residues in the receptor that may form salt bridges with the 
ligand were sought. Following the various initial placements of the ligand, the complex 
was minimised with CHARMm (using NOE distance helical constraints in the TM 
bundle, distance dependent dielectric, 2000 steps Steepest Descent (SD) and 5000 
steps Adopted Basis Newton Raphson (ABNR)). All the acceptable docked solutions 
suggested that the penultimate arginine (Arg6) was able to form a salt bridge with E213, 
which is two residues along from the disulphide bond in the second extracellular loop 
(Figure 18a). This placed the terminal phenylalanine in a hydrophobic pocket between 
the TM6 residues W291  and L294, and L323 in TM7 (Figure 18a). The terminal 
carboxamide was predicted to form a hydrogen bonding network with Q141  (TM3),
E212 (ECL2) and H321  (TM7) as shown in Figure 18a. In an earlier homology model of 
GPRtCMhat did not contain the extracellular loops, the Arg6 residue was believed to 
interact with the TM6 aspartate, D302. The second arginine residue in position 2 of 
hPrRP(25-31) (Arg2) in this older model was predicted to form a salt bridge with E202 at 
the top of TM4. However, the latest model incorporating the loops instead suggested an 
ionic interaction of Arg2 with D302 (Figure 18b). A number of other hydrogen bonding 
interactions were predicted to occur between the backbone chain of the peptide ligand 
and the receptor. Thus, N298 (TM6) formed a hydrogen bond between its side chain 
carbonyl and the backbone NH of Arg6 of hPrRP(25-31) (Figure 18a). In addition to this 
the two NH hydrogens of the sidechain formed further hydrogen bonds with the 
backbone carbonyl of E213 and the carboxylate of D302, respectively, further stabilising
126A
B
Figure 18. Predicted interactions of hPrRP(25-31) with GPR10; (A) interactions with 
the C-terminal RF-amide region and (B) Arg2  - D302 and Val4  - Q317 interactions.
127the receptor structure in its binding pocket. Q317 (TM7) formed two hydrogen bonds 
with the NH and carbonyl of Val4 of hPrRP(25-31) (Figure 18b) completely locking the 
orientation of the ligand backbone in this region. The commercially available peptide 
analogue, [pGlu1, Trp2, Lys3, Leu4] hPrRP(25-31), was also docked into the GPR10 
model. It was found that the terminal Arg-Phe-CONH2 formed identical interactions 
with the receptor as had hPrRP(25-31). [pGlu1, Trp2, Lys3, Leu4] hPrRP(25-31), 
however, is a heptapeptide with a lysine residue in position 3 (Lys3;  Figure 17). 
Sequentially, therefore, it cannot align directly with hPrRP(25-31). Despite this, the 
lysine was able to adopt an acceptable rotameric state where it could still form a salt 
bridge with D302 of the receptor. This, however, placed the N-terminal pyroglutamate 
in a different pocket to that of hPrRP(25-31). As shown in Figure 19, the two peptides 
still overlay very closely in their bound conformations.
On the basis of these docking studies, the acidic and amido residues above were 
identified as targets for SDM studies. It was very important to carry out 
complementary SDM studies along with the modelling and docking as without such 
biological validation the homology model remains simply hypothetical. It was also 
particularly interesting to gain support for the predicted-binding hypotheses because 
this was the first time that a theoretically derived ioop structure for a 7TM receptor 
has suggested critical binding elements in its sequence. If the hypothesis was correct 
then this would provide support to the loop construction methodology. The following 
mutant constructs of GPR10 were made: Q141A, E202A,  E212A, E213A, N298A, 
D302A and Q317A; sites of these residues are shown on the schematic model of 
GPR10;  Figure 20). Mutations to alanine were employed in order to remove the 
amino acid side-chains beyond the p-carbon whilst maintaining the a-helical structure 
of the transmembrane domains to minimise any gross changes to receptor 
conformation.
128(iii) HEK293-GPR10 SDM [1 2 5 l]-hPrRP-20 saturation binding assays
Saturation binding was carried out on membranes prepared from HEK293 cells 
transiently expressing either wild-type GPR10 (two separate transfections and 
membrane preparations) or mutant GPR10 constructs (single transfection and 
membrane preparation) to determine the effects of the point mutations on the KD  and 
Bm ax of [125l]-hPrRP-20 binding. Specific binding of [125l]-hPrRP-20 to membranes from 
HEK293 cells transiently transfected with wild-type GPR10 displayed similar high and 
low affinity KD  and Bm ax values to those of the stable cell line (Chapter 3; Langmead et 
al., 2000). Specific binding of [125l]-hPrRP-20 to transiently expressed GPR10 
represented more than 90% of total binding and was saturable, whereas non-specific 
binding increased linearly with radioligand concentration. Analysis of binding data 
revealed that [125l]-hPrRP-20 bound to two sites on the HEK293-GPR10 membranes 
with Kd values of 0.05 ± 0.01  nM and 1.55 ± 0.52 nM, with respective Bm ax values of 
2605 ± 1072 fmol mg protein'1  and 6275 ± 800 fmol mg protein'1.
Individual KD  and Bm ax values for each receptor construct are reported in Table 7. 
GPR10-E213A, GPR10-D302A and GPR10-Q317A displayed no specific binding at 
radioligand concentrations of up to 6 pM. GPR10-E212A exhibited 2 site binding with 
-80% specific binding and a similar Bm axfor the low affinity site (6196 ± 1602 fmol / mg) 
as for the wild-type receptor (6275 ± 800 fmol / mg). However, the Bm ax for the high 
affinity site was much reduced (421  ± 90 fmol / mg) and the KD  value for the high affinity 
site (0.0036 ± 0.0007 nM) was actually lower than the wild-type (0.050 ± 0.012 nM). 
GPR10-Q141A and GPR10-N298A exhibited relatively unchanged KD  values of 0.050 ± 
0.004 and 0.085 ± 0.018 nM, respectively, but lower Bm ax values for the high affinity site 
(519 ± 43 and 251  ± 25 fmol / mg, respectively). Binding to the lower affinity site in these 
two mutants was extremely difficult to discern and, despite these saturation isotherms
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Figure 19. Overlay of hPrRP(25-31) [pGlu1, Trp2, Lys3, Leu4] hPrRP(25-31) in their 
receptor bound conformations. The alpha carbons of hPrRP(25-31) are in yellow and 
those of [pGlu1, Trp2, Lys3, Leu4] hPrRP(25-31) are in silver.
130Figure 20. Schematic representation of GPR10 highlighting key residues which were 
predicted to be involved in interactions with hPrRP(25-31); the residues circled in red 
were mutated. The yellow bar represents a disulphide bond. For reasons of clarity 
both the C-terminus and N-terminus have been truncated.
131resulting in curvilinear Scatchard analyses, for the purposes of data analysis the low 
affinity site was effectively abolished.  It is possible that reduced Bm ax values for the 
mutant constructs represents their low cell surface expression. Saturation isotherms and 
Scatchard transformations for GPR10-wild-type,  E212A, Q141A and N298A are shown 
in Figure 21. The construct E202A was not examined in the [125l]-hPrRP-20 binding 
assay due to the lack of effect of this mutation on hPrRP-20 stimulated calcium 
mobilisation (see below).
(iv)  Calcium mobilisation studies
Functional activity at GPR10 was shown to be retained even when activated by the C- 
terminal heptapeptide fragment of hPrRP-20, hPrRP(25-31) and its analogue, [pGlu1, 
Trp2, Lys3, Leu4] hPrRP(25-31), as tested on HEK293 cells transiently expressing wild- 
type GPR10 (Figure 22). Human PrRP-20, hPrRP(25-31) and [pGlu1, Trp2, Lys3, Leu4] 
hPrRP(25-31) were all shown to be full agonists, with pEC50 values of 9.54 ±0.12, 7.39 
± 0.08 and 6.55 ± 0.02, respectively. Table 8 reports the potency of hPrRP-20, 
hPrRP(25-31) and [pGlu1, Trp2, Lys3, Leu4] hPrRP(25-31) at a range of transiently 
expressed mutant GPR10 receptors. Structures of hPrRP-20 and other peptide 
analogues are shown in Figure 17.
The individual mutation Q141A caused a significant 3-fold reduction in the potency of 
hPrRP-20 to stimulate calcium mobilisation and reduced the potency of hPrRP(25-31) 
and pGlu1, Trp2, Lys3, Leu4] hPrRP(25-31) by 10-fold. N298A produced an 
approximately 10-fold reduction in the potency of all three peptides. E213A, Q317A and 
D302A had more marked effects on agonist potencies (Figure 23; Table 8). causing 
greater than  100-fold reductions in the potency of hPrRP-20 and effectively abolishing 
the agonist activity of hPrRP(25-31) and [pGlu1, Trp2, Lys3, Leu4] hPrRP(25-31) at 
GPR10. The point mutation  E202A did not significantly affect the potency of hPrRP-20;
132Receptor
Kd 1  
(nM)
Bmax 1
(fmol/mg)
Kq2
(nM)
Bmax 2
(fmol/mg)
wild-type 0.050 ±0.012 2605 ± 1072 1.55 ±0.52 6275 ± 800
Q141A 0.050 ± 0.004 519 ±43 n.d. n.d.
E202A - - - -
E212A 0.0036 ± 0.0007 421  ± 90 0.75 ±0.14 6196 ±1602
E213A n.d. n.d. n.d. n.d.
N298A 0.085 ±0.018 251  ± 25 n.d. n.d.
D302A n.d. n.d. n.d. n.d.
Q317A n.d. n.d. n.d. n.d.
Table 7. KD  and Bm ax values for [125l]-hPrRP-20 binding to membranes from HEK293 
cells transiently expressing wild-type and mutant GPR10 constructs, n.d. indicates no 
detectable low affinity binding site (Q141A and N298A) or no specific binding at [125l]- 
hPrRP-20 concentrations of up to 6 nM (E213A, D302A, Q317A). GPR10-E202A was 
not tested in the [125l]-hPrRP-20 binding assay. Data represents the mean of 3 
separate experiments (± s.e.m.).
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Figure 23. Concentration-dependent stimulation of Ca2 +  mobilisation by hPrRP-20, 
hPrRP(25-31) and [pGlu1, Trp2, Lys3, Leu4] hPrRP(25-31) at wild type and mutant 
GPR10 receptor constructs transiently expressed in HEK293 cells. Data are the 
mean of 8 (hPrRP-20) or 3 (heptapeptides) experiments; error bars show s.e.m..
136Receptor / 
Ligand h-PrRP-20 h-PrRP(25-31) [pGlu1, Trp2, Lys3, Leu4 ] 
hPrRP(25-31)
wild-type 9.54 ±0.12 7.39 ± 0.08 6.55 ± 0.02
Q141A 9.09 ± 0.04** 6.44 ± 0.22* 5.36 ±0.16**
E202A 9.29 ± 0.03 - -
E212A 8.27 ± 0.05*** 6.68 ±0.10** 5.43 ±0.16**
E213A 7.39 ± 0.05*** < 5*** < 5***
N298A 8.59 ± 0.07*** 6.47 ±0.16** 5.63 ±0.19**
D302A 7.44 ± 0.08*** < 5*** <5***
Q317A 7.07 ± 0.04*** <5*** <5***
Table 8. pEC50 values (± s.e.m.) for Ca2+ mobilisation by hPrRP-20, hPrRP(25-31) 
and [pGlu1, Trp2,  Lys3,  Leu4] hPrRP(25-31) at wild type and mutant GPR10 
constructs transiently expressed in HEK293 cells. Data are the means of 8 (hPrRP- 
20) or 3 (heptapeptides) experiments. The heptapeptide fragments were not tested at 
GPR10-E202A.
* p < 0.05; ** p < 0.01; *** p < 0.001  significantly different from wild-type response
(Student’s T-test).
137due to the minimal effect on potency the heptapeptide fragments were not tested 
against this construct.
(v) HEK293-GPR10 SDM [1 25l]-PrRP-20 inhibition binding assays
[125l]-PrRP-20 inhibition binding assays were performed to determine whether the effects 
observed in the functional studies were reflected in the binding affinities of the three test 
peptides. Human PrRP-20, h-PrRP(25-31) and [pGlu1, Trp2,  Lys3, Leu4] hPrRP(25-31) 
inhibited [125l]-hPrRP-20 specific binding in membranes from HEK293 cells transiently 
expressing wild-type GPR10 or GPR10-E212A in a concentration-dependent manner. 
Peptide affinities at both GPR10-WT and GPR10-E212A are shown in Table 9. Of the 
SDM constructs, only GPR10-E212A displayed sufficient levels of specific binding to 
yield robust inhibition curves.
(vi) Discussion
GPR10 is a relatively novel GPCR which has been characterised by a number of 
groups (Hinuma etal.,  1998; Satoh etal., 2000; Langmead etal, 2000). It has two 
endogenous ligands, known as the prolactin releasing peptides,  PrRP-20 and PrRP- 
31. Both are high affinity, equipotent, full agonists at GPR10 (Chapter 3; Langmead 
etal, 2000). Specific binding of [125l]-hPrRP-20 to membranes from HEK293 cells 
transiently transfected with wild-type GPR10 displayed similar high and low affinity KD  
and Bm axvalues to those of the stable cell line (Chapter 3; Langmead etal, 2000). 
Analysis of binding data revealed that [125l]-hPrRP-20 bound to two sites on the 
HEK293-GPR10 membranes with KD  values of 0.05 ± 0.01  nM and 1.55 ± 0.52 nM, 
with respective Bm ax values of 2605 ± 1072 fmol mg protein'1  and 6275 ± 800 fmol mg 
protein'1. Human PrRP-20 was a potent agonist at wild-type GPR10 transiently 
expressed in HEK293 cells, with a pEC50 value of 9.54 ±0.12. This value agrees well
138Ligand / Receptor GPR10-WT GPR10-E212A
hPrRP-20 10.09 ±0.17 9.68 ± 0.08
hPrRP(25-31) 7.28 ± 0.04 7.21  ± 0.06
[pGlu1, Trp2, Lys3, Leu4 ] 
hPrRP(25-31)
6.33 ± 0.09 6.24 ±0.11
Table 9. pK, (± s.e.m.) values of hPrRP-20, hPrRP(25-31) and [pGlu1, Trp2, Lys3, 
Leu4] hPrRP(25-31) to inhibit binding of [125l]-hPrRP-20 from membranes of HEK293 
cells transiently expressing GPR10-WT and GPR10-E212A. Data are the mean of 3 
experiments.
139with previously reported potencies of hPrRP-20 at GPR10 (Langmead etal., 2000; 
Roland etal.,  1999; Wilson etal,  1998). A C-terminal heptapeptide fragment of 
hPrRP-20, hPrRP(25-31), and a similar heptapeptide analogue, [pGlu1, Trp2,  Lys3, 
Leu4] hPrRP(25-31) (Figure 17), retained significant functional agonist activity at 
GPR10, with pEC50 values of 7.39 ± 0.08 and 6.55 ± 0.02, respectively.  Furthermore, 
hPrRP-20 (pKi = 10.09 ± 0.17), hPrRP(25-31) (7.28 ± 0.04) and [pGlu1, Trp2, Lys3, 
Leu4] hPrRP(25-31) (6.33 ± 0.09) displayed affinities to inhibit [125l]-hPrRP-20 binding 
from membranes of HEK293 cells transiently expressing GPR10 that were in 
extremely good agreement with their respective functional potencies.
These data suggest that the C-terminal portion of PrRP-20 is sufficient for binding 
and receptor activation. These observations are consistent with previous studies, 
which demonstrated that substantial functional activity and binding affinity were 
retained in C-terminal hexapeptide and heptapeptide fragments of hPrRP-20 (Roland 
etal.,  1999; Danho etal., 2003) and confirm the tolerance of Lys in place of Arg2 in 
the C-terminal heptapeptide (Boyle et al., 2005). However, the potency of hPrRP(25- 
31) was reduced over 100-fold compared to hPrRP-20, suggesting that the N- 
terminal portion of hPrRP-20 must contribute to the higher potency of the longer 
peptide -  either by stabilising the C-terminal portion of the peptide in its binding 
pocket or by a direct interaction with the receptor.
In this study molecular modelling has been used to predict the key residues of 
GPR10 for binding hPrRP-20. This involved the construction of an homology model 
of the GPR10 receptor, based on the crystal structure of bovine rhodopsin, followed 
by manual docking of the two heptapeptide ligands into potential binding sites. Site 
directed mutagenesis (SDM) to alanine was then performed to determine the 
involvement of specific amino acid residues, identified by modelling, in [125l]-hPrRP- 
20 radioligand binding and functional calcium mobilisation assays. Point mutations of
140residues to alanine is a commonly used technique as this simple residue contains no 
polar or aromatic side chains, yet maintains the a-helical structure of the 
transmembrane domains to minimise any gross changes to receptor conformation. 
Mutations of residues to alanine can help identify specific side-chains that are 
involved in ligand -  receptor interactions. However, changes to the amino acid 
sequence of a receptor can also result in indirect conformational effects on ligand 
binding, hence SDM data needs to be considered carefully. A similar modelling - 
SDM approach has been used in the past for a number of 7TM receptors including 
the CCR2 (Berkhout etal., 2003) and 5-HT6 receptors (Hirst etal., 2003).
Both hPrRP(25-31) and hPrRP-20 contain two basic side chains (arginine residues in 
positions 2 and 6) for which acidic partners were sought. Prior to the publication of 
the X-ray crystal structure of bovine rhodopsin, an earlier model of GPR10 had been 
built. This was based on a 6A low resolution density map of bovine rhodopsin as 
determined by cryoelectron diffraction (Unger et al.,  1997). Models based on this 
information (Blaney etal., 2001) had good alignment of the helical axes but were not 
able to accurately place the amino acid residues. Docking of hPrRP(25-31) into this 
model, which did not contain the extracellular loops, predicted the interactions of Arg2  
with E202 (located at the extracellular end of TM4) and Arg6 with D302. The new 
crystal-based model, however, suggested that TM4 was twisted around its axis 
relative to the earlier model and therefore, that E202 was no longer accessible to 
ligands. D302 was still accessible but now all acceptable docking solutions proposed 
a salt bridge between Arg2 of hPrRP(25-31) and this TM6 aspartate (Figure 18). In 
accordance with this prediction, studies showed that mutation of D302 abolished 
specific binding of [125l]-hPrRP-20 and drastically reduced the potencies of the 
agonist peptides to stimulate calcium mobilisation. Despite the absence of specific 
radioligand binding, functional responses were observed with this construct due to 
the wider range of peptide concentrations tested in this functional assay format i.e.
141up to 1   pM.  The EC50 of hPrRP-20 at D302A was approximately 30 nM. Assuming 
that the KD  of hPrRP-20 is equal to (or greater than) the EC50 value determined in the 
functional assay, it is not surprising not to detect any specific binding at [125l]-hPrRP- 
20 concentrations of up to only 6 nM.
In contrast to the effect upon loss of D302,  E202A had little effect on the potency of 
hPrRP-20 to stimulate calcium mobilisation compared to wild-type GPR10. These 
data confirm the anticipated lack of role for E202 in the binding of hPrRP-20 and also 
the expected crucial role of D302.
In the latest model containing the extracellular loops, Arg6 of hPrRP(25-31) was 
consistently predicted to form a salt bridge with E213 in the second extracellular loop 
(ECL2). In accordance with this prediction, the mutation E213A abolished the specific 
binding of [125l]-hPrRP-20 and reduced the potency of hPrRP-20 to stimulate calcium 
mobilisation by more than 100-fold. As with D302A, this construct appeared 
functional despite a lack of specific [125l]-hPrRP-20 binding. Again, this observation is 
probably a reflection of the much higher peptide concentrations tested in the 
functional assay compared to the binding assay. Furthermore, the agonist activity of 
hPrRP(25-31) and [pGlu1, Trp2, Lys3, Leu4] hPrRP(25-31) was abolished, suggesting 
that this second salt bridge is very important for agonist binding.
In previous studies, alanine substitution of Arg2 or Arg6 of hPrRP(25-31), or longer C- 
terminal peptide fragments resulted in a profound reduction in either PrRP affinity 
(Roland etal.,  1999) or potency (Boyle etal., 2005) at GPR10. The data presented 
here correlate well with previous observations of the importance of Arg2 and Arg6 to 
the function of hPrRP(25-31) (Roland etal.,  1999; Boyle etal., 2005). Of the two 
arginine residues, Arg6 appears to be especially important to peptide binding as even 
a conservative substitution to Lys abolishes both binding affinity and functional
142potency at GPR10 (Boyle etal., 2005). However, substitution of Arg2 for Lys is well 
tolerated, with only a six-fold reduction in potency and little change in affinity (Boyle 
etal., 2005). Furthermore, an arginine residue in neuropeptide-Y (NPY; Arg35) that 
aligns with Arg30 of hPrRP-31  (Arg6 of hPrRP(25-31)) is crucial to NPY binding affinity 
at all cloned NPY receptor subtypes (Cabrele & Beck-Sickinger, 2000).
It is interesting to note the predicted interaction between E213 and Arg6 of hPrRP(25- 
31) and the dramatic effect of the mutation of this residue. Given the importance of 
the penultimate arginine residue to hPrRP-20, hPrRP(25-31) and [pGlu1, Trp2, Lys3, 
Leu4] hPrRP(25-31) activity and the conservation of this residue amongst other RF- 
amide peptides (Han etal., 2002), it is not surprising that the corresponding 
glutamate residue of GPR10 appears to be conserved in the RF-amide peptide 
receptors NPFF-1, NPFF-2 and GPR54.
Assuming that the Arg6 - E213 interaction was correct, this gave further credence to 
the placement of the C-terminal phenylalanine (Phe7) carboxamide.  In the receptor 
model the terminal carboxamide of hPrRP(25-31) was predicted to form a series of 
hydrogen bonds with Q141  (TM3), E212 (ECL2) and H321  (TM7; Figure 18a). The 
point mutations E212A and Q141A both caused a reduction in the maximal binding 
capacity of, but did not abolish, the specific binding of [125l]-hPrRP-20. E212A actually 
displays a slightly lower KD  for both the high and low affinity [125l]-hPrRP-20 binding 
sites, but this observation is not reflected in the agonist potencies in the calcium 
mobilisation assay where E212A caused a 10 - 20-fold reduction in the potency of 
hPrRP-20 and [pGlu1, Trp2, Lys3, Leu4] hPrRP(25-31) and a 5-fold reduction in 
potency of hPrRP(25-31).  Radioligand binding studies showed that loss of this 
glutamate residue did not significantly alter the affinity of hPrRP-20 (pKj = 9.68 ± 
0.08), hPrRP(25-31) (7.21  ± 0.06) or [pGlu1, Trp2, Lys3, Leu4] hPrRP(25-31) (6.24 ± 
0.11) to inhibit [125l]-hPrRP-20 binding to membranes of HEK293 cells transiently
143expressing GPR10-E212A compared to wild-type GPR10. It is possible that these 
observed effects could reflect a role for E212 in the conformational change involved 
in receptor activation and signalling, rather than in the binding of the peptide. In the 
light of these somewhat mixed observations with E212A, it would be interesting to 
model the this construct to see how loss of this glutamate residue might be predicted 
to affect the interaction of hPrRP-20 with GPR10.
Q141A did not affect the KD  for the high affinity [125l]-hPrRP-20 binding site, although 
the Bm ax was markedly reduced and the low affinity binding site was difficult to 
quantify and was effectively abolished. Q141A caused only 3-fold reduction in the 
potency of hPrRP-20 to stimulate calcium mobilisation and reduced the potency of 
hPrRP(25-31) and [pGlu1, Trp2, Lys3, Leu4] hPrRP(25-31) by 10-fold. These data 
suggest that the interactions between Q141  and E212 and the terminal carboxamide 
of hPrRP-20 play a role in the binding of the ligand, but neither is in itself essential to 
it.
A peptide ligand such as hPrRP-20 can be expected to form many interactions 
between its individual amino acids and the receptor. The overall binding energy will 
be composed of the sum of these many individual terms. Q141  and E212 were each 
believed to form a single hydrogen bond to the ligand. The model suggested, 
however, that the C-terminal phenyl ring of the peptides is tightly held in the 
hydrophobic pocket defined by W291, L294 (TM6) and L323 (TM7), with little 
conformational freedom. The removal of a single hydrogen bond to/from the 
carboxamide, particularly when the other is maintained, will have little entropic effect 
on the free energy of binding. Thus its overall effect would be expected to be much 
less than disruption of one of the essential interactions between E213 / D302 and the 
basic arginine residues of the peptide. In order to probe these theories, further 
studies could examine the effect of mutation of the hydrophobic residues thought to
144form the binding pocket for the phenyl ring. It would also be interesting to examine 
GPR10 constructs containing H321A (which was not examined in this study) and 
both double (Q141A/E212A, Q141A/H321A, E212A/H321 A) and triple 
(Q141A/E212A/H321A) mutants. The effect of these mutations may give greater 
understanding of the relative contributions of the carboxamide hydrogen bonding 
network and the hydrophobic interactions of Phe7 in hPrRP-20 binding to GPR10.
This second generation receptor model, containing the extracellular loops, 
highlighted interactions between the ligands and two residues in ECL2, E212 and 
E213. It was therefore interesting to see whether these predictions, based on the 
inclusion in the theoretical model of extracellular loops, would be verified by the SDM 
studies. The successful prediction of these interactions was particularly exciting 
because this is the first instance of a theoretically derived loop structure for a GPCR 
suggesting critical interactions in the receptor model. The data for E212A and E213A, 
therefore, support the loop construction methodology.
The current receptor model also suggested a number of potential hydrogen bonds 
between the receptor and the peptide backbones of hPrRP(25-31) and [pGlu1, Trp2, 
Lys3, Leu4] hPrRP(25-31). N298 (TM6) was predicted to form a hydrogen bond with 
the backbone NH of Arg6 in hPrRP(25-31). N298A, like Q141 A, had little effect on the 
Kd of [125f]-hPrRP-20 for the high affinity binding site, although it reduced the Bm ax. As 
for Q141 A, with N298A the low affinity binding site was extremely difficult to discern 
and was effectively abolished.  Furthermore, only a 10-fold reduction in potency was 
observed in the agonist responses of hPrRP-20, hPrRP(25-31) and [pGlu1, Trp2,
Lys3, Leu4] hPrRP(25-31) in FLIPR studies. These data suggest that like Q141, N298. 
is involved in a single hydrogen bonding interaction which has a small but significant 
effect on ligand binding and receptor activation.
145The ligand backbone region of Gly3 and Val4 (Leu4 in [pGlu1, Trp2, Lys3, Leu4] 
hPrRP(25-31)) is a potentially flexible stretch that will define the relative interactions 
of the Arg2 and Arg6 residues and other peptide residues with the receptor. Q317 
(TM7) was predicted to form a double hydrogen bond with both the backbone 
carbonyl and amide NH of Val4 of hPrRP(25-31), completely locking the orientation of 
the heptapeptide in this region of the pocket. The loss of this double hydrogen bond 
in an essential part of the binding pocket would be predicted to lead to a large 
increase in the entropic freedom of the ligands. Unsurprisingly, Q317A abolished 
specific binding of [125l]-hPrRP-20 and dramatically reduced the potencies of the 
agonist peptides, supporting previous studies that suggested that the free NH on the 
backbone was one of the main reasons that a valine residue was preferred in this 
position of hPrRP-20 (Boyle etal., 2005).
Taken together, the [125l]-hPrRP-20 binding and functional calcium mobilisation data 
with the SDM constructs largely validate the constructed theoretical model of GPR10. 
The model predicted strong interactions of the peptides with E213, D302 and Q317 
and the mutations of these residues have dramatic effects on both peptide binding 
and receptor activation. The lack of specific binding of [125l]-hPrRP-20 with mutation 
of these residues is likely to be a result of a greatly reduced affinity for the peptide  ' 
(as well as any additional effects on Bm ax) as these constructs are functionally 
responsive to hPrRP-20 in the calcium mobilisation assay but with greatly reduced 
potencies compared to wild-type GPR10.
These results provide compelling evidence to implicate D302, E213 and Q317 in 
peptide binding and receptor activation. An exciting aspect of the modelling-SDM  . 
studies was that, based on a novel loop building algorithm, predictions were made 
about potential binding sites in the second extracellular loop of GPR10. SDM
146experiments have strongly supported these hypotheses which gives added validity to 
this new methodology.
However, further credence to the predicted molecular nature of the interactions could 
be gained from complementary mutation studies. Given the predicted interaction 
between D302 and Arg2 of hPrRP(25-31), a mutant receptor construct containing 
D302R would be predicted to be unresponsive to hPrRP(25-31), but should be 
activated by an analogue of hPrRP(25-31) in which Asp was substituted for Arg2 and 
an analogue of [pGlu1, Trp2, Lys3, Leu4] hPrRP(25-31) in which Lys3 was replaced by 
Asp. Similarly, a construct containing E213R would be expected to be activated by 
an analogue of hPrRP(25-31) in which Arg6 was substituted by Glu. Additionally, if 
Q317A abolished [125l]-hPrRP-20 binding due to the loss of a carboxamide side- 
chain, then a construct containing Q317N may be expected to retain some degree of 
ligand affinity. However, these studies would be somewhat ambitious as one of the 
perceived drawbacks of SDM studies is that effects observed may not be due to 
alteration in specific ligand-residue interactions, but rather due to a local or global 
change in the receptor conformation. In complementary mutation studies, these 
issues would be exacerbated due to changes in both the receptor and agonist 
peptide sequences that wouid render results potentially more difficult to interpret.
E212, Q141  and N298 all also form interactions with the C-terminal heptapeptide of 
PrRP-20, although these do not appear to have as great an effect, as their mutation 
has more limited effects on [125l]-hPrRP-20 binding, reducing the Bm ax of the high 
affinity site (E212A, Q141A and N298A) with little effect on KD. Furthermore, for 
Q141A and N298A, despite non-linear Scatchard plots, the low affinity binding site 
was extremely difficult to quantify and for the purposes of data analysis was 
considered to be effectively abolished.  In keeping with these observations, the effect 
of these mutations on the potency of the agonist peptides was limited to
147approximately a 10-fold or less reduction. It is possible that these reductions in 
potency are a result of reduced receptor expression (as exemplified by a reduced 
Bmax), possibly due to enhanced agonist-induced receptor internalisation. This would 
result in a reduced functional receptor reserve in the calcium mobilisation assay 
compared to the wild-type receptor. However, intuitively it would be expected that the 
greater the signal amplification, the more potent an agonist may appear to be in a 
given assay system (Kenakin, 1997). A calcium mobilisation assay would be 
expected to be subject to much greater signal amplification than an inositol 
phosphate accumulation assay, yet hPrRP-20 is approximately 5-fold more potent in 
stimulating the latter compared to the former (Chapter 3). This suggests that there is 
actually relatively little, if any, signal amplification in the transiently expressed GPR10 
calcium mobilisation assays and that any apparent reduction in potency may be a 
genuine consequence of impaired ligand binding or receptor activation.
This study has led to the identification of a number residues essential to both [125l]- 
hPrRP-20 binding and receptor function (E213, D302 and Q317). However, SDM and 
modelling studies cannot possibly predict all ligand -  receptor interactions so it is 
likely that there are as yet unidentified residues that contribute towards both peptide 
binding arid receptor signalling. Hopefully the combined knowledge of these studies, 
together with the existing data on the structural features of hPrRP-20 required for 
potency and affinity at GPR10 (Boyle et al., 2005) may lead to a greater 
understanding of the molecular nature of PrRP binding and receptor activation.
One aspect of the binding of [125l]-hPrRP-20 that was not resolved by the SDM 
studies was the existence of both high and low affinity binding, sites. As discussed in 
Chapter 3 this could be a result of either high and low agonist affinity states or two 
topographically distinct binding sites for hPrRP-20. Both transiently expressed 
GPR10 wild-type and E212A constructs retained two site binding, but it was
148impossible to accurately define the low affinity binding site for both Q141A and 
N298A, even though Scatchard plots were still apparently curvilinear. It is possible 
that the apparent ‘loss’ of these binding sites was due to the limitations of the assay 
conditions (if the KD  for the low affinity site was increased at Q141A or N298A then it 
may fall outside the [125l]-hPrRP-20 concentration range of the assay). It is possible, 
therefore, that given a larger concentration range it may have been feasible to 
resolve two binding sites for all the SDM constructs that displayed specific [125l]- 
hPrRP-20 binding.
The identification of residues for SDM was based on docking of the two C-terminal 
heptapeptides, hPrRP(25-31) and [pGlu1, Trp2, Lys3, Leu4] hPrRP(25-31), rather than 
hPrRP-20 itself. Thus, the model does not take into account any additional 
interactions that may be made by the N-terminal 13 amino acids of hPrRP-20. It has 
already been noted that the full length peptide is 100-fold more potent than the C- 
terminal heptapeptide truncate at GPR10, implying that there is a substantial role for 
the N-terminal residues of hPrRP-20 in either stabilising the C-terminus in its binding 
pocket or in making their own interactions with the receptor. Any additional 
interactions of hPrRP-20 could explain both the two-site profile observed with [125l]- 
hPrRP-20 and also why SDM studies based only on the C-terminal portion of the 
peptide failed to delineate the two sites. Unfortunately, it is not possible to accurately 
model the docking of hPrRP-20 itself -  whilst the C-terminus of the peptide is thought 
to form a regular a-helical structure, the N-terminal region is much more flexible 
(D’Ursi et al, 2002) and difficult to dock into the model with great accuracy.  In this 
context, a very useful tool would be a radiolabelled form of the truncate, hPrRP(25- 
31). Despite its lower affinity, it would be interesting to observe the saturation binding 
profile of such a ligand to GPR10. If such a ligand were to display single site binding 
it would by virtue implicate the N-terminal region of hPrRP-20 in binding to a second 
site. Clearly there are numerous further studies suggested both here and in Chapter
1493 that may help to elucidate the cause of the two-site nature of [125l]-hPrRP-20 
binding toGPFMO.
150Chapter 5
Pharmacological characterisation of muscarinic M1  
receptor ectopic agonists
151(i) Introduction
(a)  Allosterism at muscarinic receptors
As discussed in the Introduction, allosteric ligands acting at muscarinic receptors 
provide some of the best characterised examples of allosterism at GPCRs. Ligands 
such as gallamine, alcuronium, C7/3-phth, brucine and closely related analogues 
have all been shown to have varying allosteric effects on muscarinic receptors. 
Analogues of brucine have been shown to be positive modulators of ACh with 
varying degrees of selectivity at muscarinic receptors. Brucine and brucine A/-oxide 
are selective enhancers of M1  and M4 receptor subtypes, whereas NCMB selectively 
enhanced the actions of ACh at the M2 and M3 receptor subtypes, while remaining 
neutrally co-operative at the M4 receptor subtype (Birdsall et al.,  1999). More recent 
data has identified thiochrome as a selective enhancer of the M4 receptor subtype 
whilst remaining neutrally co-operative at the remaining muscarinic receptor subtypes 
(Lazareno et al., 2004).
The best characterised of the negatively co-operative ligands is gallamine, whose 
allosteric properties were first described by Clark & Mitchelson (1976) and Stockton 
etal. (1983). Gallamine has been shown to be negatively co-operative with respect to 
[3H]NMS at all muscarinic receptor subtypes (Gnagey etal.,  1999), as has C7/3-phth 
(Christopoulos etal.,  1999). Gallamine is also negatively co-operative with respect to 
[3H]QNB in cardiac and smooth muscle membranes (representing populations largely 
composed of M2 and M3 receptors, respectively; Nedoma etal.,  1986). Alcuronium is 
similarly negatively co-operative with respect to [3H]QNB (Nedoma etal., 1986). 
However, alcuronium is positively co-operative with respect to [3H]NMS binding in rat 
atrial, ileal and cerebellar membranes (Tucek etal., 1990) and CHO cells stably 
expressing the human M2 receptor (Christopoulos, 2000), but negatively co-operative
152with respect to [3H]NMS in cortical and salivary gland membranes (Tucek et al., 
1990). These results underline the importance of interpreting results with allosteric 
ligands with reference to the orthosteric ligand. The phenomenon is known as ‘probe- 
dependence’, hence for therapeutic targets allosteric ligands should always be tested 
versus the endogenous agonist where possible.
Despite alcuronium and gallamine and C7/3-phth having opposing effects on 
equilibrium binding of [3H]NMS (Christopoulos etal.,  1999; Avlani etal., 2004), all 
three ligands retard [3H]NMS dissociation from CHO-M2 receptor cell membranes 
(Avlani etal., 2004). This seems counter-intuitive with their supposed opposing 
effects on the affinity of [3H]NMS for the receptor. This is thought to be due to 
location of the binding site for these ligands, which is believed to lie extracellular to 
the orthosteric binding site (see below).  It may well be that there is a component of 
steric hindrance with the binding of these modulators that precludes orthosteric 
ligand access to its binding site as well as (in the case of gallamine and C7/3-phth) or 
opposed to (in the case of alcuronium) the effect of the modulator on the receptor 
affinity for the orthosteric ligand (Tucek & Proska,  1995).
Despite circumstantial evidence that the gallamine binding site is near, but 
extracellular to, the orthosteric site, the last few years has seen an increased interest 
in trying to identify residues involved in the interaction with these ligands. In general, 
gallamine-like allosteric ligands have highest affinity for the M2 receptor subtype, with 
an approximate order of affinity as follows: M2 > Mi = M4 > M3 = M5 (Gnagey et al., 
1999). Studies have identified a number of residues that may play a role in the 
binding of gallamine. The asparagine residue at position 419 (in the third outer loop) 
of the M2 receptor has been identified as a key contact point, as mutation of the 
equivalent residue, valine, in the M5 receptor subtype to asparagine, increases the 
affinity to that seen in the M2 receptor subtype (Gnagey etal.,  1999). The equivalent
153residue in the Mi  receptor is glutamate 397 (E397). Of similar importance appears to 
be the Glu-Asp-Gly-Glu motif (EDGE motif) in ECL2 of the M2 receptor; replacement 
of this motif with the equivalent residues found in the Mi  receptor (LAGQ) reduced 
the affinity of gallamine (Gnagey et al., 1999). Conversely, replacement of the LAGQ 
motif with the EDGE motif in the Mi  receptor increased the affinity for gallamine 
(Gnagey etal.,  1999).  Other studies have implicated the tryptophan residues in 
positions 101  and 400 in the binding of gallamine to the Mi  receptor (Matsui et al., 
1995) and also suggest that the gallamine binding site is very close to the orthosteric 
site.
More recent studies have identified a second allosteric site on muscarinic receptors 
(Lazareno etal., 2000). These studies identified staurosporine analogues and 
particularly KT5720 ((9S,1 OS,12R)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1 - 
oxo-9,12-epoxy-1 H-diindolo[1,2,3,-fg:3',2',T-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10- 
carboxylic acid hexyl ester) as allosteric ligands at muscarinic receptors, especially at 
the M1   receptor subtype. These ligands enhanced the binding affinity of [3H]NMS at 
the Mi and M2 receptor subtypes, with no effect on the equilibrium binding at the M3 
and M4 receptor subtypes (Lazareno etal., 2000; Birdsall etal., 2001). Unlike a 
number of conventional aiiosteric ligands to muscarinic receptors, these analogues 
had more limited effects on the dissociation rate of [3H]NMS. This interesting 
phenomenon allowed the authors to investigate whether KT5720 was capable of 
reversing the large inhibition of [3H]NMS dissociation observed with conventional 
allosteric ligands. This reversal effect has been seen with another, weak, muscarinic 
receptor allosteric ligand, obidoxime, which also has a limited effect on [3H]NMS 
dissociation (Ellis & Seidenberg,  1992). Surprisingly, KT5720 failed to alter the 
effects of gallamine at the Mi  receptor (Lazareno etal., 2000; Birdsall etal., 2001). 
These data suggested that KT5720 and gallamine do not bind to the same site, but 
that both bind to different sites and can be simultaneously bound to a [3H]NMS
154occupied receptor, with neutral co-operativity (a = 1) with respect to each other. 
Clearly further studies are required to define the molecular nature of this second 
allosteric site on muscarinic receptors.
A number of snake venom toxins have also been shown to be highly selective 
antagonists of muscarinic receptors (Potter, 2001). One of the most well 
characterised of these polypeptide ligands is termed MT-7 (or m1-Toxin1), which 
displays > 10,000-fold selectivity for the IVh  receptor over the other muscarinic 
receptor subtypes (Mourier et al., 2003). As a consequence of its size (65 aa) and its 
retardation of [3H]NMS dissociation, this peptide is thought to interact allosterically 
with the extracellular loops and / or N-terminus of the Mi  receptor (Krajewski etal.,
2001). Of the 65 residues that make up MT-7, only 7 are not conserved amongst the 
other six snake venom toxins, suggesting that these must account for the selectivity 
of this peptide.  By mutation of the C-terminal Lys65 residue, the authors conclude that 
this residue interacts with an acidic residue on the extracellular face of the Mi 
receptor, possibly E170 in outer loop 2, D393 in outer loop 3 or E401  at the top of 
TM7, all of which are unique to the Mi  receptor (Krajewski etal., 2001). This is a very 
interesting observation, since the tryptophan in position 400 is strongly implicated in 
the binding of gallamine and Y404 and Y408 are likewise involved in the binding of 
NMS (Matsui et al.,  1995).
(b) Identification of AC-42 as a selective Mi receptor agonist
Allosteric ligands seem to offer the greatest hope of developing subtype selective 
reagents amongst the muscarinic receptor family. Given the high degree of 
conservation of the orthosteric ligand binding across the receptor subtypes, it is 
perhaps unsurprising that selective agonists and antagonists have proved difficult to 
develop (Christopoulos etal., 2001). Recently, Spalding and colleagues (2002) have
155described a compound, AC-42, which acts as an agonist at the human Mi  receptor 
and exhibits a high degree of selectivity over the human M2 -  M5 subtypes. AC-42 
activates the Mi  receptor transiently expressed in NIH 3T3 cells with a pEC50 of 6.7 
as measured using the receptor selection and amplification technology (R-SAT) cell- 
based functional reporter gene assay, with an intrinsic activity of approximately 0.7 
compared to carbachol. However, AC-42 displays no agonist activity at the M2, M3,
M4 and M5 receptors at up to 1   pM (Spalding etal., 2002). AC-42 displays a similarly 
selective, agonist profile for M! against M3 and M5 receptors when tested in assays of 
phosphoinositide hydrolysis in tSA cells (a HEK293 cell line stably transfected with 
the SV40 T-antigen) transiently expressing these receptor subtypes (Spalding etal.,
2002). This response was sensitive to concentrations of atropine that blocked 
carbachol stimulated PI hydrolysis, suggesting that the effect was mediated via 
muscarinic receptors. AC-42 did, however, act as a low affinity antagonist at both the 
M3 and M5 receptor subtypes, with plC50 values of ~ 5.
A similar selectivity profile was observed in CHO cells stably expressing either the M2 
or M4 receptor subtypes, where AC-42 failed to significantly inhibit forskolin 
stimulated cAMP levels (Spalding etal., 2002). AC-42 inhibited [3H]NMS binding with 
low affinity (plC50 ~ 5) across all five muscarinic receptor subtypes.
Subsequently, an analogue of AC-42, AC-260984 (structure undisclosed), has been 
shown to have similar selective agonist properties. AC-260984 also stimulates MAP 
kinase activity in the CA1  region of the mouse hippocampus, an area where the 
muscarinic receptor population is thought to be largely of the Mt subtype (Veinbergs 
etal., 2003). This activity was shown to be both abolished by scopolamine and 
absent in the Mt  receptor knockout mouse, confirming the Mt  receptor selectivity of 
AC-260584.
156Using chimeric receptors with regions from both the Mi and M5 muscarinic receptor 
subtypes, Spalding etal. (2002) demonstrated that AC-42 interacted with a site 
distinct from the orthosteric binding site for acetylcholine. The binding site for AC-42 
seemed to be formed by epitopes in the N-terminus, TM1  and the exofacial region of 
TM7. The molecular nature of the binding site for AC-42 is examined further in 
Chapter 6. In the absence of definitive proof that AC-42 was an allosteric ligand, 
these data prompted the authors to term AC-42 an ‘ectopic’ agonist, due to its 
interaction with a site on the M1   receptor distinct from that recognised by carbachol.
However, much remains to be determined in respect to the mode of action of AC-42 
as an agonist at the muscarinic Mi  receptor. The studies in this chapter were 
designed to characterise fully the pharmacology of AC-42, its closely related 
analogue, 77-LH-28-1, and two novel, unrelated compounds which also purport to be 
selective, ‘ectopic’ Mi  receptor agonists, compound A and compound B (Figure 24).
These compounds have been assessed functionally using both inositol phosphate 
accumulation and calcium mobilisation studies in CHO cells stably expressing the 
muscarinic Mi  receptor. The effect of signal transduction inhibitors on the intracellular 
calcium response to these compounds has also been assessed and compared to 
that for the orthosteric agonist, carbachol. Furthermore, the interaction of carbachol, 
AC-42 and compound A with the orthosteric muscarinic receptor antagonists-atropine 
and pirenzepine has been determined in order to delineate any allosteric mechanism 
of action of AC-42 and compound A at the Mi  receptor.
Radioligand binding studies have also been used to characterise the allosteric 
properties of these novel agonists. Specifically, their effects on [3H]NMS dissociation 
rate from the ^   receptor and their profiles of inhibition of two different concentrations 
of [3H]NMS have been assessed.
157To determine whether native tissue affinities reflect those observed in recombinant 
assays, inhibition binding profiles against muscarinic receptor agonist 
([3H]oxotremorine-M) and antagonist ([3H]QNB) radioligands have been determined 
for both orthosteric and non-orthosteric compounds in rat cortical membranes. 
Finally, the functional activity of 77-LH-28-1, has also been assessed in an in vitro 
gamma frequency network oscillations model in rat cortex and this compared to that 
of the non-selective agonist, carbachol, to determine whether functional agonist 
activity in recombinant cell assays translates to a native tissue receptor population.
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Figure 24. Structures of carbachol, atropine,  A/-methyl scopolamine, pirenzepine, 
AC-42 and 77-LH-28-1.
159(ii) CHO-hM! Ca2 +  mobilisation -  signal transduction studies
FLIPR-based calcium mobilisation studies were performed to determine the agonist 
profile of AC-42, compound A and the reference orthosteric agonist, carbachol, at the 
hIVh  receptor.  Furthermore, signal transduction studies were carried out on the 
calcium mobilisation mediated  via the hM1   receptor to determine whether the 
responses to the agonists were consistent with coupling to the Gq/n-phospholipase- 
C-IP3 pathway. Carbachol, AC-42 and compound A stimulated calcium mobilisation 
in CHO-hMi cells in a concentration-dependent manner (Figure 25). AC-42 appeared 
as a high efficacy partial agonist, with a pEC50 value of 7.15 ± 0.12 and an intrinsic 
activity of 0.9 compared to carbachol (p < 0.001,  F-test). The pEC50 value of 
carbachol was 8.38 ± 0.11  (Figure 25). Compound A appeared as a weaker partial 
agonist, with a pEC50 value of 7.37 ± 0.11  and an intrinsic activity of 0.4 compared to 
carbachol (p < 0.0001,  F-test; Figure 25). An example trace of the temporal calcium 
response to carbachol (10 pM) is shown in Figure 26.
The phospholipase-C inhibitor, U73122 (10 pM), inhibited carbachol and AC-42 
stimulated calcium mobilisation, producing a 20 to 30-fold parallel rightward shift in 
the concentration-response curves to both of these compounds (Figure 27). 
Furthermore, U73122 completely abolished the calcium mobilisation response 
induced by compound A.
The non-competitive inhibitor of the inositol triphosphate (IP3) receptor, 2-APB (100 
pM), almost abolished the calcium mobilisation response to both carbachol and AC- 
42 and did abolish the response to compound A (Figure 27). The Ca2+-ATPase 
inhibitor, thapsigargin (1  pM), abolished the calcium mobilisation response to all three 
agonists (Figure 27).
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Figure 25. Concentration-dependent stimulation of intracellular calcium mobilisation 
by carbachol, AC-42 and compound A in CHO-hM! cells. Data are the mean of 3 
experiments; error bars show s.e.m..
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Figure 26. Temporal calcium response to carbachol (10 jiM) in CHO-hMi cells. 
Carbachol was added at t = 10 s. Data represents the mean of 2 independent 
calcium measurements; error bars represent s.e.m..
161a >
c o c
o
Q.
(0 < D i-
s:
O
O
75
£
’x
<0
E
■  Carbachol 
a  + 10 pM U73122 
▼   +  1  jLtM  thapsigargin 
♦  +100 pM 2APB
■10  -9  -8  -7  -6
log [carbachol] (M)
120-1
O  100- 
Q.
CO
®  80- 
CM
?   60-
40-
20-
-20
11 6 5 -10 9 8 7
■  AC-42
a  +  10 jliM U73122 
▼   +  1  pM thapsigargin 
♦  +100 pM 2APB
log [AC-42] (M)
9-©  80-
Compound A 
+  10 pM U73122  j  
+  1   pM thapsigargin 
+  100 pM 2APB
-8  -7  -6  -5  -4  -3
log [Compound A] (M)
Figure 27. Effect of signal transduction inhibitors on carbachol, AC-42 and compound 
A stimulated calcium mobilisation in CHO-hMi cells. Data are the mean of 3 
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162Carbachol AC-42
Atropine Pirenzepine Atropine Pirenzepine
Ca2 +  mobilisation 
pKB/pA2f
9.39 ± 0.03 8.31  ±0.16 9.20 ± 0.33 8.44 1 0.05
Slope + + 1.09 ± 0.03 0.96 ± 0.06 0.75 ± 0.05 * 0.58 1 0.06 *
log a* n/a n/a -2.30 ± 0.09 -2.58 1 0.25
IP accumulation 
pKB/pA2f 9.33 ± 0.05 7.97 ± 0.05 9.8210.13 8.52 1 0.30
Slope t+ 1.12 + 0.04 1.0510.03 0.63 1 0.06 ** 0.58 1 0.09 *
log a* n/a n/a -2.1610.21 -2.08 1 0.33
Table 10.  Parameters describing the functional interaction between the orthosteric 
antagonists, atropine or pirenzepine, and the agonists, carbachol or AC-42, at the 
muscarinic Mi  receptor expressed in CHO cells.  Data are the mean of 3 experiments 
(± s.e.m.).
* p < 0.05, ** p < 0.01  significantly different from hypothetical value of 1  
^Student’s T-test)
f Negative logarithm of antagonist dissociation constant as estimated by linear Schild 
regression (Appendix 1).
+t Slope value of Schild regression (Appendix 1).
* Logarithm of the co-operativity factor, estimated by nonlinear regression according 
to an allosteric ternary complex model (equation 7 of the Methods; Appendix 1).
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Figure 28. Concentration-dependent antagonism of carbachol-stimulated calcium 
mobilisation in CHO-hMi cells by (A) atropine (3 nM -  300 nM) and (B) pirenzepine 
(100 nM -  10 pM) with inset Schild regressions. Dotted lines on Schild plots indicate 
a theoretical slope of 1. Data are the mean of 3 independent experiments; error bars 
show s.e.m..
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Figure 29. Concentration-dependent antagonism of AC-42-stimulated calcium 
mobilisation in CHO-hM! cells by (A) atropine (3 nM -  300 nM) and (B) pirenzepine 
(100 nM -  10 pM) with inset Schild regressions. Dotted lines on Schild plots indicate 
a theoretical slope of 1. Data are the mean of 3 independent experiments; error bars 
show s.e.m..
165(iii) CHO-hMi Ca2 +  mobilisation -  antagonist studies
In order to further understand the nature of the interaction between the hMt  receptor 
and AC-42 / compound A, the effects of the orthosteric antagonists atropine and 
pirenzepine on the calcium responses elicited by AC-42,compound A and carbachol 
were determined. All responses in the presence of antagonist are normalised to the 
% maximal asymptotic response of the control agonist.
(a) Atropine / pirenzepine-mediated antagonism of carbachol response
Increasing concentrations of the muscarinic receptor antagonist, atropine (3 -  300 
nM) caused a parallel rightward shift in the concentration response curve to 
carbachol. Schild analysis of the data set yielded an estimated pKB  value of 9.39 ± 
0.03 and a slope of 1.09 ± 0.03 (Figure 28a; Table 10; Appendix 1). Increasing 
concentrations of another muscarinic receptor antagonist, pirenzepine (100 nM -  
10 pM), produced a similar profile, with a pKB  value of 8.31  ± 0.16 and a slope of 
0.96 ± 0.06  (Figure 28b; Table 10; Appendix 1). The affinity estimates for both 
atropine and pirenzepine at the Mi  receptor are consistent with previous studies 
(Ellis, 2002).
(b) Atropine / pirenzepine-mediated antagonism of AC-42 response
Increasing concentrations of atropine (3 -  300 nM) also caused a parallel rightward 
shift in the concentration response curve to AC-42, with no depression in the 
maximal response and a pA2 value of 9.20 ± 0.33 and a slope of 0.75 ± 0.05 (Figure 
29a; Table 10). The shallow slope was shown to be significantly less than unity (p < 
0.05; Student’s T-test) and so it was not possible to estimate a pKB  value for the 
antagonist. A similar profile was observed with increasing concentrations of 
pirenzepine, yielding a pA2 value of 8.44 ± 0.05 and slope of 0.58 ± 0.06 which was
166significantly less than  1   (p < 0.05, Student’s T-test; Figure 29b; Table 10). Both sets 
of data with AC-42 could be described by an allosteric model (equation  1) to 
determine a log a value for the interaction between AC-42 and atropine / pirenzepine 
(Table 10).
(c) Atropine-mediated antagonism of carbachol / AC-42 response -  
6 point Schild analysis
An increase in the concentration range of atropine tested (3 nM -  300 pM) resulted in 
further rightward shifts of the concentration response curve to carbachol, with a 
calculated pKB  value of 9.59 ± 0.05 and a slope of 1.01  ± 0.01  (Figure 30a).
However, a similar range of concentrations of atropine, when tested against AC-42, 
produced a shallow, non-linear Schild plot that tended to plateau at the highest 
concentrations of atropine (Figure 30b). Global shared analysis of the data set 
(equation 1) provides an estimate of log a of -3.75 ± 0.23 characterising the 
interaction between AC-42 and atropine (different from the log a value for atropine 
and AC-42 estimated from the 3 point Schild analysis -  see later).
(d) Atropine / pirenzepine-mediated antagonism of compound A response
Increasing concentrations of atropine (3 -  300 nM) caused a rightward shift in the 
concentration response curve to compound A, with an approximate 50 % depression 
in the maximal response at 3 nM atropine and further reductions in the maximum 
asymptote at 30 nM and 300 nM (Figure 31a). Due to the non-parallel nature of the 
concentration response curves, it was not possible to determine a pA2 value for 
atropine-mediated antagonism of compound A.  Pirenzepine (100 nM) caused a 10- 
fold rightward shift in the concentration response curve to compound A, with an 
approximate 50 % depression in the maximal response (Figure 31b). No significant
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169calcium response was observed with in the presence of higher concentrations of 
pirenzepine (1  pM -1 0  pM). As with the atropine study, it was not possible to 
determine a pA2 value for pirenzepine-mediated antagonism of the compound A 
response. The reduction in the maximum responses to compound A by atropine and 
pirenzepine is likely to reflect the partial agonist properties of compound A, rather 
than any non-competitive interaction between this agonist and atropine and 
pirenzepine. As a partial agonist, compound A requires full IVh  receptor occupancy to 
elicit a maximal response. Any blockade of this receptor population with atropine or 
pirenzepine would reduce the occupancy by compound A and hence reduce the 
maximum response observed.
(iv) CHO-hMi inositol phosphate accumulation -  agonist studies
Both carbachol and AC-42 stimulated inositol phosphate (IP) accumulation in CHO- 
hMi cells, with pEC50 values of 6.35 ± 0.02 and 6.21  ±0.10, respectively (Figure 32). 
These values are in good agreement with previous estimates of both carbachol and 
AC-42 potency in IP studies (Lee et al.,  1996; Spalding etal., 2002). AC-42 appeared 
as a partial agonist with respect to carbachol (p <0.0001, F-test), with an intrinsic 
activity of 0.85. The AC-42 analogue 77-LH-28-1  also stimulated IP accumulation 
with a pEC50 of 7.24 ± 0.02 and appeared as a partial agonist with an intrinsic activity 
of 0.8 compared to carbachol (p < 0.0001,  F-test).
Compound A and compound B only weakly stimulated IP accumulation in CHO-hM! 
cells, with pEC50 values of less than 5 and intrinsic activities compared to carbachol 
of 0.2 and 0.1, respectively (Figure 32).
170(v) CHO-hMi inositol phosphate accumulation -  antagonist studies
A similar profile for atropine and pirenzepine-mediated antagonism of carbachol and 
AC-42 was observed in IP accumulation studies in CHO-hlVh cells. Both atropine and 
pirenzepine produced concentration-dependent rightward shifts in the concentration 
response curve to carbachol, with Schild analysis yielding pKB  values of 9.33 ± 0.05 
and 7.97 ± 0.05, respectively and Schild slopes not significantly different from unity 
(Figure 33; Table 10).
Atropine and pirenzepine also produced parallel rightward shifts in the concentration 
response curve to AC-42 (Figure 34, Table 10). As in the calcium mobilisation 
studies, antagonism of the AC-42 response by atropine or pirenzepine resulted in pA2 
values similar to those observed by antagonism of the carbachol responses, but with 
slope values significantly lower than unity (Table 10; p < 0.05, Student’s T-test).
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174(vi) CHO-hMi [3H]NMS saturation binding
Specific binding of [3H]NMS to CHO-hM! cell membranes was saturable and 
represented more than 90% of total binding (Figure 35).  Non-linear regression 
revealed that [3H]NMS bound to a single site with a KD value of 0.27 ± 0.03 nM and a 
Bm ax of 1.05 ± 0.09 pmol mg protein'1.
(vii)  CHO-hMi [3H]NMS inhibition binding
AC-42 inhibited [3H]NMS binding in a concentration-dependent manner, but did not 
fully inhibit specific binding at a radioligand concentration of 0.2 nM (minimum 
asymptote greater than zero; p < 0.05, F-test), an effect that was more marked at 2 
nM (p < 0.01, F-test; Table 11,  Figure 36). A simultaneous analysis of each pair of 
inhibition curves, according to an allosteric ternary complex model of interaction 
(equation 3), yielded an estimate of 6.18 ± 0.18 for the negative logarithm of the 
affinity constant (KB ) of AC-42 for the unoccupied ^   receptor and a value of -1.77 ± 
0.17 for the logarithm of the degree of co-operativity (a) characterising the interaction 
between AC-42 and [3H]NMS.
A similar profile of incomplete inhibition of specific [3H]NMS binding at both 0.2 and 2 
nM radioligand was observed for both 77-LH-28-1  and compound A (Figure 36; Table 
11). Allosteric modelling of the inhibition curves yielded estimates of affinity for the 
unoccupied Mi  receptor (- log KB ) of 7.08 ± 0.02 and 5.38 ± 0.08 for 77-LH-28-1  and 
compound A respectively, with log a values of -1.76 ± 0.04 and -1.70 ± 0.23 
characterising the interaction between these compounds and [3H]NMS. Compound B 
fully inhibited the specific binding of [3H]NMS at both 0.2 and 2 nM in a concentration- 
dependent manner.
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176Figure 36. Inhibition of [3H]NMS binding from 
CHO-hMi cell membranes at two different 
radioligand concentrations: 0.2 nM (■) and 2 nM 
(A). Inhibition curves for atropine, pirenzepine, 
AC-42, compound A, compound B, 77-LH-28-1 
and gallamine are shown. Data are the mean of 
3 independent experiments; error bars represent 
s.e.m..
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log [gallamine]  (M)However, despite the full inhibition of specific [3H]NMS binding, the meaned dataset 
could be fitted to the allosteric model (equation 7), yielding estimates of - log KB  = 
7.00 and log a = -3.14. Given the full inhibition of [3H]NMS binding, data was also 
analysed according to a simple competitive interaction, yielding a pKj value 7.04 ±
0.11, though statistical comparison of the two fits by F-test yielded a clear preference 
for the former.
Gallamine also displayed concentration-dependent inhibition of [3H]NMS binding 
accompanied by an inability to inhibit fully the specific binding of the radioligand 
(Figure 36). As with AC-42, 77-LH-28-1  and Compound A, this effect was manifest at 
both radioligand concentrations, being more marked at the higher concentration (2 
nM). Simultaneous analysis of the two curves yielded estimates of -  log KB  = 5.20 ± 
0.04 and log a = -1.28 ± 0.01.
Both atropine and pirenzepine fully inhibited specific [3H]NMS binding in membranes 
from CHO-hMi cells at radioligand concentrations of 0.2 nM and 2 nM (Figure 36) 
with p /l values of 9.47 ± 0.04 and 8.06 ± 0.05, respectively.  Neither atropine nor 
pirenzepine-mediated inhibition of [3H]NMS binding fitted the allosteric model.
Calculated affinities of compounds for the [3H]NMS occupied receptor (- log Kb/a) are 
also shown in Table 11.
(viii)  CHO-hM1  [3H]NMS kinetic binding
The association of [3H]NMS to CHO-hM1  cell membranes was rapid and monophasic, 
with equilibrium reached within  10 min (Figure 37a). Single site analysis of these 
results produced a ko b s  value of 0.257 ± 0.002 min'1. Atropine (1  pM) induced 
dissociation of [3H]NMS from CHO-hMi cell membranes under control conditions was 
rapid and monophasic, with a calculated ko ff value of 0.189 ± 0.022 min'1.
179Compound - log Kb log a - log Kb/<x*
Minimum asymptote 
significantly > 0 
(F-test) ?
0.2 nM 2 nM
Atropine 9.47 ± 0.04* n/a n/a No No
Pirenzepine 8.06 ± 0.05* n/a n/a No No
AC-42 6.19 ± 0.18 -1.77 ±0.17 4.50 Yes* Yes**
77-LH-28-1 7.08 ± 0.02 -1.76 ±0.04 5.32 Yes* Yes*
Compound A 5.38 ± 0.08 -1.70 ±0.23 3.16 Yes*** Yes*
Compound B 7.00** -3.14** 2.23 No No
Gallamine 5.20 ± 0.04 -1.28 ±0.01 4.06 Yes*** Yes***
f - log Kj  (pKj) values (derived from Cheng-Prussoff correction of IC50 values; 
equation 2; Appendix 1) quoted where data could not be described by allosteric 
model according to equation 7 (Methods).
ft - log Kb and log a estimate derived from meaned data.
* Theoretical affinity of antagonist for [3H]NMS occupied receptor derived from 
estimates of KB  and a (Christopoulos et ai,  1999).
* p < 0.05; ** p < 0.01 ;*** p < 0.001;  F-test.
Table 11.  Equilibrium [3H]NMS inhibition binding parameters for atropine, 
pirenzepine, AC-42, 77-LH-28-1, compound A, compound B and gallamine in CHO- 
hM! cell membranes (Appendix 1). Data are the mean of 3 experiments (± s.e.m.).
180These values led to calculated ko n  value of 311  ±115 min'1   j l lM '1  . The KD  value 
calculated from these estimates was 0.61  nM (Appendix 1).
The presence of gallamine (1  mM) produced a marked retardation of [3H]NMS 
dissociation from CHO-hMi cell membranes, with a significantly lower ko ffo b s  = 0.0170 
± 0.0008 min'1  compared to control conditions (Figure 37b; p < 0.01, T-test).
AC-42 (100 pM) also significantly slowed the rate of [3H]NMS dissociation, yielding a 
koffobs value of 0.122 ± 0.005 min'1   (Figure 37b; p < 0.05, T-test), although this effect 
was much less marked than that for gallamine. Compound A (100 pM) did not alter 
the rate of [3H]NMS dissociation compared to control, yielding a k0ff0b s value of 0.176 
± 0.002 min'1.
Analysis of the dissociation curves in the presence of gallamine according to 
equation 4 (with ko ffB  constrained to a value of zero) yielded an estimate of the affinity 
of gallamine for the [3H]NMS occupied receptor (-log KJa) of -3.86 ±0.12. Due to the 
relatively small effect of AC-42, it was not possible to obtain an accurate estimate of - 
-log Kb/o l.
(ix)  Rat cortex [3H]QNB and [3H]oxotremorine-M inhibition binding
Affinities of a range of test compounds to inhibit [3H]QNB and [3H]oxotremorine-M 
binding in rat cortical membranes are shown in Table 12 and Figure 38. Atropine, 
scopolamine and pirenzepine displayed affinities for rat cortical membranes in line 
with their known affinities for the muscarinic Mi  receptor, with [3H]oxotremorine-M / 
[3H]QNB affinity ratios of approximately 1, consistent with previous studies using 
agonist and antagonist radioligands (Loudon etal.,  1997).
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182The muscarinic receptor partial agonists, xanomeline and pilocarpine display 
approximately 10-fold and 50-fold higher affinity, respectively, against 
[3H]oxotremorine-M compared to [3H]QNB. Muscarinic receptor agonists such as 
milameline, oxotremorine, muscarine, carbachol and oxotremorine-M displayed much 
higher affinity against [3H]oxotremorine-M binding compared to [3H]QNB binding, with 
affinity ratios ranging from approximately 500 to greater than 4000 (Table 12; Figure 
38). These ratios are consistent with previous estimates using [3H]oxotremorine-M 
and [3H]QNB in rat cortex (Loudon etal.,  1997), but higher than estimates that have 
used [3H]oxotremorine-M / [3H]NMS affinity ratios in a mixed tissue population (Sharif 
et al.,  1995). The Mi  receptor selective agonists, AC-42, 77-LH-28-1, compound A 
and compound B displayed [3H]oxotremorine-M / [3H]QNB affinity ratios ranging 
between 4 and 25 (Table 12).
183Figure 38. Inhibition of [3H]QNB (■) and 
[3H]oxotremorine-M (A) binding by a range of 
muscarinic receptor ligands in rat cortical membranes. 
Data are the mean of 3 independent experiments; error 
bars show s.e.m..
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.Compound [3H]QNB pKj [3H]Oxo-M pKj Affinity ratio
Atropine 9.25 ±0.21 8.98 ± 0.08 0.5
Scopolamine 8.90 ±0.17 8.75 ± 0.05 0.7
Pirenzepine 6.93 ±0.10 6.84 ± 0.03 0.8
77-LH-28-1 6.59 ±0.15 7.23 ± 0.08 4
Xanomeline 7.31  ± 0.08 8.33 ± 0.07 10
Compound A 5.13 ± 0.12 6.16 ±0.09 11
Compound B 6.70 ± 0.08 7.96 ± 0.04 18
AC-42 5.63 ±0.14 7.01  ± 0.24 24
Pilocarpine 5.10 ±0.02 6.84 ± 0.38 55
Milameline 5.17 ± 0.18 7.87 ±0.10 501
Oxotremorine 5.81  ±0.15 8.53 ± 0.04 523
Muscarine 4.48 ±0.15 7.63 ±0.14 1413
Carbachol 3.97 ± 0.06 7.34 ± 0.07 2301
Oxotremorine-M 4.92 ± 0.08 8.54 ±0.16 4148
Table 12. Affinities of a range of muscarinic receptor ligands generated for inhibition 
of [3H]QNB and [3H]oxotremorine-M binding to rat cortical membranes. Data are the 
mean of 3 independent experiments (± s.e.m.).
188(x) Cortical network oscillations
In order to determine whether the Mi  receptor allosteric agonist, 77-LH-28-1, 
exhibited agonist properties in a native tissue preparation, this compound, along with 
the non-selective cholinergic receptor agonist carbachol, was examined in an in vitro 
network oscillations model in the rat cortex. The non-selective agonist carbachol (15 
pM) reversibly stimulated both beta (20 -  30 Hz) and gamma (30 -  80 Hz) frequency 
network oscillations in layer IV of the temporal cortex of rat brain slices (Figure 39). 
The muscarinic Mi  receptor selective agonist, 77-LH-28-1, at both 1   pM and 3 pM, 
stimulated gamma, but not beta frequency oscillations in layer IV of the temporal 
cortex at a mean frequency of 42.1  ± 2.0 Hz (Figure 40). The power of the gamma 
oscillations at 3 pM 77-LH-28-1, described by the area under the curve over the 30 -  
80 Hz range, was 1.294 ± 0.119 pV2/ Hz.kHz, compared to 0.044 ± 0.019 pV2 / 
Hz.kHz for control (Figure 40). 77-LH-28-1 -stimulated oscillations were abolished by 
atropine (10 pM; power = 0.0329 ± 0.015 pV2/ Hz.kHz;  Figure 40).
(xi) Discussion
AC-42 is a novel, functionally selective agonist of the muscarinic Mi  receptor that has 
been described as binding to an ‘ectopic’ site on the Mi  receptor (Spalding et al., 
2002). This site, not conserved amongst the other muscarinic receptor subtypes, is 
thought to confer the unprecedented selectivity for the Mi  receptor displayed by this 
compound. The studies in this chapter have extensively characterised the 
pharmacology of the interaction between the Mi  receptor and AC-42, and, to a lesser 
extent, an analogue of AC-42, 77-LH-28-1  and two novel, unrelated compounds, 
compound A and compound B that are also purported to act as selective Mi  receptor 
‘ectopic’ agonists.
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Figure 39. Carbachol-induced beta (P) and gamma (y) network oscillations. (A) 500 
ms recording of extracellular activity from layer IV of the rat temporal cortex in the 
presence and absence of carbachol. (B) A power spectra from a 60 s epoch of 
extracellular activity before and after addition of carbachol. Data are from a single 
representative experiment that was replicated 5 times with similar results.
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Figure 40. (A) 500 ms recording of extracellular activity from layer IV of the rat 
temporal cortex during (i) control conditions (red trace), (ii) after application of 77-LH- 
28-1  (black traces with corresponding autocorrelations from a 1   s epoch of activity) 
and (iii) after application of atropine (blue trace). (B) A power spectra from a 60 s 
epoch of extracellular activity (77-LH-28-1, 3 pM). Data are from a single 
representative experiment that was replicated 5 times with similar results.
191Calcium mobilisation studies in CHO cells stably expressing the human muscarinic 
Mi  receptor suggested that the non-selective orthosteric ligand carbachol, as well as 
AC-42 and compound A, were agonists at the Mi  receptor, with pEC50 values of 
approximately 8.4, 7.1  and 7.4, respectively. AC-42 appeared as a high efficacy 
partial agonist with intrinsic activity of 0.9 compared to carbachol, whereas 
compound A was a much weaker partial agonist (intrinsic activity = 0.4). All three 
agonists displayed qualitatively similar sensitivities to a range of signal transduction 
inhibitors. Agonist responses were abolished by pre-incubation with the Ca2+-ATPase 
inhibitor, thapsigargin. The phospholipase-C inhibitor, U73122, reduced the potency 
of both carbachol and AC-42 approximately 30-fold and abolished the response to 
compound A. The non-competitive inhibitor of the IP3 receptor, 2-APB, greatly 
reduced the calcium response generated by carbachol and AC-42 and abolished that 
to compound A.  The sensitivity of the calcium responses to inhibitors of 
phospholipase-C, the IP3 receptor and the endoplasmic reticulum Ca2+-ATPase is 
entirely consistent with carbachol, AC-42 and compound A stimulating the muscarinic 
Mt  receptor to signal through the Gq/n pathway. These data suggest that any 
alternative mode of receptor activation by the ‘ectopic’ agonists compared to that of 
carbachol does not alter the predominant signal transduction pathway utilised by the 
Mt  receptor.  However,  more extensive studies looking at other G protein mediated 
signal transduction including more downstream pathways, such as modulation of 
intracellular cAMP signalling, the MAP kinase cascade or arachidonic acid release, in 
both recombinant systems and native tissue, are required in order to determine 
whether ‘ectopic’ agonists exert any subtle differences in signal transduction 
compared to orthosteric agonists. Carbachol has been shown to stimulate cAMP 
accumulation, arachidonic acid release (Gurwitz etal.,  1994) and MAP kinase (Wotta 
etal., 1998) in CHO cells expressing the muscarinic Mi  receptor. Indeed, in the 
former study, the muscarinic Mi  receptor agonist AF102B (cis-2-methylspiro(1,3- 
oxathiolane-5,3')quinuclidine) displayed a different profile to carbachol in cAMP
192studies. Clearly further studies to examine the signalling pathways stimulated by AC- 
42 are required.
Carbachol and AC-42 also stimulated inositol phosphate (IP) accumulation in CHO- 
hMi cells, although AC-42 appeared as a partial agonist with respect to carbachol, 
consistent with the calcium mobilisation studies and previous reports (Spalding etal., 
2002). The analogue of AC-42, 77-LH-28-1  also stimulated IP accumulation and was 
approximately 10-fold more potent than AC-42. 77-LH-28-1, like AC-42, appeared to 
be a high efficacy partial agonist with respect to carbachol. Compound A and 
compound B only weakly stimulated IP accumulation, with pEC50 values of less than 
5 and intrinsic activity values of 0.2 and 0.1, respectively. These data suggest that 
compound A and compound B are very weak partial agonists at the Mi  receptor. The 
difference in the response generated by compound A in the calcium mobilisation 
assay compared to the IP accumulation assay may, therefore, be as a result of the 
much higher degree of signal amplification in the downstream calcium assay 
compared to the relatively proximal IP accumulation readout (Kenakin, 1997).
In functional assays, the best-characterised methods for investigating the mechanism 
of interaction between agonists and antagonists are the procedures underlying Schild 
analysis and its variants (Arunlakshana & Schild,  1959; Kenakin, 1997; Motulsky & 
Ghristopoulos, 2004). In this chapter, functional calcium mobilisation and IP 
accumulation studies were designed to examine the interaction between carbachol, 
AC-42 and compound A and the well-characterised orthosteric antagonists, atropine 
and pirenzepine.
In the calcium mobilisation assay, increasing concentrations of both atropine and 
pirenzepine cause a rightward shift in the concentration-response curve to compound 
A accompanied by a substantial depression in the maximal response. Indeed, in the
193presence of atropine (300 nM) and pirenzepine (1-10 pM), the compound A 
response was abolished. It is possible that if compound A were acting at a site on the 
receptor distinct from the orthosteric site, then the effect of an orthosteric antagonist 
could appear to be non-competitive and yield a depression in the maximal response 
with increasing antagonist concentration. If this were to be the case, the apparent 
rightward shift in the concentration response curve that was observed could be due 
to the receptor reserve in the CHO-hMi cells. It is also possible that any depression 
in the maximal agonist response could be due to the hemi-equilibrium kinetics of the 
FLIPR assay, (whereby the measurement of the agonist -  antagonist interaction 
takes place under non-equilibrium conditions due to the short agonist incubation and 
read time; Hall & Parsons, 2001). However, both calcium mobilisation and IP 
accumulation studies with compound A have already shown it to be a very weak 
partial agonist in CHO-hMi cells. To generate a functional response, such a 
compound would be required to occupy fully the hMi receptor population. However, 
the subsequent presence of an antagonist would prevent compound A from fully 
occupying the receptors and hence reduce the maximal response observed. It seems 
this is the most likely cause of the antagonist profile observed with compound A.
The interaction between carbachol or AC-42 and atropine or pirenzepine was 
examined in both calcium and IP accumulation assay formats. In both assays, 
atropine and pirenzepine antagonised the effects of carbachol in a manner that was 
consistent with the expectations of competition for a common (orthosteric) binding 
site, yielding Schild slopes not significantly different from unity. This was most 
evident with atropine in the calcium mobilisation assay, where a Schild slope of unity 
was maintained over atropine concentrations spanning six orders of magnitude 
(Figure 30). The resulting pKB  estimates (Table 10) were consistent with previously 
reported values in the literature for the binding of atropine or pirenzepine to the 
orthosteric site on the muscarinic Mi  receptor (Ellis, 2002).
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atropine or pirenzepine in either assay format led to Schild slopes significantly less 
than unity (Table 10), indicating that the antagonism was less than expected for a 
simple orthosteric interaction. Schild slopes of less than unity can arise due to a 
number of reasons (Kenakin, 1997), one possibility being an allosteric interaction. 
Negative allosteric interactions have previously been demonstrated in functional 
assays by a progressive inability of the antagonist to cause a rightward shift of the 
agonist concentration-response curve with increasing antagonist concentrations 
(Clark & Mitchelson, 1976; Lanzafame etal.,  1996), yielding a characteristic 
curvilinear Schild regression. Such Schild regressions, over a more limited range of 
antagonist concentrations, appear linear but shallow.
Accordingly, extension of the Schild analysis with AC-42 and atropine in the calcium 
mobilisation assay to cover atropine concentrations over six orders of magnitude, 
revealed a Schild plot that deviated from a slope of unity and tended to plateau at the 
highest atropine concentrations. Subsequent analysis of the data according to an 
allosteric ternary complex model yielded a pKB  estimate for atropine that was in good 
agreement with its known affinity for the orthosteric site (Ellis, 2002), but also 
provided an estimate of the co-operativity between atropine and AC-42 (a value of 
0.0002). However, the conclusion from these studies is that AC-42 must be the 
allosteric ligand, since atropine is the best-characterised orthosteric antagonist of the 
muscarinic receptors. Thus, it may be concluded that the iow Schild slopes 
associated with the interaction between atropine or pirenzepine and AC-42 actually 
reflect the saturability (governed by a in the ternary complex model) of an allosteric 
interaction between antagonist and agonist.
Due to the solubility maxima of the compounds involved relative to their affinity, it 
was not possible to extend the Schild regression for pirenzepine in the calcium assay
195or either antagonist in the IP accumulation assay. However, despite the lack of 
saturation in the allosteric effect, it was possible to generate estimates of the co- 
operativity governing the interaction between AC-42 and atropine or pirenzepine. 
These estimates also suggest negative co-operativity governing the interaction 
between AC-42 and pirenzepine or atropine. The estimate of log a for the interaction 
between AC-42 and atropine in the IP accumulation assay and also that determined 
in the calcium assay using three antagonist concentrations is 10-fold higher than the 
estimate from the calcium assay that utilised a six log unit range of antagonist. These 
differences probably represent the limitations of estimating log a values where the 
range of antagonist concentrations tested is not saturating and results in a Schild 
regression that is still apparently linear (as in the IP accumulation assays and the 
calcium mobilisation assay with pirenzepine).
More direct evidence of an allosteric mode of action for AC-42, 77-LH-28-1, 
compound A and compound B was obtained using radioligand binding. [3H]A/-methyl 
scopolamine (NMS) is an extremely well characterised radioligand used to study 
muscarinic receptors. These studies confirmed that [3H]NMS bound with rapid 
kinetics to membranes from CHO cells stably expressing the human Mi  receptor with 
sub-nanomolar affinity; ^agreement with previous studies (Christopoulos et al., 
1999). It is well established that allosteric modulators can have characteristic effects 
on the binding of orthosteric ligands (Christopoulos & Kenakin, 2002). For example, 
binding studies using two or more radioligand concentrations can reveal differences 
in the binding isotherm of the allosteric modulator because the saturability in the 
allosteric event becomes more evident as the concentration of orthosteric radioligand 
is increased (Figure 8; Christopoulos & Kenakin, 2002). Consistent with this, AC-42, 
77-LH-28-1  and compound A were unable to fully inhibit the specific binding of 
[3H]NMS at either 0.2 nM or, more strikingly (with the exception of compound A), at 
the higher concentration of 2 nM radioligand (Figure 36). This was a property shared
196by the prototypical modulator, gallamine (Figure 36), suggesting that these 
compounds act as negatively co-operative allosteric ligands at the  receptor. The 
values of affinity and co-operativity derived for gallamine from the application of an 
allosteric model are in excellent agreement with similar values determined previously 
(Matsui et a/., 1995), whereas this study is the first to apply such a model to the IVh 
receptor ‘ectopic’ agonists.
These data contrasted strikingly with the profile observed with both atropine and 
pirenzepine, which fully inhibited [3H]NMS binding at radioligand concentrations of 
0.2 nM and 2 nM and whose inhibition isotherms were entirely consistent with a 
simple, competitive interaction.
Compound B fully inhibited the binding of [3H]NMS, yet the pair of inhibition curves 
derived from meaned data could be fitted to an allosteric model. In fact, statistical 
comparison of both the allosteric and a competitive model yielded a clear preference 
for the former. Full inhibition of orthosteric radioligand binding does not preclude a 
compound from acting allosterically, but would then suggest a high degree of 
negative co-operativity with the radioligand (Christopoulos & Kenakin, 2002). 
Unsurprisingly, given the full inhibition of [3H]NMS binding, the estimate of log a for 
compound B suggested a much higher degree of negative co-operativity with respect 
to [3H]NMS than was determined for AC-42, 77-LH-28-1  and compound A.
In contrast to the calcium mobilisation assays, it has already been observed that both 
AC-42 and 77-LH-28-1  appear as partial agonists in the IP accumulation assay. As 
such, they require full receptor occupancy to generate their maximal responses and 
the pEC50 value of a partial agonist is a useful approximate measure of its affinity for 
the receptor (Kenakin,  1997).  In this respect it is noteworthy that the pKB  values 
estimated for the binding of AC-42 and 77-LH-28-1  according to an allosteric model
197(6.19 ± 0.18 and 7.08 ± 0.02, respectively) are in excellent agreement with the 
potency values in the IP accumulation assay (6.21  ± 0.10 and 7.24 ± 0.02, 
respectively).
Additionally, the estimated a value for the interaction between AC-42 and [3H]NMS 
was markedly different from the value describing the interaction between AC-42 and 
atropine. This highlights a second characteristic of allosteric interactions (in addition 
to saturability), namely, that the degree of co-operativity between orthosteric and 
allosteric sites depends on the chemical nature of the ligands occupying each site. 
This ‘probe-dependence’ of allosterism can explain why in some studies, an allosteric 
interaction may be missed altogether if it is characterised by either neutral co- 
operativity (i.e. appears as if there is no interaction) or by very high negative co- 
operativity (i.e. appears as if the interaction is competitive).
One of the most definitive methods used to validate an allosteric mechanism of 
action is to monitor the effects of a putative modulator on the dissociation of a pre­
formed orthosteric ligand-receptor complex; any alteration in the dissociation of such 
a complex must be indicative of a conformational change mediated via a 
topographically distinct site (Kostenis & Mohr, 1996).  Indeed, prototypical allosteric 
modulators of muscarinic receptors, such as C7/3-phth (Christopoulos etal.,  1999), 
strychnine (Lazareno & Birdsall, 1995) and gallamine (Stockton etaU, 1983) have all 
been shown to allosterically retard the rate of [3H]NMS dissociation from muscarinic 
receptors in a concentration-dependent fashion.  Thus, the most striking confirmation 
of the allosteric nature of AC-42, as with gallamine, was obtained from [3H]NMS 
dissociation kinetic assays.  As illustrated in Figure 37b, both AC-42 and gallamine, 
but not compound A, retarded the dissociation of [3H]NMS from the Mi  receptor, 
although the effect was much more pronounced for gallamine relative to AC-42. 
These results can be explained by at least two reasons: First, at the concentrations
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calculated from their relative KB  and a values that 1   mM gallamine would occupy 
approximately 98% of the [3H]NMS-bound receptors, whereas 100 juM AC-42 would 
only occupy approximately 77% of the [3H]NMS-bound receptors and 100 jllM  
compound A would only occupy approximately 13% of [3H]NMS-bound receptors. 
Therefore, it is not surprising that gallamine is able to exert a larger effect on 
[3H]NMS dissociation than AC-42 and that compound A does not alter the 
dissociation rate. Second, it is possible that AC-42 and compound A simply cannot 
exert the same maximal effect on radioligand kinetics as gallamine. Indeed, other 
prototypical modulators of muscarinic receptors such as obidoxime have been shown 
to have limited effects on radioligand dissociation (Ellis & Seidenberg,  1992).
Collectively, the data presented herein provide unambiguous evidence that the 
‘ectopic’ agonist, AC-42, is an allosteric ligand.  As such, it is more appropriate to re­
class this ligand as an allosteric, rather than ectopic, agonist.  The prevalence of 
other confirmed allosteric agonists of G protein-coupled receptors remains relatively 
limited in the current literature.  There is some evidence that the adenosine At 
receptor enhancer, PD 81,723 ((2-amino-4,5-dimethyl-3-thienyl)-[3- 
(trifluoromethyl)phenyl] methanone), is able to promote a modest degree of receptor 
G protein-coupling in its own right (Bhattacharya & Linden,  1995).  Similarly, the 
peptide, ASLW, has been shown to activate the chemokine CXCR4 receptor in a 
manner that is likely to be allosteric (Sachpatzidis et al., 2003).  For the muscarinic 
receptor family, Jakubik etal. (1996) showed that gallamine and alcuronium could 
promote receptor activation, but these results have not been consistently reproduced 
(Lazareno & Birdsall, 1995; May etal., 2005), and may reflect the requirement of 
particular stoichiometries of receptor to G protein (Jakubik et al., 1998).  Earlier 
radioligand binding studies suggested that the partial agonist, McN-A-343 (N-[3- 
chlorophenyl] carbamoyloxy)-2-butynyl-trimethylammonium chloride), was also an
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subsequent functional study was unable to conclude whether this compound 
interacted allosterically with very high negative co-operativity or via simple orthosteric 
competition when tested against carbachol (Christopoulos & Mitchelson,  1997).
This chapter has shown, using functional, equilibrium binding and dissociation kinetic 
assays, that the mechanism of action of AC-42 at the IVh  muscarinic receptor is 
qualitatively and quantitatively consistent with an allosteric model.  Equilibrium 
binding has also provided evidence to suggest that that 77-LH-28-1, compound A 
and compound B act allosterically at the Mi  receptor. Clearly further studies on the 
mechanism of interaction of these compounds with the Mi  receptor are warranted.
These findings have important ramifications for muscarinic receptor-based drug 
discovery, but also raise additional considerations.  For instance, is the allosteric site 
recognised by AC-42 and 77-LH-28-1  the same site as that recognised by gallamine, 
or a second allosteric site recognised by certain staurosporine derivatives (Lazareno 
etal., 2000), or even a third topographically distinct allosteric site?  Given that AC-42 
has approximately the same affinity for all the muscarinic receptor subtypes 
(Spalding et al., 2002), what is it about the nature of the AC-42 binding site that 
allows almost exclusive activation of the Mi  receptor relative to other muscarinic 
receptor subtypes? Clearly further studies are warranted to elucidate the molecular 
nature of this allosteric site, in this context it would be interesting to examine using 
dissociation kinetic studies whether AC-42 and 77-LH-28-1  compete for the same 
binding site as gallamine and C7/3-phth, as has been tested with other allosteric 
ligands such as obidoxime (Ellis & Seidenberg, 1992). Furthermore, studies of the 
interactions and affinity of AC-42 and 77-LH-28-1  at the other muscarinic receptors 
may shed light on why these agonists display such a selective profile.
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performed in recombinant systems, native tissue radioligand binding and functional 
assays were performed to see if this class of compounds was able to interact with 
native muscarinic receptors.
The ratio of affinities of a muscarinic receptor ligand to inhibit agonist (usually 
[3H]oxotremorine-M) and antagonist ([3H]NMS or [3H]QNB) radioligand binding is a 
well established method used to qualitatively approximate efficacy at muscarinic 
receptors (Freedman etal., 1988; Loudon etal., 1997; Watson etal.,  1999; Tayebati 
etal.,  1999). In agreement with previous studies, the muscarinic receptor antagonists 
atropine, scopolamine and pirenzepine displayed approximately equal affinity in 
inhibiting the binding of either [3H]oxotremorine-M or [3H]QNB to rat cortical 
membranes, generating affinity ratios close to unity (Loudon etal., 1997).
Conversely, muscarinic receptor agonists such as carbachol, muscarine and 
oxotremorine-M display much greater affinity to inhibit [3H]oxotremorine-M binding 
compared to [3H]QNB binding, yielding oxotremorine-M / QNB affinity ratios in excess 
of 1000. These values are consistent with previously reported studies in rat cortex 
with muscarinic receptor agonists (Loudon etal., 1997; Watson etal.,  1999).
It has been suggested that intermediate agonist / antagonist affinity ratios, greater 
than .1   but less than 500 represent ligands that possess partial agonist activity at the 
muscarinic receptor population being examined (Tayebati etal.,  1999; Watson etal., 
1999). Accordingly, the muscarinic receptor partial agonists, xanomeline and 
pilocarpine, displayed oxotremorine-M / QNB affinity ratios of 10 and 55, respectively, 
whilst milameline and oxotremorine displayed ratios of approximately 500. These 
data are consistent with these compounds acting as partial agonists in this tissue. 
Interestingly, despite the allosteric mode of action described earlier, AC-42, 77-LH- 
28-1, compound A and compound B all displayed higher affinity to inhibit
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to xanomeline. If the same conclusions can be applied to allosteric, as well as 
orthosteric muscarinic receptor ligands, these data predict that AC-42, 77-LH-28-1, 
compound A and compound B are all partial agonists at cortical muscarinic 
receptors. However, this method does not seem to provide an accurate estimate of 
intrinsic activity. In the CHO-hMi  IP accumulation assay, 77-LH-28-1  displayed much 
higher efficacy than compound A and compound B and was approximately as 
efficacious as AC-42. However, 77-LH-28-1  displayed the lowest oxotremorine-M / 
QNB affinity ratio of all the allosteric  receptor agonists.  This comparison of 
[3H]oxotremorine-M / [3H]QNB binding and CHO-IiMt  IP accumulation assays does 
make the assumptions that the muscarinic receptor population in cortical tissue is 
predominantly of the Mt receptor subtype and that there are no significant differences 
between the rank order of efficacies at rat and human receptor subtypes. However, 
the affinity ratio assay appears to be limited to qualitative resolution of full agonists, 
partial agonists and antagonists rather than an accurate determination of intrinsic 
activity.
To conclude the characterisation of this novel class of selective Mr receptor agonists, 
77-LH-28-1  was examined in an in vitro neuronal network oscillations model in the rat 
temporal cortex. The non-selective cholinergic agonist, carbachol, has been shown to 
induce persistent rhythmical oscillatory activity in the 30 -  80 Hz (gamma) range in 
both rodent hippocampal (Fisahn etal., 1998) and cortical (Buhl etal:, 199i8) slices. 
Furthermore, muscarine induced gamma oscillations in CA3 neurons of the 
hippocampus are absent in mice lacking the muscarinic Mt receptor (Fisahn etal., 
2002), clearly implicating this receptor subtype in the induction of the gamma 
frequency oscillations. In the studies described in this chapter, carbachol (15 pM) 
induced persistent rhythmical oscillatory activity in both the beta (20 -  30 Hz) and 
gamma (30 - 80 Hz) frequency ranges in layer IV of the rat temporal cortex.
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region at a mean frequency of 42.1  ± 2.0 Hz. These oscillations were abolished in the 
presence of the muscarinic receptor antagonist, atropine, confirming that the 
response was muscarinic receptor mediated. However, 77-LH-28-1  did not induce 
oscillations in the beta frequency range. These results show that 77-LH-28-1  acts as 
a muscarinic receptor agonist in native cortical tissue, mimicking the gamma 
frequency oscillations induced by carbachol. Furthermore, these results suggest that 
given the selectivity profile of 77-LH-28-1, carbachol induced gamma frequency 
oscillations in layer IV of the temporal cortex are probably mediated entirely via 
activation of the muscarinic Mi receptor subtype. In contrast, 77-LH-28-1  was unable 
to induce the beta oscillatory activity that was observed with carbachol, suggesting 
that activation of other muscarinic receptor subtypes or nicotinic acetylcholine 
receptors, either alone or in combination with the Mi  receptor subtype, are required 
to stimulate this oscillatory behaviour.
The studies in this chapter have extensively characterised the pharmacology of the 
Mi  receptor selective agonist, AC-42. Furthermore, they have examined a related 
analogue, 77-LH-28-1  and two novel Mi receptor selective agonists in compound A 
and compound B. Both AC-42 and compound A were shown to signal through similar 
signal transduction pathways to carbachol at the Mt receptor. Antagonist studies also 
provided direct evidence that the functionally selective IVh  receptor agonist, AC-42, is 
an allosteric modulator.  An investigation of the mode of interaction of this agonist 
with various orthosteric ligands confirmed that AC-42 exhibited characteristics 
associated with prototypical allosteric ligands, including (i) a saturability to its 
allosteric effects (a property that was also shown to be shared with 77-LH-28-1  and 
compound A), (ii) a dependence of these effects on the nature of the orthosteric 
ligand with which it interacted and (iii) the ability to significantly retard the dissociation 
of [3H]NMS from the muscarinic Mi  receptor.  These results reveal that the Mi
203receptor possesses an allosteric site capable of mediating receptor activation in its 
own right, and further reinforce the utility of allosteric binding sites for achieving 
selectivity at G protein-coupled receptors. Finally, these compounds were shown to 
interact with cortical muscarinic receptors in both radioligand binding and 
electrophysiological assays in a manner that suggests they possess agonist activity 
in a native tissue system. The discovery of an allosteric agonist site on the 
muscarinic M1  receptor provides a great opportunity for future drug discovery in this 
area. The increasing awareness of allosteric ligands and their uses has the potential 
to lead to more selective drugs that target GPCRs in the future -  the only currently 
marketed allosteric drug that acts at a GPCR is cinacalcet, an allosteric enhancer of 
the calcium-sensing receptor (Wess, 2005).
204Chapter 6
Characterisation of the ectopic agonist -  muscarinic Mt
receptor interaction
205(i) Introduction
As discussed extensively in Chapter 1, the orthosteric binding site of the muscarinic 
Mi  receptor, deep within the TM bundle, has been extensively studied by means of 
homology modelling and SDM. Many interactions for both agonist (eg. ACh, 
carbachol) and antagonist (eg. NMS, atropine) binding have been identified. As such 
the Mi receptor orthosteric site probably remains one of the best characterised 
amongst the GPCR superfamily. Furthermore, as shown in Chapter 5, the interaction 
of a number of allosteric ligands with muscarinic receptor subtypes has also been 
probed by SDM. Generally, ligands such as gallamine and C7/3-phth have been 
shown to bind to the exofacial region of the receptor, making contacts with epitopes 
at the top of the TM domains and with the extracellular loops.
As discussed in Chapter 5, AC-42 has recently been identified as an ectopic agonist 
of the muscarinic Mi  receptor (Spalding etal., 2002). This compound displays a 
highly selective profile, activating the M1   receptor alone amongst the muscarinic 
receptor family (Spalding etal., 2002). The studies in Chapter 5 have clearly 
demonstrated that AC-42 (and possibly other ectopic agonists) are actually allosteric 
ligands, a property that is likely to account for their unprecedented selectivity profile.
However, the molecular recognition site for AC-42 remains unknown. In order to 
understand this selective agonist activity at the Mi  receptor Spalding et al. (2002) 
constructed chimeric M1/M5 receptors to identify the regions of the Mi receptor 
involved in the binding of AC-42. A chimera in which only 45 aa in the N-terminus 
and TM1  were replaced by those in the M5 receptor was still responsive to carbachol, 
but failed to be stimulated by AC-42, suggesting that this region is key to the activity 
of AC-42 (Spalding et al., 2002). However, a chimera with only the first 50 aa of the 
Mi  receptor and the remainder from the M5 receptor was similarly unresponsive to
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sufficient for AC-42 activity (Spalding etal., 2002).
A chimera with the region from the N-terminus to the end of TM6 from the Mi 
receptor (residues 1   -  388) and the remainder from the M5 receptor was also 
unresponsive to AC-42. However a further chimera with the ‘Mi-like’ region stretching 
from the N-terminus to the middle of TM7, incorporating residues 1   -  418 of the hMi 
receptor, was responsive to AC-42, albeit with lower efficacy than the wild-type Mi 
receptor. These data suggest that residues within the third extracellular loop (ECL3) 
and the top of TM7 of the Mi  receptor may also be key to AC-42 activity (Spalding et 
al., 2002).
Studies with chimeras in which the middle of the Mi  receptor was replaced with the 
M5 receptor sequence, but retained the Mi receptor sequence in the N-terminus-TM1 
and ECL3-TM7 regions (Mi-like residues 1 -4 5  and 388 -  418; M5-like residues 46 -  
387 and 418 -  460), confirmed that both these regions are required and act 
synergistically to play a role in the activation of the Mi  receptor by AC-42 (Spalding et 
al., 2002).
Clearly these regions that have been identified are not consistent with AC-42 binding 
to the orthosteric site of the Mi  receptor. In an elegant conclusion to their study, 
Spalding et al. (2002) demonstrated that the potency of AC-42 was not attenuated by 
the mutations Y381A or N382A in TM6, which abolish the agonist activity of 
carbachol (Spalding etal., 2002; Ward etal., 1999). In the absence of definitive proof 
that this ligand was allosteric (which has now been resolved as described in Chapter 
5), these data prompted the authors to term AC-42 an ‘ectopic’ agonist, due to its 
interaction with a site on the M!  receptor distinct from that recognised by carbachol.
207Despite the identification of the gross regions involved in AC-42 binding, the precise 
molecular nature of the binding site for AC-42 and related analogues at the IVh 
receptor remains unknown. In the studies described in this chapter this question has 
been addressed through homology modelling of the IVh  receptor based on the crystal 
structure of rhodopsin. This model has allowed the prediction of some of the possible 
molecular interactions of AC-42, 77-LH-28-1, compound A and compound B with the 
Mi receptor. These predictions have been assessed by both [3H]NMS saturation and 
inhibition binding and functional calcium mobilisation studies with Mi  receptors 
containing appropriate point mutations.
(ii) Ligand docking and site directed mutagenesis
The initial placement of AC-42 within the muscarinic Mi  receptor was guided by the 
M1 /M5 chimeric receptor studies (Spalding et al., 2002; Figure 41) and the fact that 
AC-42 contained a basic nitrogen for which acidic residues within the essential 
portion of the Mi  receptor sequence were sought. The studies by Spalding etal. 
(2002) clearly defined residues 1 -4 5  and 388 -  418 of the Mi receptor as being 
crucial to AC-42 agonist activity (Figure 41). Therefore, it was within these regions 
that candidate acidic residues to partner the basic nitrogen were identified.
Following the various initial placements of the ligand, the complex was minimised 
with CHARMrn (using NOE distance helical constraints in the TM bundle, distance 
dependent dielectric, 2000 steps SD and 5000 steps ABNR).
All reasonable docking solutions suggested that the E401  on TM7 was forming a 
charge-charge interaction with the protonated nitrogen of AC-42 (Figure 42).  This 
placed the aromatic benzoyl portion of AC-42 down between helices 1, 2 and 7, with 
the phenyl ring sitting directly above Y408 and encircled by a number of other 
aromatic residues: Y82, W101, Y404 and W405.
208Figure 41. Representation of the 3-dimensional structure of the muscarinic receptor, 
modelled after the crystal structure of rhodopsin (Palczewski etal., 2000). Cylinders 
represent helices. Lines represent connecting intracellular and extracellular loops. 
The extracellular surface is at the top of the page. TM1  is on the right, and the 
helices proceed in a counter-clockwise direction. Filled cylinders and lines represent 
muscarinic M1  receptor-like sequence (residues 1  -  45 and 388 -  418); open 
cylinders and lines represent muscarinic M5  receptor-like sequence (residues 46 -  
387 and 418-460).
209Figure 42. Predicted interactions of AC-42 with the muscarinic Mi receptor. Charge- 
charge interactions of the protonated nitrogen with E397/E401  and carbonyl oxygen 
with Y82 are shown.
210Additionally, it appeared that the hydroxyl hydrogen on T34 was forming a hydrogen 
bond to the n system of the phenyl ring (Meyer et al., 2003).  The carbonyl oxygen of 
the benzoyl portion was proposed to hydrogen bond to the hydroxyl portion of Y82 
(Figure 42).  The butyl linker between the aromatic ring and the piperidine ring was 
transversing a hydrophobic pocket defined by 128 and L86, and the piperidine ring 
and the aliphatic butyl tail of AC-42 are located at the top of this pocket forming 
hydrophobic interactions with L86, V25 and A175.
The docking of AC-42 was used as a basis for the docking of compound A and 
compound B. As with AC-42, both of these compounds contain a basic nitrogen that 
was predicted to form charge-charge interactions with E397 and E401. Similarly, a 
carbonyl oxygen of compound A and compound B was predicted to form a hydrogen 
bond with Y82 in TM2 and, as with AC-42, the hydroxyl hydrogen on T34 was 
predicted to be forming a hydrogen bond to the n system of a phenyl ring.
On the basis of these docking studies, the acidic residues E397 & E401  and the 
proposed hydrogen bonding residue Y82 were identified as targets for SDM studies 
and the mutations E397A, E401 A, E397A/E401A and Y82F were made using the 
QuikChange PGR method. To compare and contrast this proposed binding mode 
with the orthosteric mode, the Y381A orthosteric mutation (Ward et al., 1999) was 
also selected for studies and made using the method of PCR SOEing (Horton et al., 
1990). The location of the chosen residues is shown in Figure 43. Mutations to 
alanine were employed in order to remove the amino acid side-chains beyond the p- 
carbon whilst maintaining the a-helical structure of the transmembrane domains to 
minimise any gross changes to receptor conformation. The Y82F mutation was 
chosen to investigate the proposed role of the phenolic hydroxyl group of the tyrosine 
residue.
211Figure 43. Schematic representation of the human muscarinic  receptor 
highlighting key residues which were predicted to be involved in interactions with AC- 
42; the residues circled in red were mutated. The yellow bar represents a disulphide 
bond. For reasons of clarity both the C- and N-termini as well a portion of the third 
intracellular loop have been truncated.(iii) U20S and CHO-K1 SDM calcium mobilisation studies
Initial functional studies on muscarinic Mi receptor SDM constructs were carried out 
in U20S cells by FLIPR based assessment of calcium mobilisation. U20S cells were 
chosen for this study due to their efficient uptake of the BacMam virus used for 
transduction of the SDM constructs (Ames etal., 2004a). Carbachol, oxotremorine- 
M, muscarine, AC-42 and 77-LH-28-1  all appeared as full agonists at the wild-type 
Mi receptor transiently expressed in U20S cells (Figure 44) with potencies as shown 
in Table 13. In contrast, compound A and compound B appeared as partial agonists 
with intrinsic activities of approximately 0.8 and 0.3, respectively (Figure 44; Table 
13). The point mutation Y82F significantly reduced the potency of all agonists by 
between 0.5 and 1   log unit with the exception of compounds A and B, although for 
compound B the very low efficacy of the response to this agonist made an accurate 
determination of potency difficult.
Mutation of E397 at the top of TM7 did not significantly affect the potency of either 
orthosteric or ectopic agonists (Figure 44; Table 13). Similarly, loss of E401  did not 
significantly alter the potency of any of the agonists tested. The double mutation, 
E397A/E401-A, did not significantly alter the potency of orthosteric agonists (with the 
exception of a 2-fold reduction in oxotremorine-M potency) or that of AC-42 and 77- 
LH-28-1. However, this mutation caused a significant 5-fold reduction in the potency 
of compound A and effectively abolished any agonist activity observed with 
compound B.
Mutation of Y381  in TM6 abolished the agonist activity of carbachol and 
oxotremorine-M and caused a 300-fold reduction in the potency of muscarine that 
was accompanied by a marked reduction in efficacy (Table 13). This mutation also 
effectively abolished the agonist activity observed with AC-42 and 77-LH-28-1.
213However, loss of Y381  yielded significant increases in the potency of compounds A 
and B, with 2-fold and 10-fold leftward shifts in the concentration response curves to 
these agonists, respectively. In the case of compound B this was accompanied by an 
increase in the efficacy of the response.
Calcium mobilisation studies were also performed using CHO-K1  cells as the 
parental cell line as a functional comparison to the [3H]NMS binding studies. Agonist 
responses to carbachol, compound A, AC-42 and 77-LH-28-1  were determined 
against wild-type, E397A/E401A and Y381A constructs (Figure 45; Table 14). 
Mutation of Y381  reduced the potency of carbachol by greater than 1000-fold. 
Surprisingly in light of the previous results, this mutation did not abolish the 
responses to AC-42 and 77-LH-28-1  in the same way that it did for carbachol. 
However, the potencies of AC-42 and 77-LH-28-1 were significantly reduced 4-fold 
and 17-fold, respectively, with approximately a 30% reduction in the maximal 
response. Conversely, loss of Y381  caused a significant 10-fold increase in the 
potency of compound A to stimulate calcium mobilisation. The double mutation, 
E397A/E401 A, did not affect the potency of carbachol but produced a 2-fold 
reduction in the potencies of AC-42, 77-LH-28-1 and compound A; only the reduction 
in compound A potency reached significance (p < 0.05; Figure 45; Table 14).
214Figure 44. Concentration-dependent stimulation of Ca2 +  
mobilisation by muscarinic receptor agonists at wild type and 
mutant muscarinic IV h  receptor constructs transiently expressed 
in U20S cells. All compounds and constructs were assesses in 
parallel, hence all data are normalised to the maximal wild-type 
carbachol response. Data are the mean of 3 experiments; error 
bars show s.e.m..
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log [Compound  B] (M)Compound WT Y82F E397A E401A E397A/E401A Y381A
Carbachol 7.36 ±0.06 
(1.0; n=6)
6.66 1 0.07***
(1.0; n=6)
7.2810.10
(1.0; n=4)
7.28 1 0.06
(1.0; n=5)
7.30 1 0.08
(1.0; n=6)
< 5***
(0.1; n=4)
Oxotremorine-M 8.38 ± 0.08
(1.0; n-6)
7.6910.12*** 
(1.1  n=6)
8.3410.10 
(1.0 n=4)
8.3410.06
(1.0;  n=5)
8.09 1 0.07*
(1.0; n=6)
< 5*** 
(0.1; n=4)
Muscarine 8.04±0.13 
(1.0; n=S)
7.1410.12**
(1.0; n=4)
7.78 1 0.03 
(1.1; n=3)
7.91  ±0.09
(1.0;  n=4)
7.7510.14
(1.0; n=5)
5.55 1 0.35*** 
(0.3; n=3)
AC-42 6.7810.14
(1.0; n=6)
5.9910.19**
(1.0; n-6)
6.6010.15
(1.0; n=4)
6.7310.18
(1.0;  n=5)
6.6010.16
(0.9; n=6)
< 5*** 
(0.3; n=4)
77-LH-28-1 7.9310.08 
(1.0; n=6)
7.22 1 0.05***
(1.0; n=5)
7.7210.16
(1-1; n=4)
7.85 1 0.09
(1.0; n=S)
7.6210.12
(0.9; n=6)
< 5*** 
(0.1; n=4)
Compound A 6.26 1 0.08
(0.8; n=7)
5.95 1 0.22
(0.7; n=5)
6.1310.22
(0.6; n=4)
5.99 + 0.11
(0.7; n=5)
5.6910.17* 
(0.6;  n=7)
6.62 1 0.04*
(0.7; n=4)
Compound B 6.86 1 0.22
(0.3; n=6)
6.98* 
(0.1; n=8)
6.74*
(0.1; n=5)
6.92*
(0.2; n-6)
n.r.***
(n-6)
7.86 1 0.20** 
(0.5; n=5)
Table 13. pEC50 and intrinsic activity values for intracellular Ca2+  mobilisation induced by muscarinic receptor agonists at wild type 
and mutant muscarinic Mi  receptor constructs transiently expressed in U20S cells. Data are the mean ± s.e.m. (intrinsic activity;
‘n’ number); each experiment was performed on a separate viral transduction. * Potency estimates derived from meaned data; n.r. = 
no response at concentrations up to 10 pM. * p < 0.05; ** p < 0.01; *** p < 0.001  significantly reduced compared to wild-type 
response;* p < 0.05;+ +  p < 0.01  significantly increased compared to wild type response (Student’s T-test).
217Ligand / 
Receptor
WT Y381A E397A/E401A
Carbachol 8.28 ± 0.11
in=5)
< 5***
(n=4)
8.25 ± 0.03
(n=4)
AC-42 7.56 ±0.13
(n=5)
6.92 ±0.10**
(n=5)
7.27 ±0.10
(n=4)
77-LH-28-1 9.13 ± 0.12
(n=6)
7.89 ± 0.04***
(.n=4)
8.84 ± 0.06#
(n=5)
Compound A 6.93 ± 0.07
(n=5)
7.95 ± 0.18tn
(n=5)
6.62 ± 0.06*
(n=4)
Table 14. pEC50 (± s.e.m.) values for intracellular Ca2+ mobilisation induced by 
carbachol, compound A, AC-42 and 77-LH-28-1  at wild type and mutant muscarinic 
IVh  receptor constructs transiently expressed in CHO-K1  cells.
* p < 0.05; ** p < 0.01; *** p < 0.001  significantly reduced compared to wild-type 
response; f p < 0.05; m  p < 0.001  significantly increased compared to wild type 
response (Student’s T-test). * p = 0.07.
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Figure 45. Concentration-dependent stimulation of Ca2 +  mobilisation induced by 
carbachol, AC-42, 77-LH-28-1 and compound A at wild type (■), E397A/E401A (T) 
and Y381A (A) mutant muscarinic Mt  receptor constructs transiently expressed in 
CHO cells. Data are the mean of 3 experiments; error bars show s.e.m..
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219(iv) CH0-K1  SDM [3H]NMS saturation binding
Specific binding of [3H]NMS to membranes from CHO cells transiently transduced 
with the wild-type muscarinic IV h receptor was saturable and represented more than 
70% of total binding. Non-linear regression revealed that [3H]NMS bound to a single 
site with a KD  value of 0.26 ± 0.04 nM and a Bm a x of 173.6 ± 29.9 fmol mg protein'1  
(Figure 46). Specific binding of [3H]NMS to membranes from CHO-M1 -E397A/E401A 
cells represented less than 50% of total binding. The affinity of [3H]NMS binding was 
unaltered by the mutation of E397 and E401  (KD  = 0.34 ±0.13 nM), although there 
was a significant reduction in the Bm a x compared to wild-type cell membranes (50.8 ±
3.1 fmol mg protein'1 ; F-test; Figure 46). CHO cells transiently expressing the Mr  
Y381A construct displayed no specific binding of [3H]NMS up to concentrations of
2.2 nM (Figure 46).
(v)  CHO-K1  SDM [3H]NMS inhibition binding
The broad spectrum muscarinic receptor antagonist atropine inhibited specific 
[3H]NMS binding to membranes from CHO-K1 cells transiently expressing the wild- 
type muscarinic Mi receptor, with a pK, value of 9.20 ± 0.05 (Table 15; Figure 47). 
Atropine displayed a similar affinity (9.18 ± 0.01) at the muscarinic M1  receptor 
containing the double point mutation, E397A/E401A. Compound A inhibited [3H]NMS 
binding to the wild-type Mi receptor with a p K , value of 5.30 ± 0.07. The affinity of 
compound A was not significantly altered at the double mutant receptor (Table 15, 
Figure 47). In contrast, AC-42 displayed a significantly reduced affinity for Mr 
E397A/E401A (p K , = 5.34 ± 0.03) compared to the wild-type receptor (5.76 ± 0.06; p  
< 0.01; T-test).
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Figure 46. Saturation analysis of specific binding of [3H]NMS to membranes from 
CHO cells transiently expressing the wild-type muscarinic Mi receptor and constructs 
containing the point mutations E397A/E401A and Y381A. Data shown are the mean 
of 3 experiments; error bars represent s.e.m..
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Figure 47. Concentration-dependent inhibition of specific [3H]NMS binding to 
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receptor and a construct containing the point mutations E397A/E401A by (A) atropine 
and compound A and (B) AC-42. Data shown are the mean of 3 experiments; error 
bars represent s.e.m..
222Ligand / 
Receptor WT E397A/E401A
Atropine 9.20 ± 0.05 9.18 ±0.01
Compound A 5.30 ± 0.07 5.07 ±0.13
AC-42 5.76 ± 0.06 5.34 ± 0.03
Table 15. pK} values (± s.e.m.) of atropine, compound A and AC-42 to inhibit binding 
of [3H]NMS from membranes of CHO cells transiently expressing 
Mi-WT and Mi-E397A/E401A. Data are the mean of 3 experiments.
223(vi)  Discussion
The studies in Chapter 5 have characterised the pharmacology of AC-42 and a range 
of other allosteric agonists at the muscarinic Mi  receptor. It is apparent from the 
chimeric M1 /M5 receptor studies performed by Spalding et at. (2002) that the binding 
site for AC-42 is at least partially or wholly distinct from the well conserved orthosteric 
binding site of the muscarinic receptor family. However, little is known of the 
molecular nature of the recognition site for these selective agonists.
In this chapter, as with PrRP and GPR10 in Chapter 4, a combined molecular 
modelling and SDM approach has been used in order to elucidate the molecular 
nature of the allosteric agonist binding site. A homology model of the muscarinic Mi 
receptor was constructed based on the crystal structure of bovine rhodopsin 
(Palczewski etal., 2000) followed by manual docking of both AC-42 and compound 
A. Site directed mutagenesis was then carried out on various amino acid residues 
identified as possible attachment points for AC-42 and compound A. Mutant 
constructs were assessed using a combination of functional calcium mobilisation 
studies and [3H]NMS binding.
Using the results from the chimera studies (Spalding etal., 2002) as a basis, acidic 
residues within the essential portion of the Mi  receptor sequence were sought to 
complement the protonated nitrogen of AC-42. All acceptable solutions placed the 
protonated nitrogen in close proximity to E401  and also near E397. This orientation 
suggested that the carbonyl oxygen of AC-42 formed a hydrogen bond with the 
phenolic hydroxyl group of Y82. In light of these predictions, constructs containing 
the single point mutations E397A and E401 A, as well as a double mutation, 
E397A/E401A were made.  Furthermore, a construct containing the point mutation 
Y82F, which lacks the hydroxyl moiety, was made to test the predicted interaction 
with the carbonyl oxygen.  Finally, a construct containing the well characterised
224mutation of the orthosteric site, Y381 A, was made. This mutation has been shown to 
reduce the potency of carbachol and acetylcholine by greater than 1000-fold (Ward 
etal., 1999). However, this mutation leaves responses to AC-42 and N- 
desmethylclozapine (a metabolite of the anti-psychotic drug, clozapine, that purports 
to be an allosteric agonist of the muscarinic  receptor) relatively unaffected 
(Spalding etal., 2002; Sur etal., 2003). Whilst not defining the recognition site of the 
allosteric Mi  receptor agonists, this mutation was key to determining whether this 
class of compounds interacted at a site that was non-orthosteric.
The loss of the hydroxyl group of Y82 caused an approximate 5-fold reduction in 
potency of all the muscarinic receptor agonists to stimulate calcium mobilisation in 
U20S cells. The mutation Y82F has previously been demonstrated to reduce both 
the affinity and potency of carbachol (the latter approximately 3.5-fold) at the rat 
muscarinic M1  receptor (Lee etal., 1996). The authors were unable to conclude 
whether Y82 played a direct role in the binding of carbachol, or rather associated with 
important residues in other TM domains to maintain proper receptor conformation.
The model presented in this chapter predicts that Y82 is positioned far removed from 
the conserved aspartate residue in TM3 (D105) to rule out any role in the direct 
binding of orthosteric agonists. Given the universal effect of Y82F on agonist 
potencies, it is possible that its effects are due to a global disruption in the receptor 
conformation that mediates agonist activation. Alternatively, this mutation could be 
directly affecting the binding of the allosteric agonists (by disruption of the carbonyl 
oxygen hydrogen bond) and indirectly affecting the binding of orthosteric agonists by 
disrupting the conformation of the receptor deeper in the TM bundle. However, given 
the relatively small effects of this mutation on the potencies of the allosteric agonists, 
it is unlikely that Y82 is the main attachment point for this class of compounds at the 
Mt   receptor.
225The results with the individual point mutations E397A and E401A were largely 
disappointing. Neither individual mutation had any significant effect on the potency of 
either orthosteric or allosteric agonists to stimulate calcium mobilisation in U20S 
cells. However, when AC-42 was docked into the homology model it did appear that 
it could adopt conformations in which the protonated nitrogen could interact with 
either of the glutamate residues. If so, then single mutation of either of the glutamate 
residues could feasibly still leave an acidic residue with which AC-42 could interact. 
Accordingly, a construct containing both the E397A and E401A mutations was made. 
This double mutation did not significantly affect the potencies of the orthosteric 
agonists, carbachol, oxotremorine-M or muscarine, or those of AC-42 or 77-LH-28-1. 
However, the potency of compound A was reduced 4-fold and the weak partial 
agonist activity of compound B was abolished. It is possible that E397 and E401  may 
play a role in the binding, or receptor activation, mediated by compound A and 
compound B. However, it may also be that as partial agonists, the responses to 
these compounds may be more sensitive to reductions in levels of receptor 
expression. This was indeed demonstrated for the E397A/E401A mutant using 
[3H]NMS binding.
It should, however,, be noted that in similar calcium mobilisation studies in CHO cells 
(designed to complement the [3H]NMS binding studies that were also carried out in 
the CHO cel! background), the effect of the E397A/E401A mutation oh compound A 
was more limited, causing only a 2-fold reduction in potency. A similar level of effect 
was observed with AC-42 and 77-LH-28-1. As in the U20S cells, there was no effect 
of E397A/E401A on the potency of carbachol to induce calcium mobilisation.
[3H]NMS binding studies were also performed in order to investigate further the role 
of E397 and E401. [3H]NMS bound to the E397A/E401A mutant with an unchanged 
Kd (re-affirming the lack of role for these residues in the binding of orthosteric
226ligands), but with a reduced Bm ax compared to wild-type.  Furthermore, the affinity of 
atropine and compound A to inhibit [3H]NMS binding was unchanged compared to 
wild-type, although the affinity of AC-42 was reduced 2.5-fold.
Taken together, these data, whilst suggesting that E397 and E401  may have a role in 
the binding of the allosteric agonists, are clearly not consistent with these residues 
mediating the major charge-charge interaction associated with ligand binding and IVh 
receptor activation. The consequences of these results in delineating the nature of 
the allosteric agonist binding site(s) are discussed later.
Probably the most interesting findings were generated with the construct in which 
Y381  in TM6 was mutated. As discussed earlier, this residue has been extensively 
implicated in both orthosteric agonist and antagonist binding of the muscarinic IVh 
receptor (Nordvall & Hacksell, 1993; Ward etal., 1999; Spalding etal., 2002; Sur et 
at., 2003). Accordingly, mutation of this residue to alanine in the human muscarinic 
Mi  receptor caused an approximately 1000-fold reduction in the potency of carbachol 
to stimulate calcium mobilisation in both U20S and CHO cells. Similar effects were 
seen in respect to the responses to the orthosteric agonists oxotremorine-M and 
muscarjne in U20S cells.  Furthermore, the Y381A construct displayed no specific 
binding of [3H]NMS.
Somewhat surprisingly, the calcium mobilisation responses to AC-42 and 77-LH-28-1 
were abolished by Y381A in the U20S cell line. This is in marked contrast to the 
results of previous studies, which have shown that loss of Y381  has only minimal 
effects on the potency of AC-42 to activate the M!  receptor, although with a reduction 
in the maximal response observed (Spalding etal., 2002; Sur etal., 2003). However, 
when tested in the CHO cell background, Y381A caused only a 4-fold reduction in 
the potency of AC-42 compared to wild-type, with a slightly more marked effect on
22777-LH-28-1  (17-fold reduction). These results are qualitatively similar to the 
observations of Spalding etal. (2002) and Sur etal. (2003).
Compound A and compound B both stimulated calcium mobilisation at the wild-type 
Mi  receptor expressed in U20S cells. Interestingly, both compounds appeared as 
partial agonists in this assay, with intrinsic activities of 0.8 and 0.3, respectively. 
These data complement the calcium mobilisation and IP accumulation data in the 
CHO-hM! stable cell line (Chapter 5), which suggested that these compounds were 
partial agonists at the Mi  receptor. Mutation of Y381  actually increased the potencies 
of compound A and compound B 2-fold and 10-fold, respectively, to stimulate 
calcium mobilisation in the U20S cell line, coupled with an increased maximal 
response for compound B.  Furthermore, when tested in the CHO cell background, 
the potency of compound A was increased 10-fold. These results are very similar to 
those observed by Sur etal. (2003) with A/-desmethylclozapine at the Y381A 
construct. The lack of deleterious effect of Y381A on compound A and compound B 
stimulated calcium mobilisation reinforces the concept that these compounds do not 
bind to the orthosteric site in the same fashion as carbachol. However, the increase 
in potencies suggests that compound A and compound B may interact with a site in 
very close proximity to the orthosteric site such that its alteration in Y381A is able to 
positively affect the binding and potency of these compounds.
The difference in the responses observed at the Y381A construct in the two cell lines 
with AC-42 and 77-LH-28-1  is puzzling. It is unlikely to be due to the Y381A being 
non-functional in the U20S cell line, as both compound A and compound B were 
agonists at this construct in the same background. The lower potencies of the 
agonists in the U20S cell line compared to the CHO background, coupled with the 
resolution of partial agonism in the U20S assay, suggests that Mj  receptor 
expression and / or level of G protein coupling may well be lower in the U20S cell
228background. Unfortunately, due to the very slow growth of the U20S cells, it was not 
possible to carry out radioligand binding studies to determine the level of receptor 
expression in comparison with the CHO cell background. Thus it is possible that the 
lack of response to AC-42 in this cell line may be due to the reduced receptor 
expression, coupled with a reduction in the intrinsic efficacy due to the mutation. 
Alternatively, the lack of response to AC-42 and 77-LH-28-1  may represent an 
example of agonist-dependent signalling at this construct whereby these two 
compounds, unlike other agonists, do not activate the necessary signal transduction 
pathways to stimulate the mobilisation of intracellular calcium. This phenomenon of 
agonist trafficking has previously been described for the muscarinic receptor family 
with pilocarpine and methacholine (Akam etal., 2001).
Overall, the calcium mobilisation data supports the notion that neither the aromatic 
portion nor the phenolic hydroxyl group of Y381  is required for the agonist activity of 
the allosteric agonists presented here. In this context, it would be extremely 
interesting to investigate the effect of mutation of other key residues thought to 
comprise the orthosteric site such as D105 (Hulme etal., 1995; Page etal.,  1995; 
Huang etal., 1999), N382 (Huang etal.,  1999; Ward etal.,  1999; Spalding etal.,
2002) and Y404 / Y408 (Lu et at., 2001). N382 may be a key residue as it lies
/
adjacent to Y381. It will be very interesting to see whether mutation of this residue 
distinguishes between orthosteric and allosteric agonists in a similar fashion to 
Y381A. Additionally, it would be interesting to examine the role of D105, the 
aspartate residue in TM3 that mediates the main charge -  charge interaction for 
classical orthosteric agonists. Given the essential nature of D105 in  receptor 
function, it seems highly likely that that this aspartate residue will prove to be 
required for receptor activation by AC-42 and other allosteric agonists. These studies 
may help elucidate the nature of the allosteric binding site and its relationship with 
the orthosteric site.
229Unfortunately, the results of the calcium mobilisation studies largely do not support 
the current modelling of the binding site for AC-42 and compound A to the Mi 
receptor. Whilst both Y82 and the E397/E401  doublet appear to play a role in the 
binding of the allosteric agonists, mutation of these residues does not alter the 
response in a manner consistent with these residues forming the main attachment 
point on the receptor for these agonists. Therefore, it remains to be seen which 
residues of the Mt  receptor form the key interaction(s) with AC-42. There has been a 
recent report suggesting that F77 in TM2 plays a key role in the binding of, and 
receptor activation by, AC-42 (Jacobson etal., 2004). However, the effect of the 
mutation F77I is limited to a 10-fold reduction in potency, again not consistent with 
F77 being the main point of ligand interaction. Furthermore, in the homology model 
described here, F77 appears on the outside face of TM2, suggesting that it is unlikely 
to play a direct role in the binding of AC-42.
As discussed earlier, it appears that two glutamate residues at the top of TM7 
probably do not form a major charge -  charge interaction with AC-42 and compound 
A.  However, it is possible that these compounds still form a hydrogen bond donor -  
acceptor interaction with E397/E401. If this is the case, then the predicted orientation 
of AG-42 and compound A becomes more extracellular, located in a similar pocket to 
that thought to accommodate gallamine and other prototypical allosteric modulators. 
In this context, it isInteresting to note that alcuronium and gallamine have both been 
shown to possess modest degrees of agonist activity at the muscarinic, IVh  receptor 
(Jakubik et al.,  1996).
A further complication in trying to identify the binding site for agonist ligands in this 
way is that homology models such as the one described here are based on the 
crystal structure of the inactive form of rhodopsin. It is now well known that the 
activation of GPCRs (such as rhodopsin and the (32 adrenoceptor) causes
230conformational changes in the TM domains, involving rotation of TM4, the 
displacement of TM6 away from TM3 and an increased flexibility of the intracellular 
portion of TM7 (Gouldson etal., 2004). A model of the muscarinic Mi  receptor based 
on the active state does not currently exist, but may help in the future identification of 
the allosteric agonist binding site.
The results in this chapter have combined molecular modelling and SDM techniques 
in an attempt to identify the molecular nature of the allosteric agonist binding site on 
the muscarinic Mi  receptor. Whilst not fully establishing the key interactions of AC-42 
and compound A with the receptor, these studies have clearly demonstrated the 
independence of their agonist activity from Y381, a key component of the orthosteric 
site. This observation further reinforces the evidence from Chapter 5 that suggests 
that this class of compounds are allosteric agonists at the muscarinic Mi  receptor.
231Chapter 7 
General Discussion
232These studies have used a combination of pharmacological techniques, homology 
modelling and site-directed mutagenesis to characterise the interaction between a 
novel GPCR, GPR10 and its recently identified peptide ligand, PrRP. Similar 
techniques have been applied to characterise the interaction between a well 
established GPCR, the muscarinic Mi  receptor and a novel class of selective 
agonists.
In Chapter 3, the binding of [125l]-hPrRP-20 to GPR10 has been characterised. [125l]- 
hPrRP-20 has been shown to be high affinity radioligand that displayed binding to 
both high and low affinity binding sites. The existence of both low and high affinity 
binding sites for [125l]-hPrRP-20 is described for the first time here, although their 
aetiology is still unclear. Furthermore, [125l]-hPrRP-20 was shown to possess 
association and dissociation kinetics consistent with its high affinity as measured 
using saturation binding. Both rat and human PrRP-31, along with the C-terminal 20 
amino acid truncates, PrRP-20, inhibit [125l]-hPrRP-20 binding to GPR10 with sub­
nanomolar affinity, in agreement with previous studies (Roland etal.,  1999).
Both rat and human PrRP-31  and PrRP-20 stimulated intracellular calcium 
mobilisation in HEK293 cells expressing GPR10 as full agonists and displayed 
sensitivity to inhibitors of phospholipase-C, the IP3 receptor and the endoplasmic 
reticulum Ca2+-ATPase. Furthermore, hPrRP-20 potently stimulated IP accumulation 
in HEK293-GPR10 cells, but did not alter intracellular cAMP levels. These data 
strongly suggest that GPR10 couples predominantly via the Gq/n pathway to 
stimulate the mobilisation of intracellular calcium. Similar studies in Chapter 5 clearly 
demonstrated that despite any alternative mode of action at the muscarinic Mi 
receptor, the agonist activity of compounds such as AC-42 and compound A display 
similar sensitivities to inhibitors of phospholipase-C, the IP3 receptor and the 
endoplasmic reticulum Ca2+-ATPase as does the orthosteric agonist carbachol. This
233suggests that AC-42 and compound A cause the Mi  receptor to signal primarily via 
the Gq/n pathway.
Unfortunately, a lack of pharmacological tools has prevented a more thorough 
characterisation of GPR10; at present only the native PrRPs and truncates thereof 
have been shown to activate GPR10 and there are no known antagonists of this 
receptor.  In contrast, the muscarinic Mi  receptor is an extremely well studied GPCR 
with many well characterised pharmacological tools. The availability of a range of 
radioligands, agonists and antagonists for the Mi  receptor has enabled a thorough 
characterisation of the interaction of a novel class of ‘ectopic’ agonists with this 
receptor. AC-42 has been shown to stimulate both calcium mobilisation and IP 
accumulation in CHO cells expressing the human muscarinic Mi  receptor. Blockade 
of these responses with orthosteric antagonists such as atropine and pirenzepine 
resulted in parallel rightward shifts of the agonist response curve, but yielded non­
linear Schild regressions characteristic of a negatively co-operative allosteric 
interaction. Analysis of the data according to the simple allosteric ternary complex 
(Ehlert etal., 1988; Christopoulos & Motulsky, 2004) has generated estimates of the 
co-operativity (a) governing the interaction between AC-42 and atropine or 
pirenzepine. Most notably, the antagonist effect of atropine on AC-42 stimulated 
calcium mobilisation in CHO-hMi cells was clearly shown to be saturable, a hallmark 
of an allosteric interaction (Christopoulos & Kenakin, 2002). It was concluded that 
AC-42 must be the allosteric ligand since atropine and pirenzepine are two of the 
best characterised orthosteric antagonists of the muscarinic receptor family.
Such saturability to an allosteric effect was also demonstrated using equilibrium 
binding assays in CHO-hMi cells with the orthosteric radioligand, [3H]NMS. AC-42, 
77-LH-28-1  and gallamine, a prototypical allosteric modulator of muscarinic 
receptors, displayed an inability to inhibit fully the specific binding of [3H]NMS, an
234effect that was more profound at a higher radioligand concentration. Compound A 
also shared this property, although its low affinity made it difficult to estimate 
accurately the minimum asymptotes of the inhibition isotherms. In contrast, both 
atropine and pirenzepine both fully inhibited [3H]NMS binding, consistent with a 
simple competitive interaction. Analysis of the data according to the allosteric ternary 
complex model generated estimates of the co-operativity factor, a, governing the 
interaction between AC-42, 77-LH-28-1, gallamine and compound A and NMS. 
Interestingly, the estimate of co-operativity between AC-42 and NMS is markedly 
different to that between AC-42 and atropine. This is an example of another hallmark 
of allosteric interactions, namely a probe dependence of the co-operativity on the 
orthosteric ligand used (Christopoulos, 2000).
In addition to saturability of effect and orthosteric probe-dependence, another key 
property of allosteric ligands is the ability to alter the dissociation rate of orthosteric 
ligands (Christopoulos etal., 1999; Lazareno & Birdsall,  1995). In these studies it has 
been shown that the prototypical allosteric modulator, gallamine, markedly retards 
the dissociation of [3H]NMS from CHO-hMi cell membranes. In addition, AC-42 
significantly slowed the rate of [3H]NMS dissociation, although not to the same extent 
as gallamine. Compound A did not alter the dissociation rate, however this probably 
reflects a combination of the solubility maximum and the low predicted affinity of 
compound A for the [3H]NMS occupied receptor. Collectively, these studies provide 
unambiguous evidence that the ‘ectopic’ agonist, AC-42, is an allosteric ligand. As 
such, it is more appropriate to re-class this ligand as an allosteric, rather than 
ectopic, agonist. There is also evidence to suggest that the other ‘ectopic’ agonists 
share this property.
The final studies in Chapter 5 were designed to determine whether the agonist 
activity of these compounds was evident at native muscarinic receptors. AC-42, 77-
235LH-28-1, compound A and compound B all displayed a higher affinity to inhibit 
[3H]oxotremorine-M binding than [3H]QNB binding in rat cortical membranes. The 
ratio of affinities against agonist and antagonist radioligands has often been used as 
a predictor of ligand efficacy (Loudon etal.,  1997; Watson etal., 1999) and the data 
presented here are consistent with these compounds possessing agonist activity in 
rat cortex. This was emphatically demonstrated with the selective muscarinic Mi 
receptor agonist, 77-LH-28-1, which evoked cortical gamma network oscillations in 
layer IV of the rat temporal cortex in vitro. These oscillations mimicked the gamma 
oscillations elicited by the non-selective cholinergic agonist, carbachol, suggesting 
(a) that the gamma oscillations produced by carbachol are mediated via the 
muscarinic Mi  receptor and (b) 77-LH-28-1  is an agonist at native tissue muscarinic 
receptors.
Having characterised the pharmacology of both the PrRPs at GPR10 and AC-42 
(plus other allosteric agonists) at the muscarinic Mi  receptor, Chapters 4 and 6 
sought to establish the molecular nature of their respective binding sites for these 
compounds at their receptors. These studies utilised homology modelling of both 
GPR10 and the muscarinic Mi  receptor based on the crystal structure of bovine 
rhodopsin. Manual docking of the C-termina! heptapep?«de of hPrRP-20, hPrRP(25- 
31) and AC-42 / compound A, respectively, led to predictions of key amino acid 
residues involved in the binding of these ligands. These predictions were tested 
using site-directed mutagenesis (SDM) in conjunction with functional calcium  . 
mobilisation and radioligand binding approaches.
For GPR10, acidic residues were sought for the two basic arginine residues in 
positions 2 and 6 of hPrRP(25-31). All acceptable docking solutions suggested the 
formation of a salt bridge between D302 (TM6) and Arg2 and E213 (ECL2) and Arg6. 
Accordingly, mutation of either of these residues to alanine resulted in a loss of
236specific [125l]-hPrRP-20 binding and a markedly reduced potency of hPrRP-20 to 
stimulate calcium mobilisation. The successful prediction of these interactions was 
particularly exciting because this was the first instance of a theoretically derived loop 
structure for a GPCR suggesting critical interactions in the receptor model.
The docking of the hPrRP(25-31) into GPR10 suggested that a double hydrogen 
bond would be formed between Val4 of hPrRP(25-31) and Q317 (TM7) -  this 
interaction was predicted to be key in defining the position of the two arginine 
residues of the heptapeptide relative to E213 and D302. As anticipated, the mutant 
Q317A abolished specific [125l]-hPrRP-20 binding and vastly reduced the potency of 
hPrRP-20 to stimulate calcium mobilisation.
Q141, E212 and N298 were also thought to form hydrogen bonds with either Arg6 or 
the terminal carboxamide of hPrRP(25-31). These interactions were not predicted to 
be as crucial to the binding of the heptapeptide as those for E213, D302 and Q317 
and, accordingly, their mutation had more limited effects on [125l]-hPrRP-20 binding 
and hPrRP-20 stimulated calcium mobilisation. These observations have clearly 
validated the homology model of GPR10 and may aid the future rational design of 
agonists or antagonists of this receptor.
In contrast, the effort to identify the molecular nature of the allosteric agonist site on 
the muscarinic Mi  receptor was less successful. Based on the essential portion of the 
muscarinic Mi  receptor sequence required for AC-42 agonist activity (Spalding etal.,
2002), manual docking of AC-42 predicted a clear interaction between the protonated 
nitrogen of this compound and either of the glutamate residues, E397 or E401, at the 
top of TM7. Additionally, a hydrogen bond was predicted between the carbonyl 
oxygen of AC-42 and Y82 in TM2. Unfortunately, none of these residues, when 
mutated, selectively affected the agonist activity of AC-42 or any other allosteric
237agonist. AC-42 displayed a small reduction in affinity for a construct containing point 
mutations of both E397 and E401; compound A also displayed a slightly reduced 
potency at this construct. However, whilst these results suggested that there may be 
a small role for E397 and E401  in the binding of allosteric agonists, these results are 
not consistent with these amino acid residues forming the major charge-charge 
interaction with AC-42.
It is possible that further refinement of the homology model may yield a better 
understanding of the allosteric binding site. There are several amino acid residues, 
which were highlighted in the ligand docking, which may play a greater role in the 
binding of AC-42 than first anticipated. These include T34 in TM1, which was 
predicted to form a hydrogen bond with the n system of the phenyl ring (Meyer et al,
2003)  and D393, which may also form an interaction with the protonated nitrogen of 
AC-42 and compound A as well as, or instead of, E397/E401. Furthermore, W101, a 
turn above D105 in TM3, was also predicted to be very close to the carbonyl oxygen 
atoms of AC-42 and compound A, so it is possible that this residue, rather than Y82, 
forms a hydrogen bond with the carbonyl oxygen. This would be of further interest if 
AC-42 and gallamine were to be occupying the same site as W101  which has 
previously been implicated in the binding of gallamine to the muscarinic Mi  receptor 
(Matsui etal.,  1995). Thus, these three amino acid residues would be strong 
candidates for future SDM work.
However, substantial evidence that these compounds interact at a non-orthosteric 
site was obtained with a Mi  receptor construct containing the Y381A mutation (Ward 
etal.,  1999). In contrast to the large deleterious effect on the potency of carbachol, 
this mutation left the agonist response to the allosteric agonists relatively unaffected, 
and even potentiated the response to compound A and compound B. However, the 
relationship between the orthosteric site and the binding site for the allosteric
238agonists still remains largely unclear. Further refinement of the homology model, 
together with more SDM work, is required in order to elucidate the precise nature of 
the allosteric agonist binding site.
The studies within this thesis have offered the first example of functional 
characterisation of the signal transduction pathways activated by GPR10 and also an 
extensive characterisation of the binding of [125l]-hPrRP-20 to GPR10. Furthermore 
the results generated have revealed the existence of high and low affinity binding 
sites and molecular modelling in combination with SDM studies have also identified 
for the first time the molecular nature of the peptide binding site for this receptor.
With respect to the muscarinic Mi  receptor extensive pharmacological 
characterisation has also shown that AC-42 displays a unique allosteric mode of 
agonist action at the receptor. Homology modelling and SDM of the muscarinic Mi 
receptor has also clearly identified a non-orthosteric molecular mechanism of action 
for this class of muscarinic receptor agonists.
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274Appendix 1  -  Definitions and Example Calculations
(i)  Definition of EC5 0  and IC5 0
Effective concentration (EC)50 represents the molar concentration of agonist required 
to produce 50% of the maximal possible response. In a radioligand binding assay, 
inhibitory concentration (IC)50 represents the molar concentration of ligand to inhibit 
50% of the specific binding of the radioligand.  For a functional assay, IC50 represents 
the molar concentration of antagonist which reduces the response to a fixed 
concentration of agonist by 50%. Both EC50 and IC50 values are calculated using a 
four-parameter logistic fit (equations 1   and 6 in Methods).
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(ii)  Definition of KD  and Bm a x
The equilibrium dissociation constant (KD ) is the molar concentration of ligand 
required to occupy 50% of the receptor population. The maximal binding capacity 
(Bm ax) for a ligand represents the amount of ligand, usually expressed in pmol / mg 
protein, which can bind specifically to a receptor population in a membrane 
preparation. Both terms are usually estimated by non-linear regression of saturation 
analysis data.
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(iii)  Conversion of IC5 0  to Ki
An IC50 value from a radioligand binding assay is converted to yield the equilibrium 
dissociation constant for the inhibitor (K,) using the Cheng-Prussoff equation 
(equation 2 in Methods):
/a K, =
'50
1+w
Ko
Assuming the equilibrium dissociation constant for the radioligand,  KD  = 0.2 nM and 
the radioligand concentration, [L]= 0.2 nM, then:
5x1 O'8 
K,  =
,  2X10"10
1 + -
2x10"10 
K, = 2.5 x 10'8 M
(iv)  Calculation of pECso / pKt
pEC50 and pKj values are the negative logarithm of EC50and R values, respectively 
eg.
K = 2.5x10'8M 
pKi = - log (2.5 x 10'8) 
pKj = 7.60
276(v) Calculation of Kon from /C^and Kobs
The association rate constant, Ko n  is calculated from the dissociation rate constant, 
/C offand the observed association rate constant, Ko b s  and the radioligand 
concentration [/_].
K„
_   ' ' obs  ' xoff
[L]
0.24min_1-0.2m in_ 1
2x10  1 0  M
Ko n  = 200 min'1
(vi)  Calculation of KD  from Koffand Ko n
The equilibrium dissociation constant, KD, is the ratio of the dissociation rate 
constant, Koff and the association constant,  Kon.
^   ^ o ff
Kon
K r t   —
0.2 min-1
D  200min  1  juM  1
Kd = 1   x 10'9 M 
Kd = 1   nM
(vii)  Calculation of pKB  for competitive antagonists
In a functional assay where agonist concentration-response curves are measured in 
the presence and absence of multiple fixed concentrations of a test antagonist,
277Schild analysis is used to determine the antagonist affinity, pKB . A Schild regression 
of the logarithm of the concentration ratio -  1   (where the concentration ratio is the 
ratio of equi-effective agonist concentrations in the presence and absence of 
antagonist) against the logarithm of the molar antagonist concentration that yields a 
straight line with a slope value not significantly different from  1   suggests that the 
antagonist is competitive. The intercept on the X-axis is then equal to the pKB  value 
for the antagonist.
Schild plot
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(viii)  Calculation of pA2 and co-operativity values (a) for allosteric interactions
In a functional assay where agonist concentration-respense curves are measured in 
the presence and absence of multiple fixed concentrations of a test antagonist, 
Schild analysis is used to determine an empirical estimate of antagonist affinity, pA2. 
A Schild regression of the logarithm of the concentration ratio -  1   (where the 
concentration ratio is the ratio of equi-effective agonist concentrations in the 
presence and absence of antagonist) against the logarithm of the molar antagonist 
concentration is often used to examine negatively co-operative interactions. Schild 
regressions for such interactions yield either a straight line with a slope value 
significantly less than  1, or a curve that eventually reaches an asymptotic value. The 
intercept on the X-axis can be taken as an estimate of the antagonist affinity (pA2), 
whereas the asymptote of the curve is approximately equal to the negative logarithmof the co-operativity (a) between the two ligands. This value is usually estimated by 
non-linear regression according to equation 7 in Methods.
Schild plot
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